UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 10-K

(Mark One)


☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, ~~2023~~2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-41859

CARGO Therapeutics, Inc.

(Exact name of Registrant as specified in its Charter)

Delaware	84-4080422
(State or other jurisdiction ofincorporation or organization)	(I.R.S. EmployerIdentification No.)
1900 Alameda Las Pulgas, Suite 350San Mateo, California	94403
835 Industrial Road, Suite 400San Carlos, California	94070
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (650) 379-6143

Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading
Symbol(s)

    Name of each exchange on which registered

    Common stock, par value $0.001 per share

    CRGX

    Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ No ☒

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ NO ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The ~~registrant~~aggregate ~~was~~market ~~not~~value aof ~~public~~the ~~company~~Registrant’s asCommon Stock held by non-affiliates of the Registrant was approximately $522.4 million based on the closing price reported by Nasdaq Global Select Market on June 30, 2024 (the last business day of ~~its~~the Registrant’s most recently completed second fiscal quarter). ~~and,~~For ~~therefore,~~purposes ~~cannot~~of ~~calculate~~making this calculation only, the ~~aggregate~~Registrant ~~market~~has ~~value~~defined ofaffiliates ~~its~~as ~~voting~~including ~~equity~~all ~~held~~executive byofficers, ~~non-affiliates~~directors asand beneficial owners of ~~such~~more ~~date~~than 10% of the Registrant’s Common Stock.

The number of shares of Registrant’s Common Stock outstanding as of March 135, ~~2024~~2025 was 3946,~~363,~~052,368.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement relating to the ~~2024~~2025 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, ~~2023~~2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.

Table of Contents

		Page
PART I
Item 1.	Business	5
Item 1A.	Risk Factors	41
Item 1B.	Unresolved Staff Comments	106
Item 1C.	Cybersecurity	106
Item 2.	Properties	107
Item 3.	Legal Proceedings	108
Item 4.	Mine Safety Disclosures	108
PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	109
Item 6.	Reserved	109
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	110
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	122
Item 8.	Financial Statements and Supplementary Data	123
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	155
Item 9A.	Controls and Procedures	155
Item 9B.	Other Information	156
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	156
PART III
Item 10.	Directors, Executive Officers and Corporate Governance	157
Item 11.	Executive Compensation	157
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	157
Item 13.	Certain Relationships and Related Transactions, and Director Independence	157
Item 14.	Principal Accountant Fees and Services	157
PART IV
Item 15.	Exhibits, Financial Statement Schedules	158
Item 16.	Form 10-K Summary	161

Table of Contents


		Page
PART I
Item 1.	Business	5
Item 1A.	Risk Factors	36
Item 1B.	Unresolved Staff Comments	100
Item 1C.	Cybersecurity	100
Item 2.	Properties	101
Item 3.	Legal Proceedings	101
Item 4.	Mine Safety Disclosures	101

PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	102
Item 6.	Reserved	102
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	103
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	115
Item 8.	Financial Statements and Supplementary Data	116
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	147
Item 9A.	Controls and Procedures	147
Item 9B.	Other Information	148
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	148

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	149
Item 11.	Executive Compensation	149
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	149
Item 13.	Certain Relationships and Related Transactions, and Director Independence	149
Item 14.	Principal Accountant Fees and Services	149

PART IV
Item 15.	Exhibits, Financial Statement Schedules	150
Item 16.	Form 10-K Summary	153

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward‑looking statements involve substantial risks, uncertainties and assumptions. All statements in this Annual Report on Form 10‑K, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future operating expenses, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward‑looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would” or “will,” and similar expressions (including the negatives thereof) are intended to identify forward‑looking statements, although not all forward‑looking statements contain these identifying words. The forward-looking statements in this report include, but are not limited to, statements about:

•

the potential for adverse events, undesirable side effects or unexpected characteristics associated with any of our product candidates;

•

the timing of achieving our scientific, clinical, manufacturing, regulatory and/or other product development objectives;

•

the timing of our planned ~~investigational~~Investigational ~~new~~New ~~drug~~Drug application (IND) submissions to the United States Food and Drug Administration (FDA) for our product candidate, our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, ~~including~~if ~~CRG-022~~approved for commercial use;

•

our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use;

our clinical and regulatory development plans;

•

our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies;

•

the number, size and design of our planned clinical trials, and what regulatory authorities may require to obtain full marketing approval;

•

our plans to research, develop and, if approved, commercialize our product candidates~~, including CRG-022 and CRG-023~~;

•

the timing of commencement of future preclinical studies and clinical trials and research and development programs;

•

our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;

•

our ability to obtain ~~designation~~certain designations, such as a Breakthrough Therapy or Regenerative Medicine Advance Therapy, for one or more of our product candidates;

•

a requirement to obtain approval of a companion diagnostic in connection with the approval of any of our product candidates;

•

our intentions and our ability to establish collaborations and/or partnerships;

•

the discovery of previously unknown or unexpected problems with our product candidates or any future product candidates or with the facilities where such product candidates are or will be manufactured;

•

the timing or likelihood of regulatory ~~filings~~submissions and potential approvals for our product candidates, including the potential requirement to adopt a Risk Evaluation and Mitigation Strategy;

•

our commercialization, marketing and manufacturing strategies, including the buildout of our own manufacturing facility, capabilities and expectations;

•

the rate and degree of market acceptance of our product candidates, if approved;

•

the success of competing products or platform technologies that are or may become available;

Table of Contents

•

impact from future regulatory, judicial, and legislative changes or developments in the United States and foreign countries;

•

our intentions with respect to the commercialization of our product candidates;

•

the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets;

•

the pricing and reimbursement of our product candidates, if approved;

•

future agreements with third parties in connection with the potential commercialization of our product candidates;

•

the potential effects of ~~public~~ health ~~crises~~epidemics, pandemics, other widespread outbreaks of contagious disease, such as COVID-19 and the post-COVID-19 ~~pandemic~~environment, on our preclinical and clinical programs and business;

•

the implementation of our business model and strategic plans for our business and product candidates, including additional indications for which we may pursue;

•

our ability to ~~effectively~~realize ~~manage~~the ~~our~~level ~~growth,~~of ~~including~~the ~~our~~anticipated ~~ability~~benefits tothat ~~attract~~we ~~and~~expect ~~retain~~from ~~key~~restructuring ~~scientific~~our ~~and~~operations, ~~management~~which ~~personnel,~~may ~~and~~adversely ~~maintain~~impact our ~~culture~~business and results of operations;

•

our ability to attract and retain key scientific and management personnel, and maintain our culture;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;

•

potential claims relating to our intellectual property and third-party intellectual property;

•

estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

our future financial performance;

•

our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a smaller reporting company as defined in Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the Exchange Act);

•

developments and projections relating to our competitors and our industry, including competing products;

•

our expectations regarding the use of proceeds from our initial public offering and our existing cash and cash equivalents; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors” in this Annual Report on Form 10-K.

We have based these forward-looking statements largely on our current expectations, estimates, forecasts and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk factors” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

Table of Contents

statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

Investors and others should note that we may announce material business and financial information to our investors using our investor relations website, Securities and Exchange Commission filings, webcasts, press releases and conference calls. We use these mediums, including our website, to communicate with the public about our company, our business and other issues. It is possible that the information that we make available may be deemed to be material information. We, therefore, encourage investors and others interested in our company to review the information that we make available on our website.

Table of Contents

PART I

Item 1. Business.

Overview

We are a clinical-stage biotechnology company ~~uniquely~~focused ~~positioned~~on todesigning, ~~advance~~engineering and developing next generation, potentially curative cell therapies for cancer patients. Our programs, ~~platform technologies~~platforms, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is aan engineered protein that ~~has~~is ~~been~~delivered ~~engineered~~into ~~to modify~~ T cells, soenabling ~~they~~recognition ~~can recognize~~ and ~~destroy~~destruction of cancer cells. We believe the limitations of approved CAR T-cell therapies include limited durability of effect, safety concerns and unreliable supply. Our ~~lead~~pipeline ~~program,~~includes CRG-~~022~~023, an ~~autologous~~investigational ~~(derived~~tri-specific ~~from a patient’s cells) CD22~~ CAR T~~-cell~~ ~~product~~designed ~~candidate,~~to ~~the~~address ~~underlying~~several ~~CAR~~known causes of ~~which~~relapse weassociated ~~exclusively~~with ~~licensed,~~existing isCAR ~~being~~T-cell ~~studied~~therapies bysuch ~~Stanford~~as ~~University~~loss ~~(Stanford)~~of intumor aantigen ~~Phase~~expression, 1loss ~~clinical~~of ~~trial in patients with large B~~co-~~cell~~stimulation ~~lymphoma~~ (~~LBCL)~~e.g., ~~whose~~via ~~disease relapsed or was refractory (R~~CD58/RCD2 signaling) toand ~~CD19 CAR~~ T- cell ~~therapy.~~exhaustion, Onresulting ~~the~~in ~~basis of~~ the ~~results~~potential ~~from~~to ~~the~~address ~~clinical~~a ~~trial,~~broad werange ~~are~~of ~~evaluating CRG~~B-~~022~~cell inmalignancies awith ~~potentially~~the ~~pivotal~~goal ~~Phase~~of 2providing ~~clinical~~more ~~trial in~~ patients with ~~LBCL~~a ~~whose~~durable ~~disease~~complete response. CRG-023 is ~~R/R~~designed to ~~CD19~~target ~~CAR~~the TB-cell ~~therapy.~~lineage Weantigens ~~also~~(CD19, ~~plan~~CD20, toCD22) ~~evaluate~~via ~~CRG~~tri-~~022~~cistronic inexpression ~~patients at earlier stages~~ of ~~disease,~~three ~~including~~distinct ~~LBCL~~CARs ~~and~~from ~~other~~a ~~hematologic~~single ~~malignancies.~~lentiviral ~~Beyond our lead program~~vector, weeach ~~are~~with ~~leveraging~~its ~~our~~own ~~proprietary~~co-stimulatory ~~cell~~domain. ~~engineering~~One ~~platform~~co-stimulatory ~~technologies~~domain toincorporates ~~develop~~CD2 asignaling ~~pipeline~~into ofthe ~~programs~~tri-specific ~~that incorporate multiple transgene therapeutic “cargo” designed to enhance~~ CAR T~~-cell~~ ~~persistence~~cell, asthe ~~well~~design asof towhich ~~help~~has ~~safeguard~~been ~~against~~informed ~~tumor~~by ~~resistance and T~~immune-~~cell~~evasion ~~exhaustion. Our founders are pioneers~~ and ~~world-class experts in~~ CAR T-cell ~~therapy,~~resistance ~~and~~mediated ~~our~~by ~~team~~the ~~has~~loss ~~significant~~of ~~experience~~CD58 ~~and~~expression ~~success~~(the ~~developing,~~ligand ~~manufacturing,~~of ~~launching~~the ~~and~~CD2 ~~commercializing~~co-stimulatory ~~oncology and cell therapy products~~receptor). ~~We aim to become a fully integrated, leading cell therapy company. Together, we are united in our mission to outsmart cancer and deliver more cures for patients.~~

~~Transformative~~In ~~advances~~January ~~have been made by commercially available CAR T-cell therapies; however~~2025, ~~resistance mechanisms in hematologic malignancies can limit~~ the ~~strength~~FDA ~~and~~allowed ~~quality~~our ofIND Tfor CRG-~~cell~~023 ~~response and contribute~~ to ~~disease~~proceed. ~~progression,~~We ~~including~~intend ~~loss~~to orevaluate ~~down~~CRG-~~regulation~~023 ofin ~~target~~a ~~antigen~~Phase ~~expression,~~1 ~~loss~~dose ofescalation ~~co-stimulation~~study ~~and~~in ~~limited~~3L+ ~~CAR~~large TB-cell ~~persistence.~~lymphoma ~~For~~(LBCL) ~~example,~~including asCAR ~~shown in the ZUMA~~T-1naïve ~~clinical trial for Yescarta in LBCL~~ patients. ~~with~~We ~~two~~plan orto ~~more~~leverage ~~prior lines~~ proof-of ~~therapy, approximately 60% of LBCL patients treated with Yescarta had their disease relapse or progress within 24 months. As CD19 CAR T~~-~~cell~~concept ~~therapies~~data ~~continue~~ to ~~expand~~support moving quickly into earlier lines of therapy and ~~additional~~to ~~geographies,~~evaluate ~~there~~CRG-023 isadditional aB-cell ~~large~~malignancies ~~growing~~for ~~unmet~~CRG-023. ~~need~~Enrollment for the ~~majority~~Phase of1 ~~patients~~study ~~who~~is doexpected ~~not experience a durable response. According~~ to ~~our~~be ~~estimates,~~initiated ~~we expect~~ by ~~2030 approximately 7,600 patients annually may need treatment post CD19 CAR T-cell therapy within~~ the ~~United~~second ~~States~~quarter asof ~~well as France, Germany, Italy, Spain and the United Kingdom (EU4/UK)~~2025.

~~Our~~We ~~lead~~are ~~program,~~also ~~CRG-022,~~leveraging isour cell engineering and manufacturing capabilities to develop a novel ~~autologous~~allogeneic ~~CAR~~platform, ~~T-cell~~which ~~product~~is ~~candidate~~a ~~designed~~universal tovector ~~address~~solution ~~resistance~~designed ~~mechanisms~~to bylimit ~~targeting~~immune-based ~~CD22,~~rejection anto ~~alternate~~enable ~~tumor~~durable ~~antigen~~response ~~expressed~~for inCAR ~~most B~~T-cell ~~malignancies~~therapy. WeThe ~~exclusively~~universal ~~licensed~~vector ~~the~~is ~~underlying~~intended to be paired with any new or pre-existing CAR ~~for~~vector ~~CRG~~to create an allogeneic CAR T-~~022~~cell ~~from~~therapy, with the ~~National~~goal ~~Cancer~~of ~~Institute~~maintaining (the ~~NCI),~~durable ~~for~~efficacy ~~use~~and assafety anassociated with autologous cell therapy inwhile ~~hematology~~creating ~~and~~an ~~oncology.~~off-the-shelf ~~Prior~~option to ~~our~~broaden ~~licensing~~availability ~~the~~to ~~underlying~~more ~~CAR~~people ~~from~~with ~~the~~cancer. ~~NCI~~To date, ~~Stanford~~we ~~had~~have ~~begun~~generated apre-clinical ~~Phase~~proof-of-concept 1activity ~~clinical~~in ~~trial~~the ofallogeneic ~~CRG-022~~vector, ~~which~~and ~~has~~we ~~enrolled~~expect 41to ~~patients~~select ~~with~~our ~~R/R~~lead ~~LBCL,~~vector 38candidate ofin ~~whom~~the ~~received~~first ~~CRG-022~~half of 2025. ~~The~~Through ~~results~~our ~~below~~allogeneic ~~reflect~~platform, awe ~~data~~also ~~cut-off~~intend asto ofpursue ~~November~~an 4,allogeneic ~~2023:~~vectorized CRG-023.

For all patients treated (n=38), the overall response rate (ORR) was 68% (26 of 38 patients), and the complete response (CR) rate was 53% (20 of 38 patients);

The November 2023 data cut-off provides a median follow-up of 27.3 months and includes the following new information from Stanford:

Since the previous May 3, 2023 data cut-off, one additional patient relapsed after a remission duration of 21 months.

At Dose Level 1, which was 1 x 106 transduced CRG-022 cells per kg and the dose we are using for our ongoing Phase 2 clinical trial, 73% of patients who achieved a CR maintained the CR for at least 12 months (29 patients were treated at Dose Level 1; 15 achieved a CR, 11 of whom maintained a CR for ≥ 12 months).

Table of Contents

AtOn ~~Dose~~January ~~Level~~29, 22025, 9we ~~patients~~elected ~~were~~to ~~treated~~discontinue FIRCE-1, ~~with~~our 5Phase 2 study of firicabtagene autoleucel (firi-cel) (previously CRG-022) in patients ~~achieving~~with aLBCL CRwhose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. ~~Four~~Firi-cel was our investigational autologous CAR T-cell product targeting the CD22 antigen and also our lead program. Based on an analysis of ~~these~~FIRCE-1 5data, ~~patients~~we ~~had~~believe ~~maintained~~the results did not support a CRcompetitive benefit-risk profile of firi-cel for 12the ~~months~~intended orpatient ~~longer~~population in the context of available treatment options.

~~With~~In aconnection ~~median~~with ~~follow~~our decision to discontinue FIRCE-up1, ofwe ~~27.3~~are ~~months~~focusing ason ofevaluating ~~the~~strategic ~~data~~options ~~cut~~while continuing to advance CRG-~~off,~~023 ~~for~~through ~~Dose~~proof-of-concept ~~Level~~data 1and progressing our allogeneic platform to lead vector selections In addition, ~~the~~our ~~median~~board OSof ~~had~~directors ~~not~~approved ~~been~~a ~~reached~~reduction ~~and~~of ~~for~~our ~~Dose~~workforce ~~Level~~by 2,approximately ~~the~~50% ~~median~~in OSconnection ~~was~~with ~~14.1~~our ~~months~~decision to discontinue FIRCE-1.

~~Five~~Our ~~patients who died of non-relapse causes were in CR at the time of death; 2 of 5 patients were in Dose Level 1 and 3 of 5 patients were in Dose Level 2.~~strategy

~~Only~~Our 1mission ~~patient~~is atto ~~Dose~~develop ~~Level~~next-generation, 2potentially ~~experienced~~curative ~~Grade~~cell 3therapies orfor ~~higher~~people ~~cytokine~~with ~~release~~cancer. ~~syndrome~~Our ~~(CRS)~~strategy to achieve this goal is to leverage our design, ~~which~~engineering ~~happens~~and ~~when~~development acapabilities to optimize the critical aspects of cell therapy in order to broaden patient’s ~~immune~~benefit ~~system~~and ~~aggressively~~access. ~~responds~~We currently have exclusive rights to andevelop ~~immunotherapy;~~and commercialize our product candidates.

NoCAR ~~patients~~T ~~experienced~~cells ~~Grade~~– 3an oremerging ~~higher~~class ~~immune~~of ~~effector~~immunotherapy ~~cell-associated~~with ~~neuropathy~~curative ~~(ICANS), which is a neurological toxicity that can occur following immunotherapy; and~~potential

~~Reliable~~Chimeric ~~supply~~antigen ~~with~~receptor ~~95%~~(CAR) ~~successful~~T ~~manufacturing~~cells ~~rate~~are T cells engineered to express synthetic receptors capable of specifically recognizing tumor antigens and ~~median~~activating ~~turnaround~~the ~~time~~T cell. Binding of 18a ~~days~~CAR to its cognate antigen results in stimulation of intracellular signals and activation of T cell activity.

~~There~~Autologous ~~have~~and ~~been~~allogeneic 32CAR ~~serious~~T-cell ~~adverse~~therapies ~~events~~offer ~~reported~~two ~~from~~approaches 23to ~~subjects~~treating oncancer, ~~this~~with ~~study~~unique asconsiderations. ofAutologous ~~the~~CAR ~~November 4, 2023 data cut~~T-~~off.~~cell ~~There~~therapies ~~were~~are ~~four~~made ~~reports~~with ofcells ~~Grade~~obtained 3from ~~sepsis/infection~~the ~~and~~patient ~~two~~being ~~reports~~treated. ofIn ~~cardiac disorders~~contrast, ~~which~~allogenic ~~included~~CAR ~~grade~~T-cell 3therapies ~~ejection~~are ~~fraction~~made ~~decreased~~with ~~and~~cells ~~grade~~obtained 2from ~~heart~~a ~~failure.~~healthy ~~The~~donor ~~largest~~and ~~category~~typically ofinclude ~~reported~~additional ~~SAEs~~genetic (nmodifications =and 14other ~~events,~~refinements ~~44%)~~intended ~~have~~to ~~been~~reduce ~~hospitalizations~~or ~~for~~ideally ~~closer~~eliminate ~~monitoring~~the ~~during~~likelihood ~~a second peak~~ of ~~CRS~~immune ~~that~~rejection ~~occurs~~or ~~between~~graft ~~Day~~versus 11host ~~and~~disease ~~Day~~when 14infused ~~post-CAR~~into ~~infusion~~patients.

InThere ~~addition,~~have ~~the~~been ~~most~~seven ~~common~~engineered ~~adverse~~T-cell ~~events~~therapies ofapproved ~~Grade~~by 3the orFDA ~~higher~~for ~~during~~the treatment ~~were neutropenia, which occurs when patients have lower-than-normal levels~~ of acancer. ~~type~~Each of ~~white~~these ~~blood~~therapies ~~cell~~has ~~and~~been isable ~~especially~~to ~~common~~deliver ~~among~~therapeutic ~~people~~benefit ~~receiving~~to ~~cancer~~patients ~~treatments,~~who ~~that~~have ~~was~~exhausted ~~observed in~~ all ~~treated~~other ~~patients,~~treatment ~~anemia that was observed in 63% of treated patients~~options, and ~~thrombocytopenia,~~for ~~which~~some ~~occurs when bone marrow does not make enough platelets~~patients, ~~that was observed in 63% of treated patients. All of~~ these ~~adverse~~benefits ~~events~~can ~~are~~extend ~~commonly~~for ~~observed in other therapeutics in this class~~years. ~~Three deaths in the trial were deemed by investigators to be possibly related to study drug at the highest dose level, which is not being used in our ongoing Phase 2 clinical trial.~~

~~On the basis of these results~~However, ~~Stanford received Breakthrough Therapy Designation from~~ the ~~FDA~~number ~~for the treatment~~ of ~~adult~~cancers ~~LBCL~~with ~~patients~~effective ~~whose disease is R/R after CD19-directed~~ CAR T-cell ~~therapy~~therapies inis ~~connection~~limited ~~with~~and ~~Stanford’s~~the ~~Investigational~~total ~~New~~number ~~Drug~~of ~~application~~patients ~~(IND).~~who Wehave ~~understand~~received ~~that~~these ~~Stanford~~therapies ~~may~~represents ~~pursue~~only ~~additional~~a ~~clinical~~small ~~trials~~fraction of apotentially ~~similar~~eligible ~~CAR~~cancer ~~T-cell~~patients. ~~therapy~~Today, towith ~~CRG-022~~the inCAR ~~other B~~T-cell ~~malignancies~~therapies ~~for~~approved ~~research~~to ~~purposes.~~treat ~~Our~~certain ~~and~~patients ~~Stanford~~with non-Hodgkin’s ~~clinical~~lymphoma ~~trials~~(NHL) ~~have~~and ~~been,~~acute ~~and~~lymphocytic ~~will~~leukemia be(ALL), ~~conducted~~over ~~independently from each other~~40,000 ~~with~~U.S. ~~the~~patients ~~exception~~may ~~that~~be ~~Stanford~~eligible isto abe ~~clinical~~treated ~~trial~~by ~~site for our ongoing Phase 2 clinical trial of CRG-022 in R/R LBCL post~~ CD19 CAR T-cell ~~therapy. In August 2023~~therapies, webut ~~initiated~~fewer athan ~~potentially~~3,800 ~~pivotal~~patients ~~multi-center~~are ~~Phase~~expected ~~2 clinical trial~~ to ~~evaluate~~receive ~~the~~such ~~safety~~treatment ~~and~~in ~~efficacy~~2023. ofSome ~~CRG-022 in~~ patients ~~with~~are ~~LBCL~~deemed ~~whose~~ineligible ~~disease is R/R~~ to ~~CD19~~or ~~CAR~~do ~~T-cell~~not ~~therapy.~~receive Inthese ~~this~~therapies ~~growing~~due ~~patient~~to ~~population~~associated ~~with~~toxicity ~~significant~~risk, ~~unmet~~underlying ~~need~~comorbidities, ~~CRG-022~~the ~~may~~time ~~provide~~needed ~~another option and opportunity~~ to ~~achieve~~manufacture atreatment ~~complete~~or ~~and~~lack ~~durable~~of ~~response.~~access Weto ~~expect~~specialized ~~interim~~treatment ~~results from this Phase 2 clinical trial in the first half of 2025~~centers. ~~Beyond~~In ~~our~~patients ~~initial~~who ~~focus~~do onmanage ~~R/R LBCL post CD19 CAR T-cell therapy, we plan~~ to ~~evaluate~~receive ~~CRG-022 in additional indications~~treatment, ~~including~~not all patients ~~with LBCL~~ who are ~~CAR~~treated Tachieve ~~naïve~~durable results. For example, as ~~well~~shown asin Bthe ZUMA-~~cell~~1 ~~acute~~clinical ~~lymphocytic~~trial ~~leukemia (B-ALL).~~

We are building upon the development of CRG-022 by leveraging our proprietary platform technologies, including our CD2 platform, to enable the development of multi-specific and multi-functional cancer product candidates designed to improve outcomes and survival by addressing multiple mechanisms of resistance and other unmet needs. Our most advanced preclinical program, CRG-023, incorporates a tri-specific CAR to address either tumor antigen loss (e.g., CD19) or low-density antigen expression, loss of co-stimulation (e.g., CD2/CD58) and lack of T-cell persistence. CRG-023 is designed to target tumor cells with three B-cell antigen targets, CD19, CD20 and CD22. This product candidate also integrates a CD2 co-stimulatory domain into the tri-specific CAR T cell to counter a target-independent mechanism, the downregulation of CD58 (the ligand of the CD2 co-stimulatory receptor), that leads to resistance to CAR T cells and other immune therapies.

The strength and quality of a T-cell response is dependent not only on cognate antigen recognition, but also on co-stimulation, which involves interaction of one or more co-stimulatory receptors on T cells, such as CD2, with their cognate ligands (a molecule that typically interacts with a receptor) expressed on the surface of tumor cells, such as CD58. Tumor cells can escape CAR T-cell destruction by downregulating the expression of ligands for the

Table of Contents

~~co-stimulatory~~for ~~receptors.~~Yescarta ~~Alteration of CD58 expression is associated with poor prognosis~~ in LBCL patients with ~~LBCL~~two ~~and~~or ~~leads~~more toprior ~~lack~~lines of ~~response~~therapy, toapproximately ~~CD19 CAR T cells. Approximately 25~~60% of LBCL patients ~~that~~treated ~~are~~with ~~eligible~~the ~~for~~CD19 CAR T-cell therapy ~~have~~had ~~mutated~~their or absent CD58 and up to 67% have decreased expression of CD58. In addition, a study published in June 2023 demonstrated that aberrant CD58 expression can also occur in a wide range of hematologic malignancies including Hodgkin and non-Hodgkin lymphomas (both B-cell and T-cell), including de novo disease, ~~suggesting~~relapse aor ~~potential~~progress ~~utility~~within ~~for~~24 ~~our CD2 platform technology to mitigate immune escape in future therapies~~months. Our CD2 platform creates constructs that couple CD2 signaling directly to CAR activation, thereby engaging CD2 signaling even in the presence of tumor cells that have reduced aberrant CD58 expression. We leveraged this platform to uniquely differentiate CRG-023.

ABarriers ~~second~~that ~~platform~~limit ~~technology,~~the ~~which~~impact ~~we refer to as STASH, is designed to enable multiplex engineering~~ of aapproved ~~variety of immune cell types. This platform could enable us to incorporate multiple transgene therapeutic “cargo” designed to enhance~~ CAR T-cell ~~persistence, as well as to help safeguard against tumor resistance and T-cell exhaustion.~~therapies

~~Despite~~Barriers the curative potential of cell therapies, we believe these treatments are not readily available to many of the patients who could benefit from them due to manufacturing challenges, supply constraints, unpredictable turnaround time and other logistical challenges. With the goal of addressing these issues, our team developed the intended commercial manufacturing process and analytical control strategy for CRG-022, while demonstrating comparability of the final drug product to that ~~produced~~limit by the ~~process~~impact ~~used in the Stanford Phase 1 clinical trial. Specifically, our CRG-022 IND included our comprehensive data supporting the comparability~~ of ~~our~~existing ~~intended~~autologous ~~commercial~~CAR manufacturing process to the process used in the Stanford Phase 1 clinical trial, as well as qualified testing methods for the lentiviral vector and cell product, including a potency assay. We developed the intended commercial process prior to initiating our potentially pivotal Phase 2 clinical trial in order to potentially minimize the need for process or analytical changes postT-pivotal clinical trial. In addition, we believe our strategy reduces the need for additional complex comparability studies post-pivotal clinical trial. Our process is designed to be readily transferrable, which we believe positions us to scale capacity if demand increases. The transferability of the process is enabled by the use of a single-cell ~~processing~~therapies ~~device coupled with automated unit operations and a comparability framework.~~include:

•

~~Our~~Target-based ~~programs~~resistance. The lack of target antigen expressed or the loss of target antigen when placed under therapeutic selective pression can facilitate disease relapse or progression. Loss of CD19 expression has been observed following CD19 CAR T treatment. Loss of CD20 expression has been observed following CD20-targeted therapy. Lack of CD22 expression has also been reported for some LBCL patients.

•

~~Our~~Heterogeneity ~~initial focus is to treat patients with high unmet need~~ and ~~poor~~dysfunction ~~survival~~of ~~outcomes who develop resistance to current guideline recommended cancer therapies~~T-cells. InThe ~~the~~health ~~future,~~and wequality ~~aim to treat patients at earlier stages~~ of ~~disease~~patient toT ~~help~~cells, ~~prevent~~which ~~resistance~~are ~~from~~required ~~emerging~~for ~~in order to extend~~ the ~~durability~~generation of ~~response.~~autologous ~~The figure below summarizes our pipeline of wholly owned~~ CAR T~~-cell~~ ~~therapies~~product, ~~designed~~have tobeen ~~address~~associated ~~key~~with ~~mechanisms~~patient ofresponse ~~resistance~~outcomes ~~for~~across ~~the~~several ~~treatment~~third-party ofclinical ~~a variety of cancers~~studies.

•

~~Based~~Immunogenicity onof ~~data~~CAR ~~from~~constructs. ~~the~~The ~~Phase~~majority 1of ~~clinical~~approved ~~trial~~CAR ~~conducted~~T-cell bytherapies ~~Stanford~~incorporate ~~and~~the ~~pending~~scFv ~~data~~portion ~~from~~of ~~our~~murine ~~ongoing~~antibodies ~~Phase~~as 2the ~~clinical~~antigen-recognition ~~trial~~domain. inThese ~~R/R~~CAR ~~LBCL~~domains –are ~~post~~antigenic ~~CD19~~and ~~CAR~~may T,elicit weboth ~~are~~a inhumoral ~~discussions~~and ~~with~~cellular ~~the~~immune ~~FDA~~response onin ~~the~~patients ~~initiation~~that ofcould atheoretically ~~Phase~~lead 2to ~~program~~the inclearance ~~LBCL~~of –therapeutic CAR T ~~naïve~~cells, ~~without~~limiting ~~completing~~cell ~~earlier~~expansion, ~~clinical~~persistence ~~trials~~and ~~in LBCL – CAR T-naïve patients~~efficacy.

•

Manufacturing challenges with autologous CAR T-cell therapies. Autologous CAR T-cell therapies require one manufacturing batch per patient which creates unique supply, capacity and logistical challenges. Manufacturing capacity of the approved CAR T-cell products has struggled to meet the demand for these therapies, while also meeting the need for maintaining rapid turn-around-time. We anticipate that this issue will persist as more patients become candidates for CAR T-cell therapy and more complex CAR T cells containing multiple genetic constructs advance into clinical development.

Barriers that limit the impact of allogeneic CAR T-cell therapies include:

•

Immune-based rejection associated with allogeneic CAR T-cell therapy. The patient’s immune system identifies the donor, allogeneic CAR T cells as foreign and mounts an immune response against them. T cells and B cells may recognize the allogeneic CAR T cells as foreign due to differences in major histocompatibility complex (MHC) molecules, leading to the targeted elimination of the CAR T cells. Allogeneic rejection may therefore limit CAR T persistence and influence the ability to achieve meaningful, durable clinical response outcomes.

•

Gene-editing-based manufacturing challenges. Off-Target Effects: CRISPR-Cas editing can sometimes induce unintended genetic alterations at sites other than the target. Cost and Manufacturing Complexity: The use of CRISPR-Cas in CAR T cell production requires sophisticated, high-precision techniques that increase the cost and complexity of manufacturing, may result in heterogenous edits if multiplexed editing is required and poses logistical challenges for widespread clinical use. The gene editing processes may also impact the quality of the CAR T cells based on methods used for delivering RNP complexes.

Our solution: next generation of potential CAR T-cell therapies

We are developing a portfolio of product candidates designed to expand the number of patients that can benefit from CAR T-cell therapies by addressing several of the limitations of currently approved CAR T-cell therapies. Our solution includes:

•

Directing CAR T cells toward alternate targets. Therapies that target single tumor antigens, such as CD19, can be rendered ineffective by genetic or non-genetic changes that diminish the expression of these targets. We are developing multi-specific CAR T-cell product candidates, starting with CRG-023, that are designed to recognize tumors that express any of the CD19, CD20 and CD22 antigens, thereby limiting potential antigen loss as a mechanism of resistance.

Table of Contents

•

~~Our~~Delivering ~~lead~~multiple, ~~program~~therapeutically beneficial transgene “cargos” from a single vector. Therapies that target single tumor antigens, such as CD19, can be rendered ineffective by changes that diminish the expression of these targets. Our product candidate CRG-~~022~~023, is a tri-specific CAR T-cell targeting three B-cell lineage antigens (CD19, CD20, and CD22) via three separately expressed CARs on a single vector. The construct enables the recognition of tumors that express any one of the CD19, CD20, and CD22 antigens, thereby limiting potential loss of antigen expression (i.e., “antigen escape”) as a mechanism of resistance. Thousands of constructs were screened to identify a vector configuration that enabled effective CAR expression and anti-tumor activity. Finally, intentional engineering and optimization of the final construct was completed to limit onset of functional T-cell exhaustion and to sustain performance across a range of antigen expression profiles in order to prevent antigen escape.

•

~~CRG-022~~Using ~~is an autologous CAR T~~fully-~~cell~~human ~~product~~binders ~~candidate that targets CD22, a B-cell specific antigen that has been reported~~ to bereduce ~~expressed in 81% to 100% of diffuse large B~~anti-~~cell~~CAR ~~lymphoma (DLBCL) patients~~immunogenicity. ~~Importantly,~~Our ~~CD22~~CAR ~~expression~~T isproduct ~~usually~~candidates ~~retained~~are ~~following~~all ~~loss~~constructed ofwith ~~CD19~~human ~~antigen~~binders, ~~expression~~thereby inreducing ~~patients~~the ~~who~~risk ~~become~~for ~~resistant to CD19~~ anti-CAR ~~T-cell~~immune ~~therapy~~responses. ~~Beyond~~For ~~targeting CD22,~~ CRG-~~022 is also designed to incorporate several key features including its short linker~~023, awe ~~single-chain~~conducted ~~variable~~an ~~fragment~~extensive ~~(scFv)~~new ~~targeting~~human abinder ~~membrane-proximal~~campaign ~~epitope~~for onCD19 ~~CD22~~ and ~~its~~CD20 ~~fully~~and ~~human~~selected ~~composition,~~binders ~~which,~~having ~~respectively,~~optimal ~~are~~activity ~~designed~~in toa ~~improve efficacy by increasing dimerization, minimizing resistance and reducing immunogenicity. Additionally, the~~ CAR ~~incorporates the 4-1BB co-stimulatory domain, which has been shown to improve long-term persistence~~format.

•

WeBroadening ~~are~~the ~~initially~~availability ~~focused~~of onsafe ~~developing~~and ~~CRG-022~~effective tocell ~~treat~~therapy. ~~patients~~Our ~~with~~novel ~~LBCL~~allogeneic ~~whose~~platform ~~disease~~ is ~~R/R~~a ~~following~~universal ~~CD19~~vector solution designed to limit immune-based rejection of allogeneic CAR T~~-cell~~ ~~therapy~~cells and enable durable response. ~~LBCL~~The isplatform comprises a ~~composite~~universal ofvector ~~different~~with ~~subtypes~~multiple transgene “cargos” to limit T and ~~includes~~NK ~~DLBCL,~~rejection ~~high-grade~~and ~~B-cell~~downregulate ~~lymphomas,~~TCR ~~primary~~expression. ~~mediastinal~~Our ~~B-cell~~lead ~~lymphoma~~candidate ~~(PMBCL)~~vector expresses protein and ~~grade~~shRNA 3Btransgenes orthat ~~transformed~~target ~~follicular~~the ~~lymphoma~~downregulation ~~(FL).~~of ~~LBCL~~MHCI, isMHCII, ~~the~~co-stimulatory ~~most~~ligand ~~common~~and ~~aggressive~~TCR ~~lymphoid~~while ~~malignancy~~also inexpressing ~~the~~a ~~United~~novel, ~~States~~tethered CD8 inhibitor to limit T and ~~Europe,~~NK ~~accounting~~cell-based ~~for~~allogeneic ~~approximately~~rejection ~~30%~~and tothe ~~40%~~occurrence of ~~all~~GvHD. ~~non-Hodgkin~~Importantly, ~~lymphomas~~the ~~(NHL)~~universal, aallogeneic-enabling ~~disease~~vector ~~with~~is ~~over~~intended ~~80,000~~to pair with new ~~diagnoses~~or aclinically ~~year.~~established ~~Many~~CAR ~~DLBCL~~vectors, ~~patients~~while ~~(approximately~~leveraging ~~30%~~existing toautologous ~~50%)~~drug doproduct ~~not~~processes ~~respond~~resulting toin oran ~~relapse~~off-the-shelf ~~after~~allogeneic ~~initial~~CAR ~~treatments~~T product designed to limit rejection, ~~and~~promote ~~then~~safety, ~~become~~improve ~~eligible~~the ~~for~~starting ~~CAR~~quality of T~~-cell~~ ~~therapy~~cells, ~~targeting~~and ~~CD19~~maintain comparable CAR-mediated activity.

•

~~Since~~Thoughtful ~~2017~~Chemistry, ~~the~~Manufacturing ~~FDA~~and ~~has~~Control ~~approved~~(CMC) ~~three~~Strategy: ~~autologous~~Our ~~CD19~~CMC ~~CAR~~strategy ~~T-cell products~~ for ~~the~~CRG-023 ~~treatment~~focused ofon ~~LBCL,~~designing ~~which~~a ~~generated~~process ~~$1.3~~and ~~billion~~analytical inmethods ~~sales~~suitable infor ~~DLBCL~~a inPhase ~~2022~~1 indose ~~the~~escalation ~~United~~and ~~States/EU4/UK~~dose ~~alone~~expansion ~~and~~study. ~~are~~Our ~~projected~~manufacturing toprocess ~~grow~~for toCRG-023 ~~$2.6~~focused ~~billion~~on ~~and~~producing ~~$3.3~~an ~~billion~~optimal ~~sales~~drug ~~annually~~product by ~~2026~~minimizing ~~and~~cell ~~2030,~~population ~~respectively,~~doublings ~~according~~for tothe ~~data~~target ~~published~~dose byand ~~Clarivate~~optimizing ~~Disease~~expansion and ~~Landscape~~harvest ~~Forecasting (NHL, CLL) 2023~~step. ~~CD19~~The ~~CAR~~process ~~T-cell~~is ~~therapies~~designed ~~can~~to ~~induce~~start ~~long-term~~with ~~remission~~cryopreserved inapheresis ~~some~~material ~~patients,~~(with ~~however,~~option asto ~~shown~~start inwith ~~the~~fresh ~~ZUMA-1~~apheresis) ~~clinical~~and ~~trial~~to ~~for~~be ~~Yescarta~~flexible insuch ~~LBCL~~that ~~patients~~the ~~with~~entire ~~two~~range orof ~~more~~doses ~~prior~~allowed ~~lines~~in ofthe ~~therapy,~~clinical ~~approximately~~protocol ~~60%~~can ofbe ~~LBCL~~supported ~~patients~~by ~~treated~~a ~~with~~single ~~the~~process. ~~CD19~~The ~~CAR~~result ~~T-cell~~is ~~therapy~~a ~~had~~portable, ~~their~~internally ~~disease~~developed ~~relapse~~process orand ~~progress~~control ~~within~~strategy ~~24 months~~(i.e., Asrelease ~~more~~methods) ~~patients~~that ~~receive~~supported ~~these~~a ~~therapies,~~rapid ~~driven~~process byand ~~recent~~method ~~approvals~~transfer into ~~earlier~~our ~~lines~~external ofCDMO ~~therapy~~partner. ~~and~~The ~~geographic~~CRG-023 ~~expansion,~~process ~~the~~uses ~~unmet~~lentiviral ~~need~~vector ~~for~~produced ~~those~~using ~~who~~modern dosuspension ~~not~~cell ~~experience~~culture aplatform ~~durable~~that ~~response~~ is ~~growing.~~adopted ~~There~~to isuse ~~currently~~our nointernally ~~broadly~~developed ~~recognized~~and ~~standard~~optimized ofplasmids ~~care~~ for ~~patients~~the ~~with~~transgene. ~~LBCL~~The ~~whose~~combination ~~disease~~of ~~does~~optimized ~~not~~vector ~~respond~~and tocell ormanufacturing ~~relapses~~process ~~following~~is ~~treatment~~designed ~~with~~to ~~CD19~~yield ~~CAR~~a ~~T-cell~~drug ~~therapies.~~product ~~The~~expressing ~~prognosis~~all ~~for~~three ~~this~~antigens ~~patient~~on ~~population~~the issurface ~~poor with a median OS~~ of ~~approximately~~the ~~five~~T ~~to eight months~~cell.

ToOur help address the significant unmet need in this patient population, we are developing CRG-022, of which the underlying autologously derived CAR we exclusively licensed from the NCI. This CAR has been included in CD22 CAR T-cell product candidates dosed in more than 120 patients in several clinical trials conducted by Stanford and the NCI. The Stanford Phase 1 clinical trial enrolled 41 patients with LBCL whose disease was R/R to CD19 CAR T-cell therapy, including one patient whose disease was CD19-negative and was CD19 CAR T naïve. The primary endpoints for the Stanford clinical trial were (1) assessing manufacturing feasibility; (2) evaluating the severity of adverse events and dose limiting toxicities (DLT); and (3) establishing the maximum tolerated dose and recommended Phase 2 dose of CRG-022. Secondary endpoints included ORR, progression-free survival and overall survival. One patient withdrew from the clinical trial prior to leukapheresis and two patients did not receive CRG-022 due to an inability to manufacture given limited patient T cells, resulting in a 95% successful manufacturing rate (38 of 40 patients) with a median turnaround time of 18 days. In the 38 LBCL patients who received CRG-022, an ORR and a CR rate of 68% and 53%, respectively, was achieved as of the November 4, 2023 cutoff date. With a median follow-up of 27.3 months, for Dose Level 1, the median OS had not been reached as of the data cut-off. For Dose Level 2, the median OS was 14.1 months. As of the November 4, 2023 cutoff date, at Dose Level 1 (the dose we are using for our ongoing Phase 2 clinical trial), 73% of patients who achieved a CR maintained the CR for at least 12 months (29 patients were treated at Dose Level 1; 15 achieved a CR, 11 of whom maintained a CR for ≥ 12 months), which we believe suggests favorable durability. At Dose Level 2, 9 patients were treated with 5 patients achieving a CR. Four of these 5 patients had maintained a CR for 12 months or longer as of the data cut-off.pipeline

~~CRG-022~~While ~~has~~we ~~been~~are ~~generally~~evaluating ~~well-tolerated~~strategic ~~as of the cutoff date~~options, ~~with~~we ~~only~~continue ~~one~~to ~~patient~~focus aton ~~Dose~~designing, ~~Level~~engineering ~~2 experiencing Grade 3 or higher CRS~~ and nodeveloping ~~patients~~next ~~experiencing Grade 3 or higher ICANS. In addition~~generation, ~~the~~potentially ~~most~~curative ~~common~~cell ~~adverse~~therapies ~~events~~for ofpeople ~~Grade~~with 3cancer. orOur ~~higher~~pipeline ~~during~~includes ~~treatment~~both ~~were~~autologous ~~neutropenia that was observed in all treated patients, anemia that was observed in 63% of treated patients,~~ and thrombocytopenia that was observed in 63% of treated patients. All of these adverse events are commonly observed in other therapeutics in this class. Three deaths in the trial were deemed by investigators to be possibly related to study drug at the highest dose level. Further, two

Table of Contents

~~dose~~allogeneic ~~limiting~~programs ~~toxicities~~and ~~were~~platforms ~~observed~~designed atwith the ~~second~~goal ~~dose level, leading to de-escalation back to the first dose level. Given this result, it was determined that the Phase 2 optimal dose was the first dose level~~ of 1expanding xpatient ~~106~~benefit ~~transduced CRG-022 cells per kg. Based on this data, we believe that CRG-022 may provide another option~~ and ~~opportunity to achieve a durable and complete response in~~ the ~~growing~~availability ~~post~~of ~~CD19~~ CAR T-cell therapy ~~patient population~~.

We received feedback from the FDA regarding the design of our potentially pivotal multi-center Phase 2 clinical trial, which we initiated in August 2023, to evaluate the safety and efficacy of CRG-022 in patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. Enrollment in the Phase 2 clinical trial is ongoing and, in September 2023, we dosed the first patient. As of January 8, 2024, we had dosed 9 patients in the Phase 2 clinical trial. We expect to report interim results from this Phase 2 clinical trial in the first half of 2025.

In addition to our initial focus on R/R LBCL, we are also evaluating the development of CRG-022 in additional indications, including LBCL in patients who are CAR T naïve, as well as B-ALL. In a Phase 1 clinical trial conducted by the NCI in children and young adults with R/R B-ALL with CD22 expression, treatment with CD22 CAR T-cell therapy using the same CAR as CRG-022 led to a 70% CR rate.

Our tri-specific program, CRG-023

~~Our~~While ~~most~~transformative ~~advanced~~advances ~~preclinical~~have ~~program,~~been ~~CRG-023,~~made ~~incorporates~~by 3commercially ~~unique~~available ~~CARs,~~CAR ~~designed~~T-cell totherapies, ~~address~~known ~~tumor~~causes ~~antigen~~of ~~loss~~relapse ~~and~~such ~~our~~as ~~CD2 platform technology to address~~ loss of ~~co-stimulatory CD58. CRG-023 is designed to target~~ tumor ~~cells with three B-cell~~ antigen ~~targets~~expression, ~~CD19,~~loss ~~CD20~~of ~~and CD22. Leveraging our CD2 platform, CRG-023 integrates a CD2~~ co-~~stimulatory~~stimulation ~~domain into one of the CAR designs to counter a target-independent mechanism~~(e.g., ~~the~~via ~~downregulation of~~ CD58 ~~(the ligand of the~~ /CD2 ~~co-stimulatory receptor~~signaling), ~~that leads to resistance to CAR T cells~~ and ~~other immune therapies. CD58 alteration is associated with poor prognosis in LBCL and leads to lack of response to CD19 CAR~~ T ~~cells. Approximately 25% of LBCL patients that are eligible for CAR T-~~cell ~~therapy~~exhaustion ~~have~~continue ~~mutated or absent CD58 and up~~ to ~~67%~~limit ~~have~~patients ~~decreased~~from ~~expression~~achieving ~~of CD58. In addition,~~ a ~~study~~durable ~~published~~complete in June 2023 in Modern Pathology demonstrated that aberrant CD58 expression can also occur in a wide range of hematologic malignancies including Hodgkin and non-Hodgkin lymphomas (both B-cell and T-cell), including de novo disease, suggesting a potential utility for our CD2 platform technology in future therapies to mitigate immune escape, which occurs when a tumor mutates to escape the patient’s immune systemresponse. Our CD2 platform creates constructs that couple CD2 signaling directly to CAR activation, thereby engaging CD2 signaling even in the presence of tumor cells that have reduced or eliminated CD58 expression. We leveraged this platform to uniquely differentiate our CRG-023 program. We are initiating IND-enabling studies with CRG-023.

~~Our~~Critical ~~strategy~~to the long-term success of CAR T-cell therapies is the ability to increase the number of patients who achieve meaningful therapeutic benefits and for whom these benefits have long-term durability. Achieving this additional breadth will likely require approaches that target more than one tumor antigen at a time. This would, we believe, both expand the pool of eligible patients and reduce the frequency of relapse.

~~Our~~CRG-023 ~~mission~~ is tothe ~~outsmart~~first ~~cancer~~known byCAR ~~developing~~T ~~the~~product ~~next~~candidate ~~generation~~with ofa ~~transformational~~tri-cistronic ~~CAR~~construct Ttargeting three B-cell ~~therapies~~lineage toantigens ~~impact~~(CD19, ~~patients~~CD20, ~~worldwide~~and CD22) via three separately expressed CARs, each with a distinct co-stimulatory domain. For the ~~aim~~CD19 and CD20 CARs, new scFv binders were selected for optimal CAR-mediated activity following an extensive antibody discovery and screening campaign involving thousands of ~~becoming~~constructs (Figure 10). Each CAR has a ~~fully~~CD3ζ ~~integrated,~~signaling ~~leading~~domain ~~cell~~and ~~therapy~~a ~~company~~distinct co-stimulatory domain. ~~Our~~The ~~strategy~~CD20 toCAR ~~achieve~~design ~~this~~incorporating ~~goal~~a CD2 co-stimulatory domain was informed by observations that CD58 expression loss is asassociated ~~follows:~~with poor response outcomes to CD19 CAR T-cell therapy. (Figure 11)

~~Build~~The aiterative ~~next~~engineering ~~generation~~of ~~CAR~~the ~~T-cell~~construct ~~company~~allowed ~~focused~~for onthe ~~developing~~selection ~~and~~of ~~delivering~~the ~~potentially~~optimal ~~curative~~co-stimulatory ~~therapies~~domain ~~to more patients~~configuration. ~~Our~~Intentional ~~programs,~~engineering ~~platform technologies~~ and ~~manufacturing~~optimization ~~strategy~~of ~~are designed to address~~ the ~~problems~~final ofconstruct ~~cancer~~sought ~~resistance mechanisms and unreliable supply. We are developing technologies that incorporate multiple transgene therapeutic “cargo”~~ to ~~potentially~~limit ~~extend~~onset ~~persistence~~ of ~~our~~functional ~~CAR~~ T-cell ~~therapy~~exhaustion ~~candidates~~and ~~with~~to ~~the~~sustain ~~goal~~performance ofacross ~~achieving~~a ~~durable~~range ~~responses~~of ~~that~~antigen ~~are~~expression ~~curative~~profiles ~~for more cancer patients. We are also executing a comprehensive manufacturing strategy~~ in anorder ~~effort~~ to ~~address~~prevent ~~supply~~antigen ~~issues and increase availability to patients~~escape.

Advance CRG-022 through a potentially pivotal Phase 2 clinical trial for the treatment of patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. Based on the results from the Phase 1 clinical trial being conducted by Stanford, we believe that CRG-022 has the potential to deliver durable anti-tumor responses in patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. In September 2023, we dosed the first patient in a potentially pivotal multi-center Phase 2 clinical trial of CRG-022 in this patient population. We expect to report interim results from this Phase 2 clinical trial in first half of 2025.

Table of Contents

~~Expand~~Figure ~~development of CRG-022 to earlier lines of therapy and additional indications~~10. WeFunctional ~~believe CRG-022 could also be used to treat patients at earlier stages of disease. We anticipate evaluating CRG-022 for LBCL patients who are naïve to CD19~~ CAR ~~T-cell~~optimization ~~therapy.~~through Inextensive ~~addition,~~screening aand ~~CD22 CAR T-cell therapy using the same CAR as CRG-022 demonstrated positive results in a Phase 1 clinical trial conducted by the NCI in pediatric B-ALL, for which we also plan to evaluate CRG-022.~~engineering

~~Leverage~~Figure ~~our intended commercial and readily transferable manufacturing process to help mitigate regulatory hurdles and facilitate predictable and reliable supply for future patients~~11. ~~We believe reliable and predictable supply remains a challenge for existing CAR T~~CRG-~~cell~~023 ~~therapies. In an effort to resolve this, we developed what we believe~~ is ~~a commercially suitable manufacturing process that uses an automated and closed platform that is~~ designed to bedeliver ~~readily transferrable to~~ multiple, ~~manufacturing~~therapeutically ~~facilities.~~beneficial ~~Our~~transgene ~~manufacturing~~“cargo” ~~process includes features that we believe are critical to long-term manufacturing success and supply reliability such as lentiviral vector~~ from ~~suspension platform and introduction of~~ a ~~cryopreservation~~single ~~step for the incoming apheresis material~~vector. We introduced these process features before the initiation of a potentially pivotal Phase 2 clinical trial with the goal of minimizing the need for complex post-pivotal comparability studies. We believe the ease of transferability of our manufacturing process will facilitate rapid scale out by onboarding new manufacturing sites to increase capacity as commercial demand grows.

~~Continue to leverage our platform technologies to advance additional CAR T-cell programs into clinical development.~~ We ~~intend~~have togenerated ~~leverage~~encouraging ~~our~~preclinical ~~platform~~data ~~technologies~~for to engineer additional T-cell products with improved design features. These features include targeting cancer cells via multiple tumor antigens, elements designed to enhance CAR T-cell persistence, as well as safeguarding against tumor resistance and T-cell exhaustion. We are initiating IND-enabling studies with CRG-023, our ~~tri-specific~~product ~~program~~ candidate ~~targeting CD19~~, ~~CD20~~which ~~and~~was ~~CD22.~~showcased ~~This~~in ~~construct~~an ~~incorporates~~abstract ~~our~~and ~~CD2~~a ~~co-stimulatory~~poster ~~platform~~presentation ~~technology~~at ~~with~~ the ~~goal~~2024 ofAmerican ~~counteracting~~Society ~~potential tumor resistance that can emerge from loss or downregulation~~ of ~~CD58~~Hematology ~~expression.~~(ASH) ~~We intend to continue to invest in our platform technologies to develop multi-specific and multi-functional cancer therapies to address cancer resistance and other unmet needs~~Conference.

~~Opportunistically~~Serial ~~pursue~~stimulation ~~strategic~~assays ~~partnerships~~allow ~~and~~us ~~collaborations~~ to ~~maximize~~assess the ~~value~~durability of ~~our~~CAR ~~pipeline~~T ~~and~~cells ~~platform~~when ~~technologies~~repeatedly challenged with antigen expressing tumor cells. WeIn ~~currently~~our ~~have~~preclinical ~~exclusive~~studies, ~~rights~~data todemonstrated ~~develop~~CRG-023 ~~and~~maintained ~~commercialize~~impressive ~~our~~anti-tumor ~~product~~activity ~~candidates,~~for ~~and~~30 days relative to ~~utilize~~mono-specific ~~our~~CAR ~~platform~~T ~~technologies~~controls included. InThis durable activity was further supported by the ~~future~~observation that both CD4+ and CD8+ CRG-023 CAR T-cells had sustained expression of surface markers associated with a less differentiated, wemore ~~may~~central ~~enter~~memory-like ~~into~~phenotype ~~other~~(Figure ~~collaborations~~12). ~~where~~CAR weT-cells ~~believe~~sustained ~~there~~durable isin anvitro ~~opportunity~~anti-tumor toactivity ~~accelerate~~throughout ~~the~~repeated ~~development~~tumor ~~and~~challenge ~~commercialization~~with tumor cells expressing all or any one of ~~our~~the ~~product~~three ~~candidates~~antigens ~~while~~(Figure ~~allowing~~13). usWhen compared to ~~retain~~multiple ~~meaningful~~benchmark ~~rights~~CARs inthat ~~major~~were ~~markets~~assessed, superior tumor control was observed without increased cytokine secretion and while sustaining a less effector-differentiated phenotype. WeAdditionally, ~~may~~the ~~also~~data ~~seek~~showed tothat ~~opportunistically~~CRG-023 ~~acquire~~T orcells durably cleared tumor cells in models mimicking antigen escape in contrast to mono-~~license~~CAR ~~product~~T ~~candidates~~cells orsuch ~~technologies~~as FMC63-containing CD19 CAR T cells (Figure 14). Finally, in vivo studies showed that ~~are~~CRG-023 ~~synergistic~~CAR ~~with~~T ~~our~~cells ~~cell~~were ~~therapy~~highly ~~discovery~~active and ~~development~~cleared ~~efforts.~~Raji lymphoma tumor cells

CAR T cells – an emerging class of immunotherapy with curative potential

Chimeric antigen receptor (CAR) T cells are T cells engineered to express synthetic receptors capable of specifically recognizing tumor antigens and activating the T cell. Binding of a CAR to its cognate antigen results in stimulation of intracellular signals and activation of T cell activity. There have been six engineered T-cell therapies approved by the FDA for the treatment of cancer. Each of these therapies has been able to deliver therapeutic benefit to patients who have exhausted all other treatment options, and for some patients, these benefits can extend for years.

However, the number of cancers with effective CAR T-cell therapies is limited and the total number of patients who have received these therapies represents only a small fraction of potentially eligible cancer patients. Today, five years after CAR T cells were first approved to treat non-Hodgkin’s lymphoma (NHL)and acute lymphocytic leukemia (ALL), over 40,000 U.S. patients may be eligible to be treated by CD19 CAR T-cell therapies, but fewer than 3,800 patients are expected to receive such treatment in 2023. Some patients are deemed ineligible to or do not receive these therapies due to associated toxicity risk, underlying comorbidities, the time needed to manufacture treatment or lack of access to specialized treatment centers. In patients who do manage to receive treatment, not all patients who are treated achieve durable results. For example, as shown in the ZUMA-1 clinical trial for Yescarta in LBCL patients with two or more prior lines of therapy, approximately 60% of LBCL patients treated with the CD19 CAR T-cell therapy had their disease relapse or progress within 24 months.

Table of Contents

~~Barriers~~expressing ~~that~~the ~~limit~~three target antigens in a dose-response manner and down to the ~~impact~~lowest ofdose ~~approved~~tested (1x105 CAR+ ~~T-cell~~cells/mouse) ~~therapies~~(Figure 15).

~~There~~Figure ~~are~~12. aSerial ~~number~~Stimulation ofwith ~~barriers~~Raji ~~that~~(CD19+, ~~limit~~CD20+, ~~the impact of existing CAR T-cell therapies including:~~CD22+)

~~Target-based~~Figure ~~resistance~~13. ~~A frequent cause of resistance to CD19~~ CAR T-~~cell~~023 ~~therapies~~Sustained ~~in patients with B~~Anti-~~ALL and LBCL, is the low level of expression of CD19 or the loss of CD19 antigenicity on~~ tumor ~~cells.~~Function ~~There~~When ~~are~~Activated aBy ~~number~~Single of mechanisms that can lead to loss of CD19 antigenicity, such as mutations, splicing variations, antigen glycosylation and antigen-masking, but the end result is the same: the lack of CD19 antigenicity allows tumor cells to escape targeting by CD19 CAR T cells.Antigen

Non-target-based resistance. The strength and quality of a T-cell response is dependent not only on cognate antigen recognition, but also co-stimulation. Tumors evolve to escape CAR T-cell destruction through the downregulation of cognate ligands for co-stimulatory signaling molecules. For example, CD58 is the ligand of the CD2 co-stimulatory receptor. Approximately 25% of LBCL patients who are eligible for CAR T-cell therapy have mutated or absent CD58 and up to 67% have decreased expression of CD58. In addition, a study published in June 2023 demonstrated that aberrant CD58 expression can also occur in a wide range of hematologic malignancies including Hodgkin and non-Hodgkin lymphomas(both B-cell and T-cell), including de novo disease. CD58 alteration and corresponding lack of CD2-mediated co-stimulation are associated with poor prognosis in LBCL and lead to decreased progression free survival (PFS) benefit to CD19 CAR T cells.

Immunogenicity of CAR constructs. The majority of approved CAR T-cell therapies incorporate the scFv portion of murine antibodies as the antigen-recognition domain. These domains elicit both humoral and cellular immune responses in patients, which can lead to increased clearance of therapeutic CAR T cells, limiting cell expansion and persistence. This anti-murine immune response increases the likelihood of tumor relapse and can lower the efficacy of CART cells upon reinfusion.

Our solution: next generation of potential CAR T-cell therapies

Directing CAR T cells toward alternate targets. Therapies that target single tumor antigens, such as CD19, can be rendered ineffective by genetic or non-genetic changes that diminish the expression of these targets. Our most advanced product candidate, CRG-022, is designed to address an alternate target, CD22, that is nearly always expressed on cancerous B cells, to kill B-cell tumors, including those that have become resistant to CD19-based therapies. We are also developing multi-specific CAR T-cell product candidates, starting with CRG-023, that are designed to recognize tumors that express any of the CD19, CD20 and CD22 antigens, thereby limiting potential antigen loss as a mechanism of resistance.

Addressing common mechanism of non-target-based resistance. In addition to antigen downregulation or loss, resistance to immune therapies, including CAR T cells, can develop through the loss of co-stimulatory signaling, such as tumor cells down regulating CD58 expression. Because these mechanisms are not antigen-specific, loss of co-stimulation can lead to broad suppression of immune therapies. We are working to address loss of co-stimulatory ligands such as CD58, by creating CAR T cells that can induce CD2 co-stimulatory signaling by a tumor antigen irrespective of potential CD58 downregulation or loss on tumor cells.

Using fully-human binders to reduce anti-CAR immunogenicity. Our CAR T product candidates are all constructed with human binders, thereby reducing the risk for anti-CAR immune responses.

Table of Contents

~~Implementing~~Figure ~~robust manufacturing processes~~14. ~~Our~~1:1:1 ~~team~~Raji is applying its extensive experience in the field in an effort to implement manufacturing processes that are highly reliable and readily transferrable to expand capacity, reduce turnaround time and minimize costs of goods. While we are confident in our team’s ability to address these manufacturing challenges, these are complex processes and there could be delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners. Further, while we believe it is more cost-efficient to outsource this manufacturing, it is possible that relying on third parties could result in increased costs that could delay, prevent or impair our commercialization efforts. We have also licensed and further developed technologies specifically designed towards the manufacturing and purification of CAR T cells containing multiple genetic inserts delivered by multiple vectors.CD19KO:CD20KO:CD22KO

~~Our~~Figure ~~programs~~15. ~~and~~B-cell ~~platform~~lymphoma ~~technologies~~Raji mouse model

Our manufacturing process for CRG-~~022~~023 focused on producing optimal drug product profile by minimizing cell population doublings for the target dose and optimizing expansion and harvest step. The process is designed to start with cryopreserved apheresis material (with option to start with fresh apheresis) and to be flexible such that the entire range of doses allowed in the clinical protocol can be supported by a single process. The result is a portable, aninternally ~~autologous~~developed ~~CD22~~process ~~CAR~~and Tcontrol strategy (i.e., release methods) that supported a rapid process and method transfer to our external CDMO partner. The CRG-~~cell~~023 ~~product~~process ~~candidate~~uses lentiviral vector produced using modern

We are developing CRG-022, an autologous CD22 CAR T-cell therapy, to be a safe, effective and durable therapy with a manufacturing process designed to increase availability by providing consistent and reliable supply. CRG-022 is manufactured using a novel CAR designed to address resistance mechanisms by targeting CD22, an alternate antigen that is expressed in a vast majority of B-cell malignancies. Our initial focus is on developing CRG-022 for the treatment of patients whose disease is R/R to CD19 CAR T-cell therapies. In September 2023, we dosed the first patient in a potentially pivotal multi-center Phase 2 clinical trial to evaluate the safety and efficacy of CRG-022 in patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. As of January 8, 2024, we had dosed 9 patients in the Phase 2 clinical trial. We expect to report interim results from this Phase 2 clinical trial in the first half of 2025.

LBCL disease background

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy in adults accounting for a projected 80,550 cases and 4.1% of all new cancer cases in 2023 in the United States. An estimated 20,180 people in the United States will die from this disease in 2023 accounting for 3.3% of all cancer-related deaths. The majority of NHL cases are of B-cell origin and can be further subdivided into aggressive and indolent lymphomas, each associated with different clinical outcomes and prognoses. LBCLs encompass aggressive subtypes including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphomas, primary mediastinal B-cell lymphoma (PMBCL) and grade 3B or transformed follicular lymphoma (FL).

Current treatment options

First-line treatment regimens for LBCL include CD20-targeted monoclonal antibodies and anthracycline-containing chemotherapy regimens administered in six to eight cycles. Many DLBCL patients (approximately 30% to 50%) do not respond to or relapse after initial treatments, and then become eligible for CAR T-cell therapy targeting CD19. For decades, the standard approach to treat patients with R/R disease had been salvage chemotherapy followed by high dose platinum-based therapy and autologous stem cell transplant (ASCT). However, this treatment is associated with significant toxicities and approximately half of patients are considered not suitable due to age or other comorbidities. Of the remaining patients considered eligible for ASCT, an additional 50% to 60% do not receive ASCT due to their disease showing no sensitivity to salvage chemotherapy.

Over the past six years, FDA has approved three autologous CD19 CAR T-cell products for the treatment of LBCL. These are axicabtagene ciloleucel (marketed as Yescarta by Kite/Gilead); tisagenlecleucel (marketed as Kymriah by Novartis); and lisocabtagene maraleucel (marketed as Breyanzi by BMS). These therapies have shown objective response rates (ORRs) of 50% to 73% in LBCL patients who have received two or more prior lines of therapy. More recently, Yescarta and Breyanzi have been approved for use in adult patients with LBCL that is refractory to first-line chemoimmuno therapy or relapses within 12 months. Breyanzi has also been approved for use in adult patients with LBCL whose disease is R/R to first-line chemoimmuno therapy and are not eligible for ASCT due to comorbidities or age. These three approved products generated $1.3 billion of global sales in DLBCL in 2022 in the United States/EU4/UK alone and are projected to generate grow to $2.6 billion and $3.3 billion global sales

Table of Contents

~~annually~~suspension bycell ~~2026~~culture platform that is adopted to use our internally developed and ~~2030,~~optimized ~~respectively,~~plasmids ~~according~~for the transgene. We have produced sufficient GMP vector supply to ~~data~~support ~~published~~our byplanned ~~Clarivate~~dose ~~Disease~~escalation trial and ~~Landscape~~can ~~ForecastingTM~~produce ~~(NHL~~additional vector batches, ~~CLL~~as needed. We optimized the vector consumption needed to manufacture the drug product using an MOI (multiplicity of infection) ~~2023~~set points in the transduction step. The combination of optimized vector and cell manufacturing process yield a drug product designed to express all three antigens on the surface of the T cell. A high-level overview of CRG-023 manufacturing process is shown in Figure 16.

~~While~~The ~~CD19 CAR T cells can induce long~~CRG-~~term~~023 ~~remissions~~lentiviral invector ~~some~~is ~~patients,~~manufactured ~~many~~using ~~patients~~an ~~who~~upstream ~~receive~~process ~~CD19~~consisting ~~CAR~~of Tserum-~~cell~~free ~~therapies experience disease relapse. For example~~transfection, ~~and~~suspension-adapted ashuman ~~depicted~~embryonic inkidney ~~the~~(HEK) ~~figure~~293T ~~below,~~cells inusing ~~the~~a ~~ZUMA~~four-1plasmid ~~clinical trial conducted by Kite in LBCL patients with two or more prior lines of therapy~~system, ~~61% and 68% of patients who received conditioning chemotherapy~~ followed by ~~Yescarta~~downstream ~~ultimately experience disease progression or death at two years and five years, respectively~~purification. AsThis ~~more~~results ~~patients receive these therapies, driven by recent approvals~~ in ~~earlier~~high ~~lines~~yield ~~of therapy and geographic expansion~~(titer), ~~the~~high ~~unmet~~quality ~~need~~vector for ~~those~~use ~~who do not experience a durable response is growing. Translational studies have shown that CD19 antigen loss or downregulation occurs~~ in ~~about~~the ~~30%~~drug toproduct ~~60% of cases~~process.

CRG-023 drug product manufacturing process begins with cryopreserved patient apheresis (with an option to begin with fresh apheresis) (Figure 116). AsThe ~~seen~~participant’s inT ~~the~~cells ~~Phase~~are 2isolated ~~clinical~~from ~~trial~~apheresis and transduced with lentiviral vector expressing CD19. CD20, and CD22 chimeric antigen receptors (~~ZUMA-1~~CARs) and expanded within a relatively short window of ~~Yescarta,~~days. ~~approximately~~At ~~60%~~the ~~percent~~end of ~~patients~~expansion, ~~were~~the ~~observed~~tri-specific toCAR-T ~~not~~cells ~~obtain~~are suspended, formulated, and cryopreserved in the final product container. Drug product attributes are assessed across a ~~long-term~~range ~~benefit~~of ~~from~~assays ~~CD19~~to ~~CAR~~fully ~~T-cell~~inform ~~therapy~~product quality prior to releasing a batch for patient infusion.

~~There~~Figure ~~is currently no standard of care for patients with LBCL whose disease does not respond to or relapses following treatment with CD19 CAR T-cell therapies~~16. ~~Treatments~~Overview ~~with radiotherapy, immunotherapies, targeted therapies and chemotherapy have failed to deliver meaningful improvements in the majority~~ of ~~these patients. Based on third~~CRG-~~party~~023 ~~studies~~drug onproduct ~~patient~~manufacturing ~~registries or real-world outcomes, the median OS for patients with aggressive B-NHL post CD19-directed CAR T failure is approximately five to eight months.~~process

~~Rationale~~In January 2025, our IND for ~~targeting~~CRG-023 ~~CD22~~was allowed to proceed by the FDA, enabling us to initiate clinical development of this product candidate. Given the encouraging pre-clinical data with CRG-023, we intend to conduct a Phase 1 dose escalation study in 3L+ LBCL including CAR T-naïve patients.

~~CD22~~LBCL, isincluding athe ~~B-cell~~diffuse ~~antigen~~LBCL ~~expressed~~(DLBCL) ~~independently~~subtype, ofis ~~CD19~~the onmost ~~benign~~common ~~and~~aggressive ~~malignant~~lymphoid Bmalignancy ~~cells.~~in ~~CD22~~the ~~has~~United ~~been~~States ~~reported~~and toEurope, beaccounting ~~expressed~~for inapproximately 8130% to ~~100~~40% of ~~DLBCL~~all ~~patients and 96% to 100% of B~~non-~~ALL~~Hodgkin ~~patients.~~lymphomas ~~Importantly~~(NHL), ~~CD22~~a ~~expression~~disease iswith ~~usually~~over ~~retained~~80,000 ~~following~~new ~~loss~~diagnoses ofa ~~CD19~~year. ~~expression~~Many inDLBCL patients ~~who~~(approximately ~~become~~30% ~~resistant~~ to ~~CD19~~50%) ~~CAR~~do ~~T-cell~~not ~~therapy.~~respond Asto aor ~~result,~~relapse weafter ~~believe~~initial ~~CD22~~treatments isand anthen ~~attractive~~become ~~target~~eligible for a CAR T-cell therapy ~~for~~targeting ~~patients with B-cell malignancies, including those patients whose disease has relapsed or become refractory to~~ CD19~~-targeted therapies~~.

Since 2017, the FDA has approved three autologous CD19 CAR T-cell products for the treatment of LBCL. Collectively those products generated $2.0 billion in sales in DLBCL in 2024 in the United States/EU5 alone; revenue

Table of Contents

~~Key~~is ~~features~~projected to grow to $3.8 billion in sales annually by 2033, according to data published by Clarivate Disease and Landscape Forecasting (CDLF December 2024) for NHL and CLL. CD19 CAR T-cell therapies can induce long-term remission in some patients, however, as shown in the ZUMA-1 clinical trial for Yescarta in LBCL patients with two or more prior lines of therapy, approximately 60% of LBCL patients treated with the CD19 CAR T-cell therapy relapsed or progressed within 24 months. As more patients receive these therapies, driven by recent approvals in earlier lines of therapy and improvements in patient access, the unmet need for those who do not experience a durable response is growing. We believe broader patient benefit in earlier lines is possible with the development of CRG-~~022~~023. Based on the CDLF 2024 data, we believe the addressable market for CRG-023 in LBCL for 1L+ high risk and 2L+ CAR Naïve patients could reach approximately 43,000 by 2032.

~~Our~~We ~~lead~~plan ~~program,~~to ~~CRG~~leverage proof-~~022,~~of-concept ~~was~~data ~~made using a CAR designed~~ to ~~optimize~~support ~~its~~moving ~~potential~~CRG-023 todevelopment ~~deliver~~into ~~antitumor~~earlier ~~activity~~lines ~~against~~of ~~CD22~~therapy ~~expressing~~and ~~cells.~~B-cell ~~Key~~malignancies ~~characteristics~~for of CRG-~~022~~023. ~~include:~~

~~Membrane~~The ~~proximal~~Phase ~~binding~~1, open-label, multi-center, dose escalation and dose expansion study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CRG-023 and to establish the recommended Phase 2 dose of CRG-023. Dose escalation is expected to begin at a dose level of 25 million cells, which was informed by preclinical data that demonstrated in vivo tumor clearance at low dose levels (Figure 17).

~~CD22~~Enrollment isfor ~~a protein expressed on~~ the ~~surface~~Phase of1 Bstudy, ~~cells~~including ~~that~~CAR ~~has an extracellular domain comprised of seven immunoglobulin domains and twelve putative N~~T-~~linked~~naïve ~~glycosylation sites. Antibodies have been developed against CD22 and at least three anti-CD22 product candidates have been tested in~~ patients ~~with B-cell malignancies. However~~, ~~these~~is ~~three~~expected ~~antibodies~~to ~~all~~initiate ~~target~~by the ~~N-terminal~~second ~~domain~~quarter of ~~CD22, a region of CD22 that may not be ideal for CAR T-cell activation~~2025. ~~For~~We ~~example,~~plan ~~a third-party study using mesothelin-targeting antigen-binding domains found that membrane-proximal binding led~~ to ~~improved~~leverage ~~CAR~~our Testablished ~~signaling,~~manufacturing ~~potentially because the membrane distal regions interact with other extracellular elements~~ and ~~also~~supply ~~because~~chain ~~targeting~~infrastructure ~~antigen regions close~~ to ~~the~~accelerate ~~membrane~~readiness ~~increases~~for ~~the~~our ~~likelihood~~Phase ~~that~~1 ~~intracellular co-stimulatory domains will be brought into close proximity~~study.

~~The~~Figure ~~gene encoding CD22 contains 15 exons and third-party studies have found multiple splice variants of the CD22 mRNA transcript that encode alternative forms of the protein~~17. ~~CD22-targeted~~Phase ~~drugs~~1 ~~may~~dose ~~fail~~escalation tostudy bind to certain splice variants lacking their targeted epitope. Splice variants for CD19 represent a common mechanism that leads to resistance to CD19 CAR T-cell therapy. Similarly, splice variants of CD22 have been reported in pediatric B-ALL patients treated with a CD22 CAR created by researchers at the University of Pennsylvania.design

~~CRG-022~~Our ~~was~~allogeneic ~~made~~platform using a CAR that incorporates the antigen-binding domain from an antibody known as m971. This antibody has been shown to bind to the membrane proximal domains of CD22, potentially improving its ability to activate CAR signaling and reducing the potential for splice variants involving the more distal domains, which can lead to resistance.

~~Figure~~We 2continue to learn more about mechanisms that contribute to poor outcomes in cell therapy, to develop strategies to increase availability of these potentially transformative treatments for patients to apply this knowledge to development of our pipeline. ~~The~~We ~~m971~~are ~~antigen-binding~~focused ~~domain~~on ~~incorporated~~solving ~~into~~the current challenges in cell therapy, including improving the ~~CD22~~quality ~~CAR~~of ~~binds~~T tocells aderived ~~membrane~~from ~~proximal~~sick ~~domain~~patients, improving manufacturing reliability and availability of ~~CD22~~autologous cell therapies, and achieving durable efficacy of allogeneic cell therapy products.

Short linker

The CD22 CAR incorporates a synthetic version of the m971 antibody – commonly referred to as a single chain variable fragment (“scFv”)– comprising a truncated polypeptide having both antigen-binding domains of the antibody connected by a flexible peptide linker. The length and sequence of this linker can affect several key performance aspects of CARs, including their expression, oligomeric state, affinity, stability and in vivo activity. The linker used in the CD22 scFv binder in CRG-022 has a short length, a characteristic that has been shown to increase dimerization, which can improve efficacy. By contrast, a CD22 CAR with the same binding domains but a longer linker created by researchers at the University of Pennsylvania was found to have reduced activity both in vitro and in two clinical trials. From two trials in six children and three adults whose disease was R/RCD22+ B-cell ALL, the complete remission

Table of Contents

~~rate~~Developed ~~was~~with ~~50%~~sophisticated ~~(four~~design ~~out~~and ofengineering, ~~eight~~CARGO’s ~~evaluable~~novel ~~patients)~~allogeneic ~~and~~platform ofis ~~the~~a ~~four~~universal ~~patients~~vector ~~who~~solution ~~achieved~~designed orto ~~remained~~effectively inlimit ~~CR,~~immune-based ~~all~~rejection ~~four~~to ~~progressed~~enable ~~with~~durable ~~CD22+~~response ~~disease~~of CAR T-cell therapy while at the same time simplifying the manufacturing of complex therapies.

~~Figure~~Our 3differentiated platform is intended to transform potentially curative autologous CAR T-cell therapies into allogeneic products for broader patient benefit and access. ~~Incorporation~~The ofuniversal avector ~~short~~is ~~linker~~engineered ~~resulted~~with multiple transgene “cargos” to prevent T and NK cell allogeneic rejection in ~~increased~~order ~~activity~~to ofenable durable responses and to downregulate TCR expression to prevent GvHD. Importantly, the ~~CD22~~vector can be combined with new or clinically established CAR ~~used~~vectors to create ~~CRG~~an allogeneic CAR T-~~022~~cell therapy product. Further, this pairing can be accomplished while leveraging existing autologous drug product processes. We have generated preliminary data at meaningful manufacturing scale to demonstrate ability to produce T cells co-transduced with both allogeneic vector and CAR vector. Furthermore, we have established a framework for rapid tech transfers. Altogether, we believe our platform has the potential to deliver an off-the-shelf allogeneic CAR T product candidate designed to maintain the efficacy, durability and safety associated with autologous cell therapy while eliminating some of its limitations and increasing availability to more people with cancer (Figures 18 and 19).

~~4-1BB~~Figure co18. CARGO’s universal allogeneic-~~stimulatory~~enabling ~~domain~~vector.

Binding of the extracellular domain of CARs to cells expressing their corresponding ligands results in activation of T cells through the combined function of intracellular co-stimulatory domains and activation domains. Approved CAR T-cell therapies incorporate co-stimulatory domains from CD28 or from 4-1BB and an activation domain from CD3. It has been shown in a third-party study that the choice of co-stimulatory domain influences the persistence and memory phenotype of CAR T cells. The inclusion of a 4-1BB co-stimulatory domain has been associated with reduced frequencies of serious adverse events and improved clinical outcomes in tumor models. The CD22 CAR used to create CRG-022 contains a 4-1BB co-stimulatory domain.

Fully human antigen-binding domain

The CD22 CAR used to create CRG-022 contains an antigen-binding domain that is a fully human sequence, which we believe reduces the risk of development of anti-CAR antibodies and T-cell-mediated rejection. Patients treated with CD19 CAR T-cell therapies derived from murine sequences can develop antibodies or T-cell mediated immune responses to the CAR, which may lower persistence of CAR T cells and increase the chances of relapse of the disease. Retreatment of patients with murine-sequence-derived CAR T cells has been shown to primarily result in responses that increase the chance of relapse. A third-party retrospective analysis conducted by researchers at Fred Hutchinson Cancer Research Center evaluated the efficacy of a second infusion of CD19 CAR T cells in 44 patients with R/R B-cell malignancies. A CR rate of 22% in CLL patients, 19% in NHL patients and 21% in ALL patients with median duration of response of 33, 6 and 4 months, respectively was observed. This result was potentially due to host immune rejection after the initial treatment with transgenic T cells. By contrast, retreatment of patients with R/R B-ALL who had received prior CD19 CAR T-cell therapy that failed and used a humanized CD19 CAR T-cell product candidate as a second CAR T treatment, led to a 64% overall response rate at one month with durable remissions. Published data has confirmed that fully human CARs have antitumor activity and tolerability profiles that are similar, if not superior, to those containing murine sequences and may address one mechanism of resistance to CAR T-cell therapy.

Phase 1 Clinical Trial Results for our CRG-022 Program

As described below, CRG-022 or CD22 CAR T-cell therapy using the CRG-022 CAR has been studied in one Phase 1 clinical trial and continues to be studied in two ongoing Phase 1 clinical trials. In addition, in September 2023, we dosed the first patient in a potentially pivotal multi-center Phase 2 clinical trial to evaluate the safety and efficacy of CRG-022 in patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. We licensed the technology

Table of Contents

~~underlying~~Figure ~~the CD22 CAR used in CRG-022 from the NCI~~19. ~~CRG-022~~CARGO’s ~~was~~differentiated ~~produced~~approach ~~at Stanford for the Phase 1 clinical trials. We have made additional process and analytical improvements~~ to ~~the~~limit ~~Stanford~~allogeneic ~~process~~CAR toT ~~create~~rejection ~~the intended commercial manufacturing process for CRG-022 in an effort to improve manufacturing yields~~ and ~~efficiency.~~achieve ~~These~~durable ~~improvements are reflected in the intended commercial process being used to produce CRG-022 in our potentially pivotal Phase 2 clinical trial~~response. We have performed comparability analyses of CRG-022 produced with our intended commercial process to that produced by the process used in the Stanford Phase 1 clinical trial and concluded that the two are comparable. Moreover, our CRG-022 IND included our comprehensive package to establish the comparability of our CRG-022 produced using the intended commercial process to the CRG-022 produced using the process used for the Stanford Phase 1 clinical trials. We cannot assure you that the FDA will agree with our claim of comparability and the sufficiency of the data to support it, or agree with our ability to reference the preclinical, manufacturing or clinical data generated by the Stanford clinical trial even if we receive a right of reference from Stanford. If the FDA disagrees, there may be limitations on the inclusion of Phase 1 clinical trial data in the product label.

~~Phase~~We 1have ~~interim~~made ~~clinical~~significant ~~trial~~progress ~~results~~ in ~~adults~~developing ~~with~~our ~~CD19~~universal allogeneic vector platform. Autologous CAR T Rcells still express the native T cell-receptor (TCR)/RCD3 ~~LBCL~~complex. This means that the drug product has the ability to recognize its cognate tumor antigen but also retains the ability to recognize and target patient/recipient tissues as foreign via the native TCR/MHC interaction. We believe preventing this graft versus host interaction requires the disruption of this interaction, typically by reducing or eliminating surface expression of the TCR/CD3 complex. We utilize two redundant methods to achieve TCR knock down.

AnMajor ~~open-label~~histocompatibility ~~Phase~~complex 1I ~~clinical~~(MHCI) ~~trial~~and ofII ~~CRG-022~~(MHCII) ismolecules ~~being~~present ~~conducted~~antigenic bypeptides ~~Stanford~~to ~~enrolled~~CD8+ 41cytotoxic ~~adult~~T ~~patients~~lymphocytes ~~with~~(CTLs) ~~CD19~~and ~~CAR~~CD4+ helper T ~~R/R~~(TH) ~~LBCL~~cells, respectively. ~~Patients~~Substantially ~~had~~reducing ~~received~~MHCI anexpression ~~average~~and ofreducing ~~four~~or ~~lines~~eliminating ofMHCII ~~prior~~expression ~~therapy~~limits ~~including~~the ~~CD19~~ability ~~CAR~~of ~~T-cell~~a ~~therapy for all but one~~ patient’s ~~whose~~CD8+ ~~disease~~CTLs ~~was CD19-negative~~ and ~~was~~CD4+ ~~CD19~~TH ~~CAR~~cells ~~T naïve. One patient withdrew prior~~ to ~~leukapheresis~~recognize and ~~two~~attack ~~patients~~infused ~~did~~CAR ~~not receive CRG~~T-~~022~~cells ~~due~~as to“foreign” ~~an inability to manufacture given limited patient T cells~~tissue, ~~resulting~~such inthat athe ~~95%~~host ~~successful~~mounts ~~manufacturing~~an ~~rate~~immune ~~(38~~response oftargeting ~~40 patients). As of~~ the ~~November~~engrafted 4,allogeneic ~~2023~~CAR ~~cutoff date, 38 patients had been treated with CRG~~T-~~022~~cells inand ~~this~~limiting ~~Phase~~their ~~1 clinical trial~~persistence.

~~Patients~~Low ~~underwent~~expression ~~conditioning~~of ~~chemotherapy~~MHCI ~~with~~serves ~~fludarabine~~another ~~and~~purpose. ~~cyclophosphamide~~Because ~~before~~most ~~receiving~~NK ~~one~~cells ofexpress ~~the~~inhibitory ~~two~~receptors ~~different~~recognizing ~~doses~~self-MHCI that prevent NK cell activation, maintaining low levels of ~~CAR~~MHCI Texpression ~~cells~~minimizes ~~(DL1~~or [1prevents xactivation ~~106~~of ~~CD22~~an ~~CAR+~~NK ~~cells/kg]~~cell ~~and~~response ~~DL2~~in [3patients xreceiving ~~106~~an ~~CD22~~allogeneic CAR+ ~~cells/kg])~~T-cell therapy. AsHowever, ~~shown~~since inallogeneic ~~the~~CAR ~~figure~~T-cells ~~below,~~made aswith ofour ~~the~~universal ~~November~~allogeneic 4,vector ~~2023,~~technology ~~cutoff~~will ~~date~~nevertheless retain low levels of MHCI expression, ~~the~~we ~~ORR~~also ~~was~~employed ~~68%~~a ~~and~~novel CD8 inhibitor to limit the CRability ~~rate~~of ~~was~~CD8+ ~~53%.~~CTLs ~~There~~to ~~was~~interact nowith ~~clear~~MHCI ~~dose-dependence~~without ofaffecting the ~~ORR~~interaction orbetween CRNK ~~rate~~cells and MHCI.

~~Figure~~Finally, 4we also designed the vector to reduce co-stimulatory ligand expression. ~~ORR~~We ~~and~~have CRreduced ~~observed~~the inexpression ~~Phase~~of 1a ~~clinical~~key ~~trial~~co-stimulatory ~~with~~ligand to reduce the activation response of host T cells. Because CRG-~~022~~023 asincludes ofa ~~November~~CAR 4comprising a CD2 co-stimulatory domain, ~~2023~~however, we expect that the allogeneic CAR T cells will retain the ability to activate co-stimulatory signaling via the CD58/CD2 pathway.

Additionally, as of the cutoff date and as depicted in the graphs below, the overall rate of progression free survival (PFS) at 6 months was 47% and median PFS was 3.0 months (95% CI 1.7-28.7). The median survival in this clinical trial was 14.1 months in the overall population.

Table of Contents

~~Figure~~We 5.have ~~PFS~~advanced several development candidates employing this novel engineering to limit immune rejection and OSprevent GvHD, in both cases without the use of ~~LBCL~~gene ~~patients~~editing, ~~treated~~and expect to select a lead candidate in the first half of 2025. On the manufacturing side, we have demonstrated T cells co-transduced with a GMP vector encoding CRG-~~022~~023 asand our universal allogeneic vector platform retained CAR activity and the feasibility of ~~November~~co-transduction 4,to ~~2023~~produce allogeneic CAR T cells with high purity and multiple doses at meaningful manufacturing scale.

~~Patients~~Preclinical ~~treated~~data ~~with~~has ~~CRG~~demonstrated proof-~~022~~of-concept ~~experienced~~for anpreventing ~~immune~~GvHD ~~toxicity referred to as CRS. CRS is a systemic inflammatory response caused by cytokines released by infused CAR T cells that in severe cases can lead to widespread reversible organ dysfunction~~ and ~~death.~~HvG ~~The~~across ~~majority~~multiple ofassessments ~~patients~~(Figures ~~treated with CRG~~20-~~022~~23). ~~had~~Human ~~mild~~T ~~to moderate CRS~~cells, ~~reported~~transduced ~~as Grades 1 or 2. Only one patient at DL2 experienced Grade 3 CRS. One patient treated~~ with ~~CRG-022~~the atuniversal ~~DL2~~allogeneic ~~had Grade 2 CRS and developed septicemia~~vector, ~~deemed~~durably ~~possibly~~prevented ~~related~~graft ~~to CRG-022, which led to multi-organ failure and death due to sepsis on Day 40~~vs. ~~Two~~host ~~additional~~disease ~~patients~~in ata ~~DL2~~xenograph ~~developed~~mouse ~~treatment-related MDS/AML without evidence of LBCL relapse at 11- and 28-months post infusion~~model. The ~~One~~results ~~patient~~were atcomparable ~~DL1 experienced unrelated heart failure and a second patient treated at DL1 died due~~ to ~~unknown~~the ~~causes~~TRAC ~~after~~(TCR) ~~being~~knockout ~~lost~~control tothat ~~follow-up~~used atthe ~~six~~CRISPR ~~months~~Cas ~~post~~approach ~~CRG-022~~(Figure ~~infusion~~20).

AHvG ~~second~~avoidance, ~~type~~which ofmay ~~toxicity~~be ~~associated~~key ~~with~~to achieving durable responses for allo CAR T, is achieved through a novel, multi-~~cell~~layered ~~therapies~~immune iscloaking ~~ICANS~~approach. InThrough ~~the~~iterative ~~Phase~~design, 1we ~~clinical~~have ~~trial,~~reduced ~~13%~~MHC-I ofexpression ~~patients~~and ~~experienced~~CD58 ~~ICANS~~co-stimulation ofto ~~Grades~~attenuate 1NK ormediated 2immune ~~severity~~rejection through ‘missing self’ (Figure 21). ~~There~~Furthermore, ~~were~~this noapproach ~~reports~~has ofdemonstrated ~~patients~~robust ~~with~~performance ~~ICANS~~across ofa ~~Grades~~diverse 3array orof ~~above~~NK donors. WeThe ~~believe~~universal ~~the~~allo ~~lack~~vector ofis ~~reports~~designed ofto ~~serious~~address ~~grade~~CD4 ~~ICANS~~T ~~could~~cell ~~potentially~~based berejection ~~attributable~~by tofully ~~the~~knocking ~~differential~~down ~~expression~~MHCII and CD8 T cell-based rejection through three methods: partial knockdown of ~~CD19~~MHC-I, overexpression of a CD8 inhibitor and ~~CD22~~downregulation onof ~~cells~~CD58 ~~within~~co-stimulation. Pre-clinical results demonstrated that the ~~central~~presence ~~nervous~~of ~~system.~~the ~~CD19~~CD8 isinhibitor ~~expressed~~reduced onCD8 ~~mural~~activity against allogeneic T cells ~~which~~even ~~are~~with ~~part~~residual ofMHC-I ~~the~~expression ~~neurovascular~~(Figure ~~unit~~22). ~~surrounding~~Alloreactive ~~endothelial~~T cells ~~and~~were ~~which~~unable ~~are~~to ~~critical~~sufficiently ~~for~~proliferate ~~maintaining~~when ~~the~~co-cultured ~~integrity~~with graft T cells transduced with various versions of the ~~blood~~allo ~~brain barrier~~vector. ~~In contrast~~Importantly, ~~researchers~~the ~~have~~T ~~shown~~cells ~~that~~transduced ~~CD22~~with isthe ~~not~~allo ~~expressed~~vector onwere ~~neurovascular~~protected ~~cells,~~from ~~such~~mis-matched asprimed ~~mural~~CD8 ~~cells~~T cell killing upon co-culture, ~~endothelial~~similar ~~cells~~to orthe ~~neurovascular~~B2M ~~progenitors~~knockout control which elicited robust NK cell missing self-response (Figure 21-22).

Finally, we conducted serial killing assays to assess if the universal allogeneic vector platform affected the activity of a co-transduced CAR vector encoding CRG-023 (Figure 623). ~~CRS~~In ~~and~~this ~~ICANS~~assay, ~~observed~~CRG-023-expressing inCAR ~~Phase~~T-cells 1(CAR-023) ~~clinical~~were ~~trial~~repeatedly challenged with new tumor cells. CRG-~~022~~023-expressing asCAR ofT-cells ~~November~~co-transduced 4,with ~~2023~~our universal allogeneic vector were functionally indistinguishable from autologous CRG-023-expressing CAR T-cells.

~~Source:~~Figure ~~Stanford~~20. ~~Phase~~Preclinical 1GvHD data ~~analysis shared at ASH 2023 Investigator meeting~~.

Additionally, 18% of patients (7% of DL1 and 33% of DL2) also developed clinical and laboratory abnormalities consistent with hemophagocytic lymphohistiocytosis (HLH), a condition involving excessive activation of histiocytes and lymphocytes resulting in a hyperinflammatory syndrome requiring prolonged hospitalization or re-admission for medical monitoring or treatment. HLH is recognized as a distinct toxicity associated with CAR T-cell therapies, and it has been observed in approximately 15% of patients treated with CD19 CAR T cells. More recently, a consensus

Table of Contents

~~grading~~Figure ~~system and management guidelines that include the administration of steroids and anakinra have been developed~~21. ~~This~~Preclinical ~~toxicity is now called immune effect or~~ NK-cell ~~HLH-like~~rejection ~~syndrome (IEC-HS)~~data. IEC-HS was higher in patients who received the highest dose (DL2) of CRG-022 without any meaningful increase in efficacy which prompted the selection of DL1 for the expansion phase of this clinical trial.

There have been 32 serious adverse events reported from 23 subjects on this study. There were four reports of Grade 3 sepsis/infection and two reports of cardiac disorders, which included grade 3 ejection fraction decreased and grade 2 heart failure. The largest category of reported SAEs (n = 14 events, 44%) have been hospitalizations for closer monitoring during a second peak of CRS that occurs between Day 11 and Day 14 post-CAR infusion.

In addition, the most common adverse events of Grade 3 or higher during treatment were neutropenia that was observed in all treated patients, anemia that was observed in 63% of treated patients, and thrombocytopenia that was observed in 63% of treated patients. All of these adverse events are commonly observed in other therapeutics in this class. Three deaths in the trial were deemed by investigators to be possibly related to study drug at the highest dose level, which is not being used in our ongoing Phase 2 clinical trial.

Phase 1 clinical trial of CRG-022 in pediatric and adolescent/young adult patients with R/R B-ALL at Stanford

A Phase 1 clinical trial of CRG-022 was initiated by researchers at Stanford in pediatric and adolescent/young adult patients with R/R B-ALL or LBCL. As of June 26, 2022, ten pediatric patients and nine adult patients with B-ALL had been enrolled and 16 have been treated. At Day 28, four achieved CR. One pediatric patient developed Grade 3 CRS, carHLH and prolonged neutropenia. This patient developed sepsis, seizure and died on Day 60 of multi organ failure. The eight adult patients treated in this clinical trial all achieved a complete response with five patients achieving MRD-negativity. The median duration of response, either until relapse or next therapy, was 105 days in adult patients, 47.5 days in pediatric patients, and 74 days overall. Twelve patients relapsed after treatment with CRG-022 and overall survival at one year was 50%.

Phase 1 clinical trial of CD22 CAR T-cell therapy including the CRG-022 CAR in pediatric and adolescent/young adult patients with R/R B-ALL at the NCI

A single-center Phase 1 clinical trial of a CD22 CAR T-cell therapy using the same CAR as CRG-022 in patients with CD22 positive B-ALL is being conducted at the NCI in children and young adult patients (up to age 30). This clinical trial used a 3 + 3 dose-escalation design with a large expansion cohort and enrolled 73 patients as of April 2019, of which 88% had received CD19-targeted therapy (e.g., CD19 CAR, blinatumomab or both), 67% hematopoietic stem cell transplantation and 24% inotuzumab ozogamicin (a CD22-directed antibody-drug conjugate). The results from 58 patients with highly refractory disease were published in the Journal of Clinical Oncology in 2020. The CR rate was 70% with 88% of responders achieving minimal residual disease negative status. Cytokine release syndrome occurred in 82% of participants but was largely limited to lower grade (i.e., grade 1/2) events (90%). Neurotoxicity occurred in 33% of participants and was severe (i.e., grade ≥3) in 2%. Hemophagocytic lymphohistiocytosis-like manifestations were seen in 32.8% of participants which prompted the use of anakinra.

Our ongoing potentially pivotal Phase2 clinical trial in LBCL

In September 2023, we dosed the first patient in a potentially pivotal multi-center Phase 2 clinical trial to evaluate the safety and efficacy of CRG-022 in patients with LBCL whose disease is R/R to CD19 CAR T-cell therapy. This clinical trial is enrolling patients whose disease is refractory to or has relapsed subsequent to CD19 CAR T-cell therapy. In addition, this clinical trial includes a separate cohort of patients who have received two prior lines of therapy with one of these lines of therapy including a bispecific T cell engager (TCE). The primary objective of this clinical trial is the ORR as determined by a blinded independent review committee. This clinical trial is anticipated to enroll up to 123 patients and dose approximately 101 patients. As of January 8, 2024, we had dosed 9 patients in the Phase 2 clinical trial. We expect to report interim results from this Phase 2 clinical trial in the first half of 2025.

Following fludarabine/cyclophosphamide conditioning, patients will be dosed with 1 x106 viable CAR+ cells/kg, the same dose as the DL1 dose administered in the Stanford Phase 1 clinical trial in LBCL. Initial response assessment is planned for Day 28 with subsequent assessments at Day 90 and then every three months.

Table of Contents

Figure 722. ~~Design~~Preclinical ofT-cell ~~our~~rejection ~~potentially pivotal Phase 2 clinical trial of CRG-022~~data

~~Establishment~~Figure of23. aPreclinical ~~commercial~~comparable ~~manufacturing~~CAR ~~process~~anti-tumor ~~for~~activity ~~CRG-022~~demonstrated with allo vector

~~CRG-022~~With isour anprogress ~~autologous CAR T-cell product generated from a patient’s own T cells that have been obtained by leukapheresis (a process for patient immune cell collection) and shipped~~ to ~~a manufacturing facility. At the manufacturing facility~~date, CRG-022 is generated, cryopreserved and then shipped back to the treating clinic to be infused into the patient. The manufacturing process for CRG-022 builds upon the process used to manufacture CRG-022 used by Stanford, with the addition of several improvements that we ~~proactively~~expect ~~identified as necessary for reliability of long-term supply and that we believe are best implemented prior~~ to ~~initiating~~have ~~a pivotal clinical trial of CRG-022. We believe~~ our ~~manufacturing~~lead ~~strategy~~candidate isselection ~~designed~~completed toin ~~directly address some of~~ the ~~key~~first ~~known~~half challenges that cell therapy manufacturers have faced. We are seeking to achieve this by: (1) introducing process design features that enable the process to be rapidly transferable, (2) implementing key process and method changes prior to the start of our potentially pivotal Phase 2 clinical trial, which we believe could reduce the need for changes post-pivotal, (3) automating and closing the process and (4) developing a plan to introduce multiple manufacturing sites for pivotal supply2025.

~~Based~~Through onour ~~the~~allogeneic ~~experience~~platform and as part of our ~~team~~development inplan ~~developing~~for CRG-023, we intend to pursue an allogeneic vectorized CRG-023 and ~~launching~~evaluate ~~cell~~early ~~therapies,~~proof weof concept through a Phase 1 study. We believe ~~that~~our ~~these~~allogeneic ~~changes~~development path for CRG-023, inif ~~addition~~successful, tohas ~~being~~the ofpotential ~~practical~~to ~~benefit,~~change ~~will~~the ~~also~~treatment ~~help~~paradigm ~~address~~of ~~critical~~B-cell ~~issues~~malignancies, ~~such~~further asexpanding ~~supply~~CARGO’s ~~capacity~~pipeline value and ~~cost~~partnership ~~of goods~~opportunities.

~~Reliable~~Firicabtagene ~~supply.~~autoleucel We have successfully transferred the Stanford manufacturing process to our internal technical development lab, made appropriate process changes and transferred our intended commercial manufacturing process for our potentially pivotal Phase 2 clinical trial to contract development manufacturing organizations (~~CDMOs~~firi-cel). We have identified additional CDMO capacity to help ensure redundancy of supply and increase available capacity in anticipation of commercialization. As an additional focus on our supply chain, we have secured a reliable source of lentiviral vector produced using a suspension-based platform through a collaboration with a CDMO.

~~Cost~~On ofJanuary ~~goods.~~29, ~~We have automated a number of steps in the manufacturing process to increase throughput and reliability while minimizing costs. For example~~2025, we ~~have~~announced ~~changed~~our ~~from~~decision ~~manual~~ to ~~automated~~discontinue ~~filling~~the asFIRCE-1 ~~part~~Phase of2 ~~the~~study ~~intended~~of ~~commercial~~firicabtagene ~~manufacturing~~autoleucel ~~process. In addition~~(firi-cel), weour ~~have~~previous ~~introduced~~lead ~~the~~program. ~~ability~~Firi-cel tois ~~cryopreserve~~a ~~the~~novel ~~starting~~autologous ~~apheresis~~CAR ~~material~~T-cell ~~which~~product ~~enables~~candidate ~~more~~designed ~~efficient~~to ~~use~~address ofresistance ~~our~~mechanisms ~~manufacturing~~by ~~slots~~targeting ~~and~~CD22, ~~flexible~~an ~~supply~~alternate ~~chain~~tumor ~~strategy~~antigen ~~that~~expressed ~~can serve patients~~ in ~~wider~~most ~~geographic~~B-cell ~~areas~~malignancies. We ~~addressed~~exclusively ~~the~~licensed ~~supply of critical reagents required, such as~~ the ~~lentivirus~~underlying ~~vector~~CAR ~~that is used to insert the gene~~ for ~~the~~firi-cel ~~CD22~~from ~~CAR into T cells. We transitioned~~ the ~~design~~NCI, ~~and production of the lentivirus vector used by Stanford to one that is more suitable~~ for ~~commercial~~use ~~applications~~as ~~while~~an ~~still~~autologous ~~delivering~~cell ~~the~~therapy ~~same~~in ~~CD22~~hematology ~~CAR~~ and ~~demonstrating analytical comparability to CRG-022 produced at Stanford~~oncology.

Table of Contents

Predictable patient experience. We believe CRG-022 has the potential to deliver life-changing benefits to cancer patients whose disease has failed to respond to prior therapies; however, similar to other autologous cell therapies, a significant amount of time is required to manufacture this autologous CAR T-cell product. The turnaround time encompasses every step from apheresis of the starting cells from the patients, shipping, introduction of the CAR construct, cell expansion, harvesting, final filling and quality control before a product can be released and shipped back to the treating clinic. We believe the process and operational improvements we have implemented will provide greater control of the manufacturing turn-around-time.

Regulatory strategy considerations. We benefit from the experience of pioneering CAR T-cell products to help pave the way through the regulatory process and to identify critical steps with the potential to stall the development of CRG-022. We have, for example, implemented our intended commercial manufacturing process and analytics prior to initialization of our potentially pivotal Phase 2 clinical trial in an attempt to reduce the need to introduce further changes moving from clinical to commercial production. We are utilizing current regulatory guidance to design comparability strategies to manage life cycle changes. We implemented key requirements of the control system, before the start of the potentially pivotal Phase 2 clinical trial, for example by establishing a suitable potency assay and qualifying all release methods.

Our manufacturing approach aims to establish processes that are highly reliable and consistent and that can readily be transferred to commercial cell therapy manufacturing. We believe that this will help ensure that our therapy candidates, if approved, can be generated for all patients that need them. We believe our strategy to focus on these steps prior to initiating our potentially pivotal Phase 2 clinical trial will both simplify later efforts to establish comparability across manufacturing sites and increase our potential to rapidly expand our manufacturing network as dictated by demand.

Our CD2 co-stimulation platform technology and CRG-023, a tri-specific CAR T product candidate

Our first platform technology involves the integration of a CD2 co-stimulatory domain designed to counter a target-independent mechanism that leads to resistance to CAR T-cells and other immune therapies. The strength and quality of a T-cell response is dependent not only on cognate antigen recognition, but also on co-stimulation, which involves interaction of one or more co-stimulatory receptors on T cells, such as CD2, with ligands expressed on the surface of tumor cells. Tumor cells can escape CAR T-cell destruction by downregulating the expression of ligands for the co-stimulatory receptors. These ligands include CD58, the ligand of the CD2 co-stimulatory receptor. Alteration of CD58 expression is associated with poor prognosis in LBCL and leads to lack of response to CD19 CAR T cells. Through our platform approach, we created constructs that couple CD2 signaling directly to CAR activation, to enhance activation of the CAR T cells against tumors that do not express CD58.

Our most advanced preclinical programs incorporate CAR multi-specificity to address tumor antigen loss and loss of co-stimulatory CD58. CRG-023, our tri-specific CAR T product candidate, targets tumor cells with three B-cell antigen targets (CD19, CD20 and CD22). One of the binders of this tri-specific T cell will incorporate our CD2 co-stimulation technology that we believe will help improve the treatment of patients that have lost CD58 expression on their tumor cells. We believe that by utilizing our tri-specific CAR T product candidate incorporating our CD2 co-stimulation technology we have the potential to simultaneously prevent relapse due to antigen down-modulation or antigen loss while improving CAR T-cell responses against an important mechanism that tumors employ to evade killing by CAR T cells. We plan to continue to leverage our platform technologies to further advance our additional pipeline programs.

Preventing emergence of resistance due to loss of co-stimulatory ligands

The loss of cell surface co-stimulatory proteins on tumors that function to activate T-cell co-stimulatory receptors is a mechanism of development of resistance to CAR T-cell therapies. Tumors that lack the expression of CD58, for example, have been found to be resistant to CAR T cells due to the inability to activate the CD2 receptor on CAR T cells. Approximately 25% of LBCL patients that are eligible for CAR T-cell therapy have mutated or absent CD58 and up to 67% have decreased expression of CD58. In a study of 51 patients with DLBCL treated with Yescarta, the prognosis for patients with mutated or absent CD58 was found to be poor with a median PFS of 3.1 months and

Table of Contents

less than 30% achieving CRs. By contrast, patients with intact CD58 expression achieved an 80% CR rate and approximately 60% survived or surviving beyond twelve months.

Figure 8. Alteration in CD58 expression was associated with poor prognosis in DLBCL patients treated with Yescarta.

This phenomenon is not confined to DLBCL. A study published in June 2023 demonstrated down regulation of CD58 in patient tumor samples across a wide range of hematologic malignancies including Hodgkin and non-Hodgkin lymphomas (both B-cell and T-cell), including de novo disease, suggesting a potential utility for our CD2 platform technology to mitigate immune escape in future therapies for a broad range of hematologic malignancies. The study also demonstrated no correlation with CD58 downregulation and any other B-cell marker (CD19, CD20, CD22 or PAX5), suggesting an independent mechanism of resistance from these cell markers. Further, we believe that this technology has the potential to lead to therapeutic benefit in other cancer indications beyond hematologic malignancies. For example, CD58 expression was reported to be reduced in melanoma patients who are resistant to checkpoint inhibitors. Similarly, sensitivity to bispecific T cell engagers (TCEs), was reported to be dependent on CD58/CD2 signaling.

In order to combat CD58 downregulation, we are developing modified CAR constructs designed to induce CD2 intracellular signaling by a tumor antigen independent of the presence of CD58 on tumor cells, thereby alleviating the need for CD58 binding to the CD2 receptor and removing a common mechanism that may lead to resistance to CD19 CAR T-cell therapy.

The potential of our CD2 platform technology was demonstrated in a cell killing assay using NALM6 tumor cells. Because these cells express CD22, they are attacked and killed by CD22-targeted CAR T cells similar to CRG-022. Those NALM6 cells that lacked expression of CD58 resisted killing by CD22-targeted CAR T cells.

We hypothesized that restoration of CD2 stimulation would resensitize NALM6 cells that lack CD58 expression to killing by CAR T cells. To test this, we created a CAR that incorporated our CD2 technology in a CD19-targeted CAR with the intent of creating a CD2 activator that was dependent on binding to CD19 rather than CD58.

We observed that although NALM6 cells express CD19, treatment with CD19-targeted CAR with CD2 technology did not sustain long-term tumor cell killing in vitro on its own. However, when CAR T cells were created that contained both CD22-targeted CAR and CD19-targeted CAR with CD2 technology, we observed efficient killing of NALM6 cells, including those that lacked CD58.We believe this result suggests that a multi-specific CAR T cell incorporating CD2 technology, can improve activity against tumor cells that lack CD58 expression relative to monospecific CAR T cells.

Table of Contents

Figure 9. Multispecific CAR T cells incorporating our CD2 technology achieves sustained killing of both CD58+ and CD58- tumor cells

We believe that this CD2 platform technology has the potential to address an important mechanism that tumors employ to evade killing by CAR T cells, across a broad range of cancers.

CRG-023, a tri-specific CAR T product candidate

Critical to the long-term success of CAR T-cell therapies is the ability to increase the number of patients who achieve meaningful therapeutic benefits and for whom these benefits have long-term durability. Achieving this additional breadth will likely require approaches that target more than one tumor antigen at a time. This would, we believe, both expand the pool of eligible patients and reduce the frequency of emergence of resistance.

We are developing CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets (CD19, CD20 and CD22).

We believe that, by targeting these three antigens, we will be able to prevent relapse due to antigen down-modulation or antigen loss while giving us optionality for treating multiple types of B-cell malignancies. In addition to the CD22 CAR used in CRG-022, we plan to utilize novel, fully human CAR binders targeting CD19 and CD20 that we believe should decrease the probability of immune cell rejection by patient recipients due to non-native elements. Finally, CRG-023 will incorporate our CD2 co-stimulation technology that we believe will help improve the treatment of patients that have loss or downregulation of CD58 expression on their tumor cells.

In order to evaluate the function of each independent CAR in CRG-023, three Nalm6 B-ALL cell lines were prepared, each expressing only one of the three targeted antigens (CD19, CD20 or CD22). The tri-specific CAR T cell and mono-specific control CAR T cells targeting each antigen were incubated with these Nalm6 cell lines, and the resulting IL-2 secretion – a measure of T cell function– was measured 24 hours later (Figure 15). Each CAR in CRG-023 was able to induce the T cells to secrete IL-2 in response to antigen at levels similar to the mono-specific CAR T cells, thereby demonstrating the independent function of each CAR in CRG-023.

Table of Contents

Figure 10. Each CAR in the CARGO tri-specific CRG-023 induced the T cells to secrete IL-2 in response to antigen at levels similar to a mono-specific CAR T control.

In order to evaluate the ability of these tri-specific CAR T cells to eliminate tumors in vivo, we employed a mouse model in which a non-Hodgkin lymphoma B cell line called Raji was implanted into immunodeficient NSG mice. These Raji cells express all three antigens (CD19, CD20 and CD22) and were engineered to express luciferase to allow for in vivo quantification of tumor burden via bioluminescent flux. On day 0, Raji cells were intravenously implanted and on Day 4, three million CAR T cells were injected, and tumor burden was measured over time. Mono-specific CAR T cells for each CAR used inCRG-023 were prepared as controls. While mono-specific CAR T cells gave partial responses at this dose, our tri-specific CAR T cells reduced bioluminescent flux values down to background levels (Figure 13).

Figure 11 Our tri-specific CAR T cells, CRG-023, showed better in vivo antitumor activity against a mouse B cell tumor model (Raji) than mono-specific CAR T cells.

To understand the impact of antigen loss on our tri-specific CAR T cells, three Raji cell lines were engineered with one of the three antigens (CD19, CD20 or CD22) knocked-out (KO). A 1:1:1 mixture of these Raji cells (CD19 KO:CD20 KO:CD22 KO) was injected into immunodeficient NSG mice on day 0. On Day 4, either our tri-specific CAR T cells or monospecific CAR T-cell controls targeting either CD19 or CD22 were injected. Tumor burden was monitored over time by measuring bioluminescent flux. As expected, the mono-specific CAR T cells were unable to control the tumor due to one-third of the cells not expressing their cognate antigen. However, our tri-specific CAR T

Table of Contents

cells reduced tumor burden down to background levels (Figure14). These data suggest that our tri-specific CAR T cells maintained activity against tumor cells that do not express one of the three target antigens.

Figure 12. Our tri-specific CAR T cells reduced tumor burden to background levels in an antigen loss in vivo tumor model.

We have initiated preclinical, process development and analytical development efforts to prepare for an IND submission for CRG-023.

We are committed to improving T-cell activation and persistence and addressing immunosuppressive mechanisms in the tumor microenvironment. We believe that our CD2 technology, along with other components of our platform technologies in development, are key to the future of CAR T-cell therapies. We intend to lead the development of these next generation product candidates with our proprietary platform technologies.

Competition

~~Our~~Oncology ~~products~~is ~~will~~a ~~compete~~highly competitive market for drug development. While we believe that our differentiated pipeline provides us with ~~novel~~competitive ~~therapies~~advantages, ~~developed~~we byface ~~biopharmaceutical~~potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic ~~research~~ institutions, and governmental agencies and public and private research institutions, inas ~~addition~~well toas standard -of -care treatments, new products undergoing development and combinations of existing and new therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies, including cell-based therapies, both autologous and allogeneic in nature, and other therapeutic modalities, including antibodies, bispecific T-cell engagers, antibody drug conjugates, and small molecule therapeutics.

~~Potential~~Due ~~competitors~~to ~~with~~the ~~autologous~~promising therapeutic effect of CAR T-cell therapies ~~that are either approved or~~ in ~~development~~clinical ~~include 2seventybio~~trials, ~~Autolus~~we ~~Therapeutics,~~anticipate ~~Bristol-Myers~~increasing ~~Squibb,~~competition ~~Janssen~~from existing and ~~AbelZeta,~~new ~~Gilead~~companies ~~Sciences,~~developing ~~ImmPACT~~these ~~Bio, Miltenyi, Mustang Bio, Novartis, and Oncternal~~therapies. ~~Potential~~Seven ~~competitors~~autologous ~~with allogenic~~ CAR T-cell therapies inhave ~~development~~been ~~include~~approved ~~Allogene~~by ~~Therapeutics,~~the ~~Atara~~FDA ~~Biotherapeutics,~~for ~~Century~~the ~~Therapeutics,~~treatment ~~CRISPR~~of ~~Cellectis,~~R/R ~~Fate,~~hematologic ~~Imugene,~~malignancies: ~~Nkarta,~~Kymriah ~~Poseida~~(Novartis ~~Therapeutics,~~AG) ~~Sana~~for ~~Biotechnology, and Takeda. Autologous CAR T~~B-cell ~~therapies~~acute ~~are~~lymphoblastic ~~made~~leukemia ~~with~~(ALL) ~~cells~~and ~~obtained~~for ~~from~~diffuse ~~the~~large ~~patient being treated. In contrast, allogenic CAR T~~B-cell ~~therapies~~lymphoma ~~are~~(DLBCL); ~~made~~Yescarta ~~with~~(Gilead/Kite ~~cells~~Pharma) ~~obtained~~for ~~from~~aggressive alarge ~~healthy~~B-cell ~~donor~~lymphoma ~~and~~(LBCL); ~~typically~~Tecartus ~~include~~(Gilead/Kite ~~additional~~Pharma) ~~genetic~~for ~~modifications~~mantle ~~and~~cell ~~other~~lymphoma ~~refinements~~or ~~intended~~B-cell toALL; ~~reduce~~Breyanzi or(Bristol-Myers ~~ideally~~Squibb ~~eliminate~~Company) ~~the~~for ~~likelihood~~aggressive ofLBCL; ~~immune~~Abecma ~~rejection~~(Bristol-Myers orSquibb ~~graft~~Company) ~~versus~~for ~~host~~multiple ~~disease~~myeloma; ~~when~~Carvykti ~~infused~~(Janssen ~~into~~Biotech) ~~patients.~~for ~~Due~~multiple tomyeloma; ~~the~~and ~~promising~~Aucatzyl ~~therapeutic~~(Autolus ~~effect~~Therapeutics ofplc) ~~CAR~~for TB-cell ~~therapies~~precursor inALL. ~~clinical~~We ~~trials,~~also weface ~~anticipate increasing~~ competition ~~from~~with ~~existing and~~ new ~~companies developing these~~ therapies. ~~Competition~~under ~~will~~development ~~also~~by ~~arise~~AbelZeta ~~from~~Pharma, ~~non-cell~~Inc., ~~based~~Autolus ~~immune~~Therapeutics ~~and~~plc, ~~other~~Galapagos ~~pursued~~NV, byGilead ~~small-cap~~Sciences, ~~biotechnology~~Inc., ~~and~~Janssen ~~large-cap~~Biotech, ~~pharmaceutical~~Legend ~~companies~~Biotech ~~including Abbvie~~Corp., ~~Amgen~~Lyell ~~Inc~~Immunopharma, ~~AstraZeneca~~Inc., ~~Bristol-Myers~~Marker ~~Squibb~~Therapeutics, ~~Genmab~~Inc., ~~Incyte~~Miltenyi Biotec, ~~Merck~~Novartis International AG, and Regeneron ~~and~~Pharmaceuticals, ~~Roche~~Inc.

Allogeneic T cell products have yet to receive FDA approval though the number of companies developing allogeneic product candidates is substantial. These include Allogene Therapeutics, Inc., AstraZeneca, plc, Atara Biotherapeutics, Inc., Beam Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis S.A., Century Therapeutics, Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics, Inc., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Imugene Ltd., Intellia Therapeutics, Inc., Legend Biotech Corp., Nkarta, Inc., Precision Biosciences, Inc., Sana Biotechnology, Inc., and Takeda Pharmaceutical Company Limited.

Competition will also arise from non-cell based immune and other therapies pursued by other biotechnology and pharmaceutical companies including Abbvie, Inc., Amgen, Inc., AstraZeneca, plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab A/S, Incyte Corporation, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.

Table of Contents

Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all our programs are efficacy, safety and reliability of supply.

These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs.

~~Certain competitor data – CD19 CAR T-cell therapies~~20

There are three currently approved CD19 CAR T-cell therapies for the treatment of LBCL. Select published clinical data from current FDA-approved CD19 CAR T-cell therapies in development for the treatment of LBCL are presented below.

Axicabtagene ciloleucel (Yescarta)

In a Phase 2 clinical trial of ZUMA-1, a single-arm, multi-center, registrational trial, Yescarta was administered to 101 patients. After 11.6 months of follow-up, the ORR and CR rate were 72% and 51%, respectively. At 18 months, the ORR and CR rate were 82% and 54%, respectively, and Grade 3 or higher CRS and neurologic events occurred in13% and 28% of patients, respectively. After 2 years of follow-up, the ORR, CR rate and PFS were 83%, 54% and 39%, respectively, as compared to after 5 years of follow-up, where the ORR, CR rate and PFS were 83%, 58%and 32%, respectively.

In a Phase 3 clinical trial of ZUMA-7, a randomized, open-label, multi-center trial, Yescarta was administered to 180 patients and supported the initial treatment in adults with 2L R/R LBCL. After 14.7 months of follow-up, the ORR, CR rate and PFS were 83%, 65% and 50%, respectively, and Grade 3 or higher CRS and neurologic events occurred in 7% and 25% of patients, respectively. After 4 years of follow-up, the ORR, CR rate and PFS were 83%, 65% and 42%, respectively. With an estimated median follow up of 46.7 months overall, the primary analysis of OS showed a statistically significant improvement in the Yescarta arm (55.9% OS at 39 months) compared to the standard therapy arm (46% OS at 39 months), a 27.4% reduction in the risk with death.

Tisagenlecleucel (Kymriah)

In a Phase 2 clinical trial of JULIET, an open-label, multi-center, single-arm trial, Kymriah was administered to 68 patients. At 9.4 months, the ORR and CR rate were 50% and 32%, respectively, and Grade 3 or higher CRS and neurologic events occurred in 22% and 12% of patients, respectively. At 24 months of follow-up, the ORR and CR rate were 52% and 38%, respectively, as compared to after 40.3 months of follow-up, where the ORR and CR rate were 53% and 39%, respectively. After 36 months of follow-up, the PFS was 31%.

Lisocabtagene maraleucel (Breyanzi)

In the pivotal TRANSCEND NHL 001 clinical trial, Breyanzi was administered to 192 patients. After 18.8 months of follow-up, the ORR and CR rate were 73% and 54%, respectively, and Grade 3 or higher CRS and neurologic events occurred in2% and 10% of patients, respectively. After 2 years of follow-up, the ORR, CR rate and PFS were 73%, 53% and 41%, respectively.

In the pivotal Phase 3 TRANSFORM clinical trial, Breyanzi was administered to 92 patients and supported the initial treatment in adults with 2L R/R LBCL. At6.2 months, the ORR and CR rate were 84% and 66%, respectively, and Grade 3 or higher CRS and neurologic events occurred in1% and 7% of patients, respectively. After 17.5 months of follow-up, the ORR, CR rate and PFS were 87%, 74% and 58%, respectively.

Table of Contents

ORR and CR rate

The following reflects the published data on ORR and CR rates of CD19 CAR T-cell therapies for the treatment of 3L+ LBCL after 2 years of follow-up: Yescarta (83% ORR, 54% CR rate), Kymriah (52% ORR, 38% CR rate) and Breyanzi (73% ORR, 53% CR rate).

Certain competitor data – bispecific T-cell engaging antibodies

There are two CD20-directed CD3 T-cell engagers for the treatment of LBCL that have received accelerated approval from the FDA. Select published clinical data from current approved CD20-directed CD3 T-cell engagers in development for the treatment of LBCL are presented below. Continued approval for any product receiving accelerated approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Epcoritamab-bysp (Epkinly)

In a Phase 2 clinical trial EPCORE NHL-1, an open-label, multi-cohort, multi-center, single-arm, registrational trial, Epkinly was administered to 157 patients. 39% had prior CAR T-cell therapy. The ORR and CR rate were 61% and 38%, respectively. Grade 3 or higher CRS and neurologic events occurred in 2.5% and 0.6% of patients, respectively.

Glofitamab-gxbm (Columvi)

In a Phase 2 clinical trial NP30179, an open-label, multi-cohort, multi-center, single-arm, registrational trial, Columvi was administered to 132 patients. 30% had prior CAR T-cell therapy. The ORR and CR rate were 56% and 43%, respectively. Grade 3 or higher CRS and neurologic events occurred in 4.2% and 2.1% of patients, respectively.

Intellectual property

Intellectual property (IP) rights are important to the success of our business. We rely on a combination of patent, trademark and trade secret laws in the United States and in jurisdictions outside of the United States, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand, Russia, Singapore, South Africa and the United Kingdom, as well as license agreements, confidentiality and non-disclosure agreements with third parties, and other contractual protections to protect our IP rights, including proprietary technology, know-how, trademarks, trade secrets, and brands.

We protect the proprietary technologies produced by our continuing technological innovation that are important to our business using a combination of approaches, including by filing patent applications that cover our product candidates, platform technologies, and methods of using such candidates and technologies, as well as any improvements to existing inventions that are commercially important to the development of our business. We protect the IP we have licensed from third parties and work collaboratively with our licensors on patent prosecution to ensure we obtain commercially relevant patent protection. We also rely on trademarks, copyrights, trade secrets, and know-how to develop, protect and maintain our other IP. Our commercial success depends in part on our ability to obtain, maintain, enforce and defend our IP rights covering the technology, inventions and improvements that are important to our business, by preventing others from infringing any IP we may own or in-license in the future, preserving the confidentiality of our trade secrets, and operating without infringing, misappropriating or otherwise violating the valid and enforceable IP rights of third parties.

As of ~~February~~March 231, ~~2024~~2025, we owned ~~five~~three pending U.S. provisional patent applications and ~~seven~~nine pending Patent Cooperation Treaty (PCT) applications comprising applications drawn to the following technical subject matter: (a) ~~cytokine receptors switch polypeptides and uses thereof; (b) CD2-recruiting chimeric antigen receptors and fusion proteins; (c)~~ compositions and methods for improved immunotherapies; (db) compositions and methods for allogeneic immunotherapies; (ec) split receptor switch polypeptides and uses thereof; (fd) multiplex cell selection compositions and uses thereof; (ge) modified immune effector cells; (f) compositions and methods for immunotherapies; (g) methods for manufacturing CRG-022 CAR T cells; (h) anti-CD22 chimeric antigen receptor (CAR) therapies; (i) compositions and methods for immunotherapies; (j) compositions and methods for ~~manufacturing~~allogeneic ~~CAR~~immune T cells; and (k) ~~modified~~methods ~~immune~~for ~~effector~~manufacturing CRG-023 CAR T cells. Any patents ~~issuing~~issued from these patent applications are expected to expire in 2043, 2044, or 2045, without taking into account any possible patent term adjustments or extensions. In addition, we have exclusively licensed from the NCI three patent families together comprising seven issued U.S. patents, two pending U.S. patent applications, 15 granted or allowed foreign patents (in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, and Russia) and six pending foreign patent applications (in Australia, Canada, Europe, Japan, Korea, and Singapore). We have also licensed or optioned from Stanford University four patent families together comprising four pending U.S. patent applications, and 56 pending foreign patent applications (in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, South Africa and the United Kingdom) that cover a wide range of compositions of matter (including pharmaceutical compositions) and methods (including methods of use) drawn to the following technical subject matter: (a) human monoclonal antibodies specific for CD22; (b) m971 chimeric antigen receptors; (c) bicistronic chimeric antigen receptors and their uses; (d) chimeric antigen receptors with CD2 activation; (e) methods for diagnosing or treating health conditions or optimizing therapeutic efficacy of CAR T cell therapies; (f) recombinant polypeptides for regulatable cellular localization; and (g) cell selection methods and related compositions. These patent applications and any patents issued therefrom are expected to expire between 2029 and 2042, without taking into account any possible patent term adjustments or extensions.

Table of Contents

2044, without taking into account any possible patent term adjustments or extensions. In addition, we have exclusively licensed from the NCI three patent families together comprising seven issued U.S. patents, two pending U.S. patent applications, 15 granted or allowed foreign patents (in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Japan, and Russia) and six pending foreign patent applications (in Australia, Canada, Europe, Japan, Korea, and Singapore). We have also licensed or optioned from Stanford University four patent families together comprising four pending U.S. patent applications, and 56 pending foreign patent applications (in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, South Africa and the United Kingdom) that cover a wide range of compositions of matter (including pharmaceutical compositions) and methods (including methods of use) drawn to the following technical subject matter: (a) human monoclonal antibodies specific for CD22; (b) m971 chimeric antigen receptors; (c) bicistronic chimeric antigen receptors and their uses; (d) chimeric antigen receptors with CD2 activation; (e) methods for diagnosing or treating health conditions or optimizing therapeutic efficacy of CAR T cell therapies; (f) recombinant polypeptides for regulatable cellular localization; (g) cell selection methods and related compositions. These patent applications and any patents issuing therefrom are expected to expire between 2029 and 2042, without taking into account any possible patent term adjustments or extensions.

Our ability to maintain our IP rights covering our product candidates, platform technologies, methods of using such candidates and technologies, as well as any improvements to existing inventions that are important to our business will depend on our success in obtaining commercially relevant patent claims and enforcing those claims if necessary. However, our pending provisional and PCT patent applications and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to protect our IP in relation to the commercialization of our products or platform technologies. We also cannot predict the breadth of claims that may be allowed in any patent applications we may own or in-license in the future. Notwithstanding the scope of the patent protection available to us, a competitor could develop competitive technologies and products that are not covered by our IP, and we may be unable to stop such competitor from commercializing such technologies and products.

Table of Contents

Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. Because patent applications publish no earlier than 18 months after filing, there may be applications currently unknown to us which may later result in issued patents that our existing or future products or technologies may be alleged to infringe. Additionally, we cannot be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and file patent applications in the United States that also claim technology and products to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office (USPTO) to determine priority of invention, which is highly unpredictable and which could result in substantial costs, even if the eventual outcome is favorable to us. In addition, because of the extensive time required for clinical development and regulatory review of technologies and product candidates we may develop, it is possible that, before any of our products can be commercialized, any patent covering a certain product may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide.

The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In the United States and most other countries, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent’s term may be lengthened by patent term adjustment (to compensate a patentee for administrative delays by the USPTO in examining a patent application) or patent term extension (to compensate a patent holder for delays associated with regulatory review), or may be shortened if a patent is terminally disclaimed over another patent.

There can be no assurance that the pending provisional or PCT patent applications we own or have in-licensed now or that we may own or in-license in the future will ultimately result in issued patents or that we will benefit from any patent term adjustment or extension. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its claims, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for the entire product lifecycle.

27As of March 1, 2025, we had no outstanding IP litigation matters pending nor any threats of litigation against us. In the future, we may need to enforce one or more of the patents issued or licensed to us or to protect our trade secrets or know-how by litigation. We may also need to defend ourselves against claims of patent infringement, trade secret misappropriation, or the like filed by other parties. Litigation can be costly, may divert our attention from other corporate functions and responsibilities, and the outcome is always uncertain. There are numerous possible outcomes to such litigation, including an award of money damages, the grant of a preliminary or permanent injunction preventing us from selling an allegedly infringing product temporarily or permanently, invalidation of one or more claims of the asserted patent(s), or a requirement to grant or take a license subject to the payment of ongoing royalties. Monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer’s competition in the market. Adverse determinations in litigation could subject us to significant liabilities to third parties, could require us to seek licenses from third parties and pay significant royalties to such third parties and could prevent us from manufacturing, selling or using our product or technologies, any of which could severely harm our business.

Table of Contents

As of March 21, 2024, we had no outstanding IP litigation matters pending nor any threats of litigation against us. In the future, we may need to enforce one or more of the patents issued or licensed to us or to protect our trade secrets or know-how by litigation. We may also need to defend ourselves against claims of patent infringement, trade secret misappropriation, or the like filed by other parties. Litigation can be costly, may divert our attention from other corporate functions and responsibilities, and the outcome is always uncertain. There are numerous possible outcomes to such litigation, including an award of money damages, the grant of a preliminary or permanent injunction preventing us from selling an allegedly infringing product temporarily or permanently, invalidation of one or more claims of the asserted patent(s), or a requirement to grant or take a license subject to the payment of ongoing royalties. Monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer’s competition in the market. Adverse determinations in litigation could subject us to significant liabilities to third parties, could require us to seek licenses from third parties and pay significant royalties to such third parties and could prevent us from manufacturing, selling or using our product or technologies, any of which could severely harm our business.

Although we rely on IP rights, including patents, copyrights, trademarks and trade secrets, as well as contractual protections to establish and protect our proprietary rights, we believe that factors such as the technological and creative skills of our personnel, creation of new solutions, features and functionality, and frequent enhancements to our platform technologies are also essential to establishing and maintaining our technology leadership position.

We control access to and use of our proprietary technology and other confidential information through the use of internal and external controls, including confidentiality/nondisclosure agreements and the addition of confidentiality and nondisclosure obligations in company contracts with employees, contractors, suppliers, and partners. We require our employees, consultants and other third parties to enter into confidentiality and nondisclosure agreements and we control and monitor access to our solutions, documentation, proprietary technology and other confidential information. Our policy is to require all employees and independent contractors to sign agreements assigning to us any inventions, trade secrets, works of authorship, developments, processes and other IP generated by them on our behalf and under which they agree to protect our confidential information. In addition, we generally enter into confidentiality agreements with our partners. See the section titled “Risk factors — Risks related to our intellectual property” for a more comprehensive description of risks related to our IP.

Table of Contents

into confidentiality agreements with our partners. See the section titled “Risk factors — Risks related to our intellectual property” for a more comprehensive description of risks related to our IP.

License agreements

Stanford license agreement

In August 2022, we entered into a license agreement with ~~the~~Stanford ~~Board~~University ofrelating ~~Trustees~~to ofour ~~Stanford~~platform ~~University,~~technologies asrelating ~~amended~~to inCAR ~~January~~T-cell ~~2023~~therapies (the Stanford License). Pursuant to the ~~terms of the~~ Stanford License, Stanford ~~grants~~University togranted us a worldwide, exclusive license under certain patent rights, and a worldwide non-exclusive license under certain technology, in each case, owned or controlled by Stanford University to make, use and sell products, methods or services in the field of human therapeutic and diagnostic products. The licensed patent rights cover platform technology relating to the use of CD2/CD58 co-stimulatory signaling in cell therapy.

As consideration for the licenses granted under the Stanford License, we ~~paid~~made aan ~~one-time, non-refundable~~ upfront ~~license~~payment ~~issue fee~~ of $50,000 and issued 67,605 shares of our common stock with a fair value of $0.1 million, of which 22,317 shares were issued to Stanford University, 27,100 shares were issued to two non-profit organizations that supported the research, and 18,188 shares were issued to various Stanford University inventors. We also agreed to pay annual license maintenance fees of up to $0.1 million per year, up to $7.5 million for sales milestone payments, up to $4.0 million in development milestone payments for each therapeutic product covered by licensed patent rights upon initiation of specific clinical trials or receipt of regulatory approvals, up to $50,000 in a milestone payment upon achievement of specific commercial milestone event, up to $0.5 million in a milestone payment upon achievement of certain additional milestone event, a double-digit percentage in milestone payments applicable to products covered by licensed patent rights on the first two licensed non-patent products and, subject to certain royalty reductions, as applicable, low single-digit percentage royalties on net sales of products that are covered by the licensed patent rights or licensed technology. Subject to the terms of the Stanford License, we also agreed to pay Stanford University a certain percentage of non-royalty sublicense related revenue that we may receive from third-party sublicensees.

28In addition to annual license maintenance fees of up to $0.1 million per year, we may be required to pay up to $7.5 million upon achievement of sales milestones, up to $4.0 million upon achievement of development milestone events for each product covered by licensed patent rights, including upon initiation of specific clinical trials or receipt of regulatory approvals, up to $50,000 in a milestone payment upon achievement of a certain commercial milestone event, up to $0.5 million in a milestone payment upon achievement of certain additional development milestone events, and a double-digit percentage of milestone payments on the first two licensed non-patent products and, subject to certain royalty reductions, as applicable, low single-digit percentage royalties on net sales of products that are covered by the licensed patent rights or licensed technology. Subject to the terms of the Stanford License, we also agreed to pay Stanford University a certain percentage of non-royalty sublicense-related revenue that we receive from third-party sublicenses.

Table of Contents

Stanford University may terminate the Stanford License in the event of a material breach, delinquency in payment or if we provide any materially false report, and any of these events remains uncured for 60 days following written notice of such event. We may terminate the Stanford License in its entirety or on a field-by-field basis at any time upon 30 days’ advance written notice to Stanford University.

We agreed to pay Stanford University $0.3 million if we are acquired by a third party or if we sell all or substantially all of our assets to which the Stanford License relates.

Oxford license and supply agreement

In June 2022, we entered into a license and supply agreement (the Oxford Agreement) with Oxford Biomedica (UK) Limited (Oxford ~~Biomedica~~) for ~~Oxford~~the ~~Biomedica to~~ manufacture and supply of lentiviral vectors for clinical and potentially commercial purposes by us. Pursuant to the Oxford Agreement, Oxford granted to us a non-exclusive worldwide, sub-licensable, royalty-bearing license under certain ~~lentiviral~~intellectual ~~vectors~~property ~~(Vectors)~~rights for the purposes of research, development, manufacturing and commercialization of ~~T-cells~~products transduced with ~~such~~the ~~Vectors~~vectors ~~(Licensed~~manufactured ~~Products)~~by Oxford or by us following a technology transfer by Oxford, which products are directed against certain initial targets, and upon payment of certain fees, additional targets as agreed by Oxford and us. As consideration for the license granted under the Oxford Agreement, we paid an upfront license fee of $0.2 million.

~~Pursuant~~In March 2024, we entered into an amendment to the Oxford Agreement, ~~Oxford~~pursuant ~~Biomedica~~to ~~agrees~~which we and Oxford agreed to ~~provide~~an ~~services~~amended ~~related~~payment structure for certain lentiviral vectors. We may be obligated to ~~the~~pay ~~development~~up to an aggregate amount of $9.5 million in additional target fees, ~~manufacture~~regulatory and ~~supply~~commercial ofmilestones for each target if such milestones are achieved by the ~~Vectors~~licensed ~~and~~product ~~grants~~directed to ussuch atarget, ~~non~~except for the firi-~~exclusive~~cel ~~worldwide~~program, ~~sub-licensable~~for which we may be obligated to pay up to an aggregate amount of $4.8 million, and pay an earned royalty~~-bearing~~ ~~license~~at ~~under~~low ~~certain~~single-digit percentages of ~~Oxford~~net ~~Biomedica’s~~sales IPof ~~rights~~licensed products, except for usthe tofiri-cel ~~research~~program, ~~develop,~~for ~~manufacture~~which ~~and~~we ~~commercialize~~are ~~the~~no ~~Licensed~~longer ~~Products~~obligated ~~targeting~~to ~~CD22,~~pay ~~and~~earned ~~any~~royalties ~~additional~~on ~~target~~net ~~agreed~~sales of licensed products if vectors are manufactured by Oxford. ~~Biomedica~~In ~~and~~addition, uswe ~~upon~~may ~~payment~~be obligated to pay up to an aggregate amount of $1.3 million in technology transfer milestones to an affiliate or strategic collaborator or $3 million to a ~~certain~~third ~~additional~~party ~~target~~that ~~fee~~is not a strategic collaborator.

AsUnless ~~consideration~~terminated ~~for~~earlier, the ~~rights and licenses granted under the~~ Oxford Agreement, wewill ~~paid~~expire ~~Oxford~~when ~~Biomedica~~no anfurther ~~upfront~~payments ~~fee~~are ofdue ~~$0.2~~to ~~million~~Oxford. We ~~also~~can ~~paid~~terminate ~~$0.3 million upon~~ the ~~achievement~~agreement ofat awill ~~certain~~upon ~~development~~advance ~~milestone.~~written Wenotice ~~agreed to pay up to $1.0 million of regulatory milestones~~ and ~~$8.0~~may ~~million~~be ofsubject ~~commercial milestones for each target if such milestones are achieved by Licensed Products directed~~ to ~~such target and up to an aggregate of $4.3 million if~~ certain ~~milestones related to the transfer of~~ manufacturing ~~capabilities~~slot ~~are~~cancellation ~~achieved for each target~~fees.

In March 2024, we entered into an amendment (the Oxford Amendment) to the Oxford Agreement. Pursuant to the Oxford Amendment, we and Oxford Biomedica agreed to an amended royalty payment structure for Vectors manufactured by Oxford Biomedica. We will no longer owe royalties on CRG-022 and still will owe royalties in the low single-digit percentages on the net sales of Licensed Products for Vectors used for product candidates other than CRG-022 that are manufactured by Oxford Biomedica and for any Licensed Products (including CRG-022) that are manufactured by us or a third-party following a Technology Transfer (as defined in the Oxford Agreement). We will pay up to $1.0 million of regulatory milestones for each target if such milestones are achieved by the Licensed Products directed to such target, except for CRG-022, for which a reduced regulatory milestone has been agreed. In addition, we and Oxford Biomedica have agreed a reduced commercial milestone for CRG-022.23

Pursuant to the terms of the Oxford Agreement, we solely own any and all IP rights generated under the Oxford Agreement that either relate solely and exclusively to a nucleic acid sequence encoding our CAR that recognizes CD22 or consist solely and exclusively of any improvement or modification of any proprietary materials that we provide to Oxford for use in the performance of services under the Oxford Agreement, or require the use of such proprietary materials or our confidential information.

Unless terminated earlier, the Oxford Agreement will expire when we have no further payments due to Oxford Biomedica under the agreement. We may terminate the Oxford Agreement without cause upon 120 days’ advance written notice, but we may be subject to fees involved in cancelling manufacturing slots that Oxford Biomedica has reserved for manufacturing the Vectors under the Oxford Agreement. Either party may terminate the Oxford Agreement or any applicable scope of work or work order in the event of a material breach that is not cured following written notice of such material breach. Either party can also terminate the Oxford Agreement upon insolvency of the other party.

Table of Contents

2022 National Cancer Institute license agreement

In March 2022, we entered into aan exclusive license agreement (the 2022 NCI License) with the U.S. Department of Health and Human Services, as represented by the NCI ~~(the 2022 NCI License)~~, pursuant to which ~~the~~we ~~NCI~~obtained ~~grants~~a ~~to us an exclusive,~~ worldwide, royalty-bearing, exclusive license under certain patent rights to make, use, sell, offer for sale, and import ~~products~~certain ~~(Autologous~~autologous ~~Products)~~products ~~and~~covered toby ~~practice~~such ~~processes~~licensed patents in the field of ~~certain autologously derived~~ CAR -T immunotherapies for the treatment of B-cell malignancies that express CD22, and a non-sublicensable exclusive license for evaluation purposes only to make, use, and import, but not sell, ~~products~~certain ~~(Allogenic~~allogenic ~~Products)~~products and to practice processes in the field of certain ~~allogenically-derived~~ CAR -T immunotherapies for the treatment of B-cell malignancies that express CD22 for evaluation purposes, with an exclusive option to negotiate a non-exclusive or exclusive commercialization license,. inIn ~~each~~March ~~case~~2024, ~~under~~we ~~certain~~exercised ~~patents~~our ~~owned~~right byto extend the ~~NCI. The~~ exclusive option ~~can~~one betime ~~extended once~~ for ~~one~~an additional year onand ~~payment~~paid of an option extension royalty of $050,000.~~1 million.~~

As consideration for the licenses granted under the 2022 NCI License, we ~~agreed~~are required to pay the NCI a non-refundable license fee of $0.6 million, of which $0.2 million was paid in 2022, $0.1 million was paid in 2023, and ~~the remaining balance of~~ $0.32 million iswas ~~payable~~paid in ~~two~~March ~~equal~~2024, ~~annual~~and ~~installments beginning on~~ the ~~second~~remaining ~~anniversary~~balance of ~~the effective date of the agreement. We accrued these non-refundable upfront fees on entering the 2022 NCI License. We agreed to pay up to~~ $0.~~2 million in regulatory milestone payments upon making specific regulatory filings, up to $~~1.8 million inis ~~development~~payable ~~milestone~~on ~~payments upon achieving specific clinical milestones comprising~~ the ~~initiation~~third ofanniversary ~~clinical or registrational trials, and up to $16.0 million in sales milestones upon achievement~~ of ~~specific commercial milestones. Subject to~~ the ~~terms~~effective ofdate ~~the agreement, we also agreed to pay low single-digit percentage royalties on net sales~~ of ~~Autologous Products and, if we choose to exercise~~ the ~~exclusive option mentioned above, on net sales of Allogenic Products~~agreement. We ~~also~~accrued ~~agreed to pay~~ the ~~NCI a percentage (ranging from low single-digit to low double-digit) of~~ non-~~royalty~~refundable ~~revenue~~upfront ~~received~~fees ~~by us for granting a sublicence~~ of ~~the licensed patent rights. Additionally, in the event we are granted a priority review voucher (PRV), we agreed to pay the NCI a minimum of~~ $5.0 ~~million upon the sale, transfer or lease of each PRV or $0~~.54 million upon ~~submission~~entering ~~of each PRV for use by~~ the FDA. We also agreed to pay the NCI a royalty based on a percentage (ranging from low single-digit to low double-digits) of the fair market value of the consideration we receive for any assignment of the 2022 NCI License ~~to a non-affiliate (subject to the NCI’s prior written consent) or on an allocated portion of the fair value of consideration received in connection with a change in control (including an IPO)~~. ~~On closing of the Company's IPO in November 2023, the change in control milestone was met.~~

~~Unless~~We ~~earlier~~agreed ~~terminated~~to pay up to $0.2 million in regulatory milestone payments upon achieving specific regulatory filings, ~~the~~up ~~2022~~to ~~NCI~~$1.8 ~~License~~million ~~will~~in ~~expire~~development milestone payments upon ~~the~~achieving ~~expiration~~specific clinical trials or registration trials, and up to $16.0 million in sales milestones upon achievement of ~~the~~specific ~~last~~commercial milestone events for up to ~~expire~~three distinct licensed ~~patent~~products, ~~right~~and an earned royalty on net sales of autologous cell therapy products covered by the licensed intellectual property rights, ~~but~~at a low single-digit percentage, depending on the ~~exclusive~~amount ~~license~~of ~~for~~annual ~~evaluation~~net ~~purposes~~sales and, ~~the~~if ~~accompanying~~we choose to exercise the exclusive option ~~will~~mentioned ~~expire~~above, ~~two~~on ~~years~~net ~~from~~sales of allogenic products, at a low single-digit percentage, depending on the ~~effective~~amount ~~date~~of annual net sales and subject to the terms of the 2022 NCI License. ~~The~~We ~~option~~are ~~can~~also required to make minimum annual royalty payments of $50,000 per year, which will be ~~extended~~creditable ~~once~~against royalties due for ~~one~~sales ~~additional~~in that year. ~~upon~~In ~~payment~~addition, ofwe are obligated to pay the NCI a percentage of non-~~creditable~~royalty revenue received by us from our right to sublicense. Additionally, ~~nonrefundable~~in ~~extension~~the ~~royalty~~event ofwe ~~$50~~are granted a priority review voucher (PRV),~~000~~ we would be obligated to pay the NCI a minimum of $5.0 ~~The~~million ~~NCI~~upon ~~may~~the ~~terminate~~sale, transfer or ~~modify~~lease of the PRV or $0.5 million upon submission of the PRV for use by the U.S. FDA. We are also obligated to pay the NCI a royalty based on a percentage of the fair market value of the consideration we receive for any assignment of the 2022 NCI License into a non-affiliate (upon the ~~event~~NCI’s prior written consent) or on an allocated portion of the fair value of consideration received in connection with a ~~material~~change ~~breach,~~in control (including ifan weIPO). doOn ~~not~~the ~~meet~~closing ~~certain~~of ~~milestones~~our byIPO ~~certain~~in ~~dates~~November 2023, orthe ~~upon~~change ~~certain~~of ~~insolvency~~control ~~events~~milestone, ~~that~~as ~~remain~~defined ~~uncured~~in ~~within~~the 90license ~~days~~agreement, ~~following~~was ~~written~~achieved, ~~notice~~and we and the NCI have exchanged communications regarding the amount of, ~~such~~and ~~breach~~underlying ormethodology ~~insolvency~~to ~~event~~determine the amount of this milestone. We ~~may~~accrued ~~terminate~~a ~~the~~total ~~2022~~of ~~NCI~~$0.3 ~~License,~~million orrelated ~~any~~to ~~portion~~this ~~thereof~~milestone under both license agreements, atand we continue to believe that the accrual represents our ~~sole~~best ~~discretion~~estimate atof ~~any~~this ~~time~~milestone ~~upon~~amount. 60However, ~~days’~~there ~~advance~~can ~~written~~be ~~notice~~no assurances that the amount accrued will be the amount agreed to between the ~~NCI~~parties.

Unless earlier terminated, the 2022 NCI License will expire upon the expiration of the last to expire of the licensed patent rights. The NCI may terminate or modify the 2022 NCI License in the event of an uncured material breach, including, but not limited to, if we do not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. We may terminate the license, or any portion thereof, at our sole discretion at any time upon 60 days written notice to the NCI.

2023 National Cancer Institute license agreement

In February 2023, we entered into aan ~~second~~exclusive license agreement ~~with the NCI~~ (the 2023 NCI License) with the NCI, pursuant to ~~acquire~~which anwe ~~exclusive,~~obtained a worldwide, royalty-bearing, exclusive license under certain patent rights owned by the NCI to make, use, sell and import products and to practice processes in the field of certain CAR T immunotherapies for the treatment of B-cell malignancies, wherein the T cells are engineered to express CD22 in combination with binders, CARs, or other receptors targeting CD19, CD20, and/or CD79b; and at least one of the following: manufacturing the product with the STASH platform technology and/or a technology to activate CD2 signaling in the CAR T cell. As consideration for the license granted under the 2023 NCI License, we agreed to pay the NCI a non-refundable license fee of $0.3 million, of which $0.1 million was paid in 2023, and the remaining balance of $0.2 million is payable in two equal annual installments beginning on the first anniversary of the effective date of the agreement, and up to $0.1 million in regulatory milestone payments upon making specific regulatory filings, up to $1.7 million in development milestone payments upon achieving specific clinical trials or registration trials, and up to $16.0 million in sales milestone upon achievement of specific commercial milestone events. Subject to the terms of the agreement, we also agreed to pay a low single-digit percentage royalties on net sales of Allogenic Products. We also agreed to pay the NCI a low double-digit percentages of non-royalty revenue received by us for granting a sublicence of the licensed patent rights.

30As consideration for the licenses granted under the 2023 NCI License, we agreed to pay the NCI a non-refundable license fee of $0.3 million in three installments whereby the first installment was payable within 60 days

Table of Contents

~~Additionally,~~of in the ~~event~~execution weof ~~are~~the ~~granted~~agreement aand ~~PRV, we agreed to pay~~ the ~~NCI~~remaining atwo ~~minimum~~payments ofare ~~$5.0~~due ~~million~~on ~~upon~~ the ~~sale,~~first ~~transfer~~and orsecond ~~lease~~anniversaries of ~~each~~the ~~PRV~~effective ordate ~~$0.5 million upon submission~~ of ~~each PRV for use by~~ the ~~FDA~~agreement. WeAdditionally, ~~also~~we agreed to ~~pay~~reimburse the NCI ~~a royalty based on a low single-digit percentage of the fair market value of the consideration that we receive~~ for ~~any~~$0.1 ~~assignment~~million ofin ~~the~~expenses ~~2023~~incurred ~~NCI~~by ~~License to a non-affiliate (subject to~~ the NCI’s prior ~~written~~to ~~consent)~~January or1, on2022, anrelated ~~allocated~~to ~~portion of~~ the ~~fair value of consideration received in connection with a change in control (including an IPO). On closing of the Company's IPO in November 2023~~preparation, ~~the change in control milestone was met. As of December 31~~filing, ~~2023~~prosecution, weand ~~accrued~~maintenance ~~a total~~ of ~~$0.3~~all ~~million~~patent ofapplications ~~research~~ and ~~development~~patents ~~expense~~included ~~related to the change~~ in ~~control royalty for both~~ the ~~2022~~license ~~NCI~~under ~~License and~~ the 2023 NCI License.

~~Unless~~We ~~earlier~~agreed ~~terminated~~to pay up to $0.1 million in milestone payments upon achievement of certain regulatory milestone events, ~~the~~up ~~2023~~to ~~NCI~~$1.7 ~~License~~million ~~will~~in ~~expire~~milestone payments upon ~~the~~achievement ~~expiration~~of certain development milestone events including initiation of ~~the~~specific ~~last~~clinical totrials ~~expire~~or ~~licensed~~registration ~~patent~~trials, and up to $16.0 ~~The~~million ~~NCI~~in ~~may~~milestone ~~terminate~~payments orupon ~~modify~~achievement of specific commercial milestone events. Subject to the terms of the 2023 NCI License, inwe also agreed to pay a low single-digit percentage on earned royalties on net sales of products covered by the ~~event~~licensed patent rights. We also agreed to make minimum annual royalty payments of a$50,000 ~~material~~per ~~breach~~year, ~~including~~which ifwill be creditable against royalties due for sales in that year. In addition, we doare ~~not~~obligated ~~meet~~to ~~certain~~pay ~~milestones~~the NCI a percentage of non-royalty revenue received by ~~certain~~us ~~dates~~from our right to sublicense at defined percentages. Additionally, orif ~~upon~~we ~~certain~~are ~~insolvency~~granted ~~events~~a ~~that~~PRV, ~~remain~~we ~~uncured~~would ~~within~~be 90obligated ~~days~~to ~~following~~pay ~~written~~the ~~notice~~NCI a minimum of ~~such~~$5.0 ~~breach~~million upon the sale, transfer or ~~insolvency~~lease ~~event~~of the PRV or $0.5 million upon submission of the PRV for use by the FDA. We ~~may~~are ~~terminate~~also obligated to pay the NCI a royalty based on a percentage of the fair market value of the consideration that we receive for any assignment of the 2023 NCI License, to a non-affiliate (upon the NCI’s prior written consent) or ~~any~~on an allocated portion ~~thereof~~of the fair value of consideration received in connection with a change in control (including an IPO). On the closing of our IPO in November 2023, atthe change in control milestone, as defined in our ~~sole~~license ~~discretion~~agreement atwas ~~any~~achieved, ~~time~~and ~~upon~~the 60parties ~~days’~~have ~~advance~~exchanged ~~written~~communications ~~notice~~regarding the amount of, and underlying methodology to determine the ~~NCI~~amount of this milestone. We accrued a total of $0.3 million related to this milestone under both license agreements, and we continue to believe that the accrual represents our best estimate of this milestone amount. However, there can be no assurances that the amount accrued will be the amount agreed to between the parties.

Unless earlier terminated, the 2023 NCI License will expire upon the expiration of the last to expire of the licensed patent rights. The NCI may terminate or modify the 2023 NCI License in the event of an uncured material breach, including, but not limited to, if we do not meet certain milestones by certain dates, or upon certain insolvency events that remain uncured following the date that is 90 days following written notice of such breach or insolvency event. We may terminate the license, or any portion thereof, at our sole discretion at any time upon 60 days written notice to the NCI.

Government regulation

The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as those we are developing. We, along with third-party contractors and service providers, will navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies in the US and other countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.

U.S. biologics development process

In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:

•

completion of certain preclinical laboratory studies in accordance with Good Laboratory Practice (GLP) regulations, and other applicable regulations;

•

submission to the FDA of an IND, which must become authorized before human clinical trials may begin;

•

approval by an independent institutional review board (IRB), or ethics committee at each clinical site before each trial may be initiated;

Table of Contents

•

performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice (GCP) regulations to evaluate the safety, purity and potency (or efficacy) of the product candidate for its intended use;

•

submission to the FDA of a Biologics License Application (BLA), after completion of all pivotal trials;

•

a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biologic is produced to assess compliance with current Good Manufacturing Practice requirements (cGMP), to ensure that the facilities, methods and controls are adequate to preserve the biologic’s identity, strength, quality and purity;

•

satisfactory completion of potential inspection of selected clinical investigation sites to assess compliance with GCP;

•

satisfactory completion of an FDA advisory committee review, if required; and

•

Table of Contents

FDA review and approval of the BLA to authorize commercial marketing of the product for the treatment of one or more specific indications in the United States.

Once a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for FDA allowance to administer an investigational product to humans. An IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and any effectiveness criteria to be evaluated . Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the IND on a clinical hold. If FDA issues a clinical hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance with FDA requirements, in which case clinical trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

In addition to the submission of an IND to the FDA, under the NIH Guidelines, supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.

Clinical trials involve the administration of an investigational product to human subjects and must be conducted under the supervision of one or more qualified investigators in accordance with GCP, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under detailed protocols setting out the objectives of the trial, dosing procedures, subject inclusion and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and a separate amendment to the existing IND must be made for each successive clinical trial protocol and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for unexpected suspected serious adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs or biologics, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

Furthermore, an independent IRB or ethics committee at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the informed consent form that must be provided to each potential trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB requirements and regulations governing experimentation with human subjects. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the biologic has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to and evaluation of certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries, including clinical trials.gov.

Table of Contents

regulations governing experimentation with human subjects. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the biologic has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to and evaluation of certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries, including clinical trials.gov.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

•

Phase 1: The product candidate is initially introduced into healthy human subjects or subjects with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness.

•

Table of Contents

Phase 2: The product candidate is administered to a limited patient population having a specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage.

•

Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide an adequate basis for product labeling.

Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after BLA approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the biologic in order to finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer must, among other things, develop methods for testing the identity, strength, quality and purity of the final product. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

BLA review and approval process

Assuming successful completion of all required studies in accordance with applicable regulatory requirements, the results of product development, including among other things, results from preclinical studies and clinical trials, are submitted to the FDA as part of a BLA requesting authorization to market the product candidate for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, and controls (CMC), and proposed labeling, among other things. Data can come from company-sponsored clinical studies or from alternative sources, such as studies initiated by investigators or other third parties. The submission of a BLA requires payment of a substantial user fee to FDA, and the sponsor of an approved BLA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances.

The FDA conducts a preliminary review of a BLA within the first 60 days after submission to determine whether they are sufficiently complete to permit substantive review before accepting the application for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the requested additional information before FDA will review the application. Once filed, the FDA reviews a BLA to determine, among other things, whether the biologic is safe and efficacious and the facility in which it is manufactured, processed, packed, or held meets cGMP designed to assure the product’s continued safety, purity and potency. Under the Prescription Drug User Fee Act (PDUFA), guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of an original BLA to review and act on the submission. This review typically takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to decide whether to accept a BLA application for filing.

The FDA may refer an application for a novel biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation on whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.27

Table of Contents

isoriginal ~~complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the~~ BLA ~~identified by the FDA and may include requirements~~ to ~~conduct~~review ~~additional clinical trials, or other significant~~ and ~~time-consuming~~act ~~requirements~~on ~~related to~~ the ~~sufficiency of the clinical data provided, nonclinical studies or CMC-related activities~~submission. IfThis areview ~~CRL~~typically istakes ~~issued,~~twelve ~~the~~months ~~sponsor~~from ~~must submit a revised BLA addressing all of~~ the ~~deficiencies~~date ~~identified in~~ the ~~letter~~BLA oris ~~withdraw~~submitted ~~the~~to ~~application. Even if~~ the ~~applicant~~FDA ~~submits~~because the ~~requested~~FDA ~~data~~has ~~and~~approximately ~~information~~two ~~the~~months ~~FDA~~to ~~may~~decide ~~still~~whether ~~decide~~to ~~that~~accept ~~the~~a BLA ~~does~~application ~~not satisfy the criteria~~ for ~~approval~~filing.

IfThe ~~a product receives regulatory approval, referred to as “licensure” by the~~ FDA, ~~such approval~~ may berefer ~~significantly~~an ~~limited~~application ~~to specific diseases and dosages, or the indications~~ for ~~use~~a ~~may~~novel ~~otherwise~~biologic beto ~~limited,~~an ~~which~~advisory ~~could restrict the commercial value of the product~~committee. InAn ~~addition,~~advisory ~~the~~committee ~~FDA~~is ~~may~~a ~~require~~panel ~~the sponsor~~ of anindependent ~~approved BLA to conduct one or more post-marketing clinical trials designed to further assess a biologic’s safety and efficacy~~experts, ~~and~~including ~~may~~clinicians ~~also require testing~~ and ~~surveillance~~other ~~programs~~scientific toexperts, ~~monitor~~that ~~the~~reviews, ~~safety~~evaluates ~~of the product once commercialized~~ and ~~may~~provides ~~limit~~a ~~further~~recommendation ~~marketing of the product based~~ on ~~the~~whether ~~results of these post-marketing studies. The FDA may also place other conditions on BLA approval. including~~ the ~~requirement~~application ~~for~~should abe ~~risk~~approved ~~evaluation~~ and ~~mitigation~~under ~~strategy~~what ~~(REMS), to assure the safe use of the product~~conditions. IfThe ~~the~~ FDA ~~concludes~~is anot ~~REMS~~bound isby ~~needed,~~ the ~~sponsor~~recommendations of ~~the~~an ~~BLA~~advisory ~~must submit a proposed REMS in conjunction with the BLA~~committee, ~~which~~but ~~could~~it ~~include~~considers ~~medication guides, physician communication plans or other elements to assure safe use,~~ such asrecommendations ~~restricted~~carefully ~~distribution~~when ~~methods,~~making ~~patient registries and other risk minimization tools~~decisions. ~~Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of any approved products.~~

Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. Additionally, before approving a BLA, the FDA may inspect one or more clinical trial sites to ensure such sites complied with GCP. After the FDA evaluates a BLA and inspects the manufacturing facilities where the investigational product and/or the commercial drug product will be produced, the FDA typically issues either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the biologic with prescribing information for specific indications. A CRL indicates that the review cycle for the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the BLA identified by the FDA and may include requirements to conduct additional clinical trials, or other significant and time-consuming requirements related to the sufficiency of the clinical data provided, nonclinical studies or CMC-related activities. If a CRL is issued, the sponsor must submit a revised BLA addressing all of the deficiencies identified in the letter or withdraw the application. Even if the applicant submits the requested data and information the FDA may still decide that the BLA does not satisfy the criteria for approval.

If a product receives regulatory approval, referred to as “licensure” by the FDA, such approval may be significantly limited to specific diseases and dosages, or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require the sponsor of an approved BLA to conduct one or more post-marketing clinical trials designed to further assess a biologic’s safety and efficacy, and may also require testing and surveillance programs to monitor the safety of the product once commercialized and may limit further marketing of the product based on the results of these post-marketing studies. The FDA may also place other conditions on BLA approval, including the requirement for a risk evaluation and mitigation strategy (REMS), to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS in conjunction with the BLA, which could include medication guides, physician communication plans or other elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of any approved products.

In addition, the Pediatric Research Equity Act (PREA), requires a sponsor to conduct pediatric clinical trials for most biologics, as well as for new indications, new dosage forms, new dosing regimens or new routes of administration. Under PREA, original BLAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe, pure and potent. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the biologic is ready to be approved for use in adults before pediatric clinical trials are complete or that additional data need to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.

Orphan designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product (including biologics) intended to treat a rare disease or condition, defined as a disease or condition that affects fewer than 200,000 individuals in the United States or where, if the disease or condition affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same biologic for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The receipt of orphan drug designation for a biologic entitles a party to certain financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors may receive approval of different products for the disease or condition for which the orphan product has exclusivity or obtain approval for the same product but for a different disease or condition for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of a competing product for seven years if a competitor obtains approval of the “same drug,” as defined by the FDA, or if the biologic is determined to be contained within the competitor’s product for the same disease or condition. In addition, if an orphan-designated product receives approval for a disease or condition broader than covered in the orphan designation, the product may not be entitled to orphan exclusivity.28

Table of Contents

Expedited development and review programs

The FDA has a number of programs intended to expedite drug development and/or review of an application for marketing authorization for an investigational biologic. For example, the fast-track designation program is intended to expedite or facilitate the process for developing and reviewing product candidates that meet certain criteria. Investigational biologics are eligible for fast-track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for that disease or condition. The sponsor of a fast-track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. Also, for product candidates in development under a fast-track designation, the FDA may agree to review sections of the BLA on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.

A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible to receive a Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast-track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.

Certain investigational biologics may also be eligible for regenerative medicine advanced therapy RMAT) designation. This designation may be available where the product candidate qualifies as an RMAT, meaning that, with limited exceptions, the investigational new drug: (1) is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products; (2) is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides all the benefits of a Breakthrough Therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review of a BLA submission. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, as discussed below, or through reliance upon data obtained from a meaningful number of clinical trial sites, including through expansion of trials to additional sites.

Product candidates submitted to the FDA for approval, including product candidates with Fast Track, Breakthrough Therapy, or RMAT designations, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review. A BLA is eligible for priority review if the product candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of a BLA designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of original BLAs under its current PDUFA review goals.

In addition, depending on the design of the applicable clinical trials, certain products may be eligible for accelerated approval. A product candidate intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that it has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability of alternative treatments or lack thereof. As a condition of approval, the FDA generally requires that a sponsor of a biologic receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials and may require that such confirmatory trials be underway prior to granting accelerated approval. Biologics receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory trials in a timely manner or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition of accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.29

Table of Contents

None of these specific designations or mechanisms for accelerated or expedited review of applications for marketing authorization change the standards for approval but may expedite development or the regulatory approval processes. Even if a product candidate qualifies for one or more of those programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

FDA regulation of companion diagnostics

We believe that certain of our product candidates may require an in vitro diagnostic (IVD) to identify appropriate patient populations for investigation and/or use of our product candidates. IVDs, often referred to as companion diagnostics, are regulated by FDA as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, IVDs require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (PMA). Most companion diagnostics for oncology product candidates utilize the PMA pathway.

If use of companion diagnostic is deemed essential to the safe and effective use of a drug product, then the FDA generally will require approval or clearance of the diagnostic for the use indicated on the product label contemporaneously with the approval of the product. On August 6, 2014, the FDA issued a final guidance document addressing the development and approval process for “In Vitro Companion Diagnostic Devices.” According to the guidance, for novel product candidates, a companion diagnostic device and its corresponding drug candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the IVD may be determined to be a significant risk device under the FDA’s Investigational Device Exemption (IDE) regulations, in which case the sponsor of the IVD will be required to submit and obtain approval of an IDE application, and subsequently to comply with the IDE regulations. However, according to the guidance, if an IVD and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets the requirements of both the IDE regulations and the IND regulations. The guidance provides that, depending on the details of the study plan and degree of risk posed to subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.

The FDA has generally required IVDs intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic simultaneously with approval of the therapeutic. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device’s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. In addition, PMAs for certain devices must generally include the results from extensive preclinical studies, as well as from well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for an IVD, the applicant must demonstrate that it produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer’s facilities for compliance with the current Quality System Regulation (QSR), which imposes comprehensive testing, control, documentation and other quality assurance requirements.

If the FDA’s evaluation of the PMA application is favorable, the FDA may issue an approvable letter requiring the applicant’s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA’s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and the data submitted in an amendment to the PMA. If and when the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. 30

Table of Contents

~~The~~particular, ~~PMA~~for ~~may~~an ~~also~~IVD, ~~include~~the ~~post-approval~~applicant ~~conditions~~must demonstrate that ~~the~~it ~~FDA~~produces ~~believes~~reproducible ~~necessary~~results towhen ~~ensure~~ the ~~safety~~same ~~and~~sample ~~effectiveness~~is oftested ~~the~~multiple ~~IVD,~~times ~~including,~~by ~~among~~multiple ~~other~~users ~~things,~~at ~~restrictions~~multiple onlaboratories. ~~labeling,~~As ~~promotion,~~part ~~sale~~of ~~and~~the ~~distribution.~~PMA ~~Once granted~~review, ~~PMA~~the ~~approval~~FDA ~~may~~will betypically ~~withdrawn~~inspect by the ~~FDA~~manufacturer’s iffacilities for compliance with ~~post-approval~~the ~~requirements,~~current ~~conditions~~Quality ofSystem ~~approval~~Regulation or(QSR), ~~other~~which ~~regulatory~~imposes ~~standards~~comprehensive istesting, ~~not~~control, ~~maintained~~documentation orand ~~problems~~other ~~are~~quality ~~identified~~assurance ~~following initial marketing~~requirements.

After an IVD is approved for marketing, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. IVD manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which currently cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.

Post-approval requirements

Biologics are subject to rigorous and ongoing regulation by the FDA following receipt of a marketing authorization, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their manufacturing facilities with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which imposes certain procedural and documentation requirements upon drug developers and third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort on production and quality control to maintain compliance with cGMP and other compliance requirements.

The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of requirements for post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of the product, up to and including complete withdrawal of the product from the market or product recalls;

•

fines, warning letters, or untitled letters;

•

clinical holds on ongoing or planned clinical studies;

Table of Contents

•

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of approvals;

•

product seizure or detention, or refusal to permit the import or export of products;

•

consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;

•

mandated modification of promotional materials and labeling and the issuance of corrective information;

•

the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or

•

injunctions or the imposition of civil or criminal penalties.

Table of Contents

In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of biological products. A company can make only claims relating to safety and efficacy that have been approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Biosimilars and exclusivity

The Affordable Care Act, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in respect of safety, purity, and potency, can be shown through analytical studies, animal studies, and one or more clinical studies. Interchangeability requires that a proposed biosimilar product can be substituted for the reference product and the biosimilar manufacturer must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient.

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. ~~At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.~~

A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds an extra six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.

Other healthcare laws

Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, pricing reporting, and physician payment transparency laws and regulations regarding drug pricing and payments or other transfers of value made to physicians and other licensed healthcare professionals as well as similar foreign laws in jurisdictions where the company does business outside the United States. Violation of any of such laws or any other governmental regulations that apply may result significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional reporting requirements and oversight obligations, contractual ~~damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and/ or imprisonment.~~

~~Coverage and reimbursement~~32

Table of Contents

~~Further~~damages, third-party payors are increasingly reducing reimbursements for medical drugs and services and implementing measures to control utilization of drugs (such as requiring prior authorization for coverage). For products administered under the ~~supervision~~curtailment ofor arestructuring ~~physician, obtaining coverage and adequate reimbursement may be particularly difficult because~~ of ~~the higher prices often associated with such drugs. Additionally~~operations, ~~separate~~exclusion ~~reimbursement~~from ~~for~~participation ~~the~~in ~~product~~governmental ~~itself~~healthcare orprograms ~~the~~and/ ~~treatment~~ or ~~procedure in which the product is used may not be available, which may impact physician utilization~~imprisonment.

Coverage and reimbursement

Successful sales of our drug candidates in the U.S. market, if approved, will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs or private health insurance (including managed care plans). Patients generally rely on such third-party payors to reimburse all or part of the costs associated with their prescriptions and therefore adequate coverage and reimbursement from such third-party payors are critical to new and ongoing product acceptance. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly. Further, third-party payors are increasingly reducing reimbursements for medical drugs and services and implementing measures to control utilization of drugs (such as requiring prior authorization for coverage). For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.

Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs. Adoption or expansion of price controls and cost-containment measures could further limit our net revenue and results. Decreases in third-party reimbursement for our investigational drug products, if approved, or a decision by a third-party payor to not cover our investigational drug products could have a material adverse effect on our sales, results of operations and financial condition.

General legislative cost control measures may also affect reimbursement for our products. If we obtain approval to market a drug candidate in the United States, we may be subject to spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs and/or significant related taxes or fees.

U.S. healthcare reform

The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.

For example, in March 2010, the Affordable Care Act, or ACA, was enacted in the United States and substantially changed the way healthcare is financed by both the government and private insurers. The ACA contains provisions that may reduce the profitability of drug products. Among other things, the ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers’ Medicaid rebate liability to covered outpatient drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the 340B drug pricing program; and increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in place in its current form.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. Most significantly, onin August ~~16,~~ 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare ~~(beginning in 2026)~~, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new ~~discounting~~manufacturer discount program (beginning in 2025). CMS ~~The~~has ~~IRA~~published ~~permits~~ the ~~Secretary~~negotiated ofprices ~~the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation,~~ for the initial ~~years.~~ten ~~HHS~~drugs, ~~has~~which ~~and~~ will ~~continue~~first tobe ~~issue~~effective ~~and~~in ~~update its guidance documents as these programs are implemented. On August 29~~2026, ~~2023,~~and ~~HHS~~has ~~announced~~published the list of the ~~first~~subsequent ~~ten~~15 drugs that will be subject to ~~price negotiations, even though this part of the IRA remains subject to ongoing legal challenges~~negotiation. The ~~impact of the~~ IRA ~~on the pharmaceutical industry and our business cannot yet be fully determined but is likely to be significant. Additional drug pricing proposals could appear in future legislation.~~

Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.33

Table of Contents

Atpermits the ~~state~~Secretary ~~level,~~of ~~legislatures~~the ~~have~~Department ~~increasingly~~of ~~passed~~Health ~~legislation~~ and ~~implemented~~Human ~~regulations~~Services ~~designed~~(HHS) to ~~control~~implement ~~pharmaceutical~~many ~~and~~of ~~biological~~these ~~product~~provisions ~~pricing~~through guidance, ~~including~~as ~~price~~opposed orto ~~reimbursement constraints~~regulation, ~~discounts,~~for ~~restrictions~~the oninitial ~~certain~~years. ~~product~~HHS ~~access~~has and ~~marketing~~will ~~cost~~continue ~~disclosure~~to issue and ~~transparency~~update ~~measures,~~guidance ~~and,~~as inthese ~~some~~programs ~~cases~~are implemented, ~~designed~~although tothe ~~encourage~~Medicare ~~importation~~drug ~~from~~price ~~other~~negotiation ~~countries~~program ~~and~~is ~~bulk~~currently ~~purchasing.~~subject Into ~~addition,~~legal ~~regional~~challenges. The ~~healthcare~~impact ~~authorities~~of ~~and~~the ~~individual~~IRA ~~hospitals~~on ~~are~~the ~~increasingly~~pharmaceutical ~~using~~industry ~~bidding~~and ~~procedures~~our tobusiness ~~determine~~cannot ~~what~~yet ~~pharmaceutical~~be ~~products~~fully ~~and~~determined ~~which~~but ~~suppliers~~is ~~will~~likely to be ~~included~~significant. inAdditional ~~their~~drug ~~prescription~~pricing ~~drug~~proposals ~~and~~could ~~other~~appear ~~healthcare~~in ~~programs~~future legislation.

Existing healthcare reform measures, as well as the implementation of additional cost containment measures or other reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

Data privacy and security

Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

Corporate information

We were incorporated in the state of Delaware in December 2019 as Syncopation Life Sciences, Inc. and changed our name to CARGO Therapeutics, Inc. in September 2022. Our principal executive offices are located at ~~1900~~835 ~~Alameda~~Industrial ~~Las Pulgas~~Road, Suite ~~350~~400, San ~~Mateo~~Carlos, California, and our telephone number is (650) 379-6143. Our corporate website address is www.cargo-tx.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K.

Employees and human capital resources

As of December 31, ~~2023~~2024, we had approximately ~~116~~167 full-time employees. None of our employees are represented by a labor union or party to a collective bargaining agreement. We consider our relationship with our employees to be good.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can ~~have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.~~

Table of Contents

have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

Available information

We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, and related amendments, exhibits and other information with the Securities and Exchange Commission (SEC). You may access and read our filings without charge through the SEC’s website at www.sec.gov or through our website at https://investors.cargo-tx.com/financial-information/sec-filings, as soon as reasonably practicable after such materials are electronically filed with or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K.

4035

Table of Contents

Item 1A. Risk Factors.

Risk factors

Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, as well as the other information contained in this Annual Report on Form 10-K, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K, before making investment decisions regarding our common stock. The risks described below are not the only ones facing us. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, reputation or results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment.

Risk Factor Summary

Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are more fully described in the section titled “Risk factors” immediately following this summary. These risks include, among others, the following:

•

We are a clinical-stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.

•

Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.

•

The substantial obligations from our license agreements may result in dilution to our stockholders, may be a drain on our cash resources or may cause us to incur debt obligations to satisfy the payment obligations.

•

If we are unable to successfully identify, develop, obtain regulatory approval and ultimately commercialize any of our current or future product candidates, or experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.

•

We ~~have~~may ~~experienced~~be ~~rapid~~unable ~~operational growth since our inception in December 2019, and expect~~ to ~~continue~~realize ~~to grow in~~ the ~~future~~level asof ~~our clinical and preclinical trials progress, we begin to advance~~ the ~~development~~anticipated ofbenefits ~~new~~that ~~and current product candidates and our headcount increases. If~~ we ~~fail~~expect tofrom ~~effectively~~restructuring ~~manage~~ our ~~growth~~operations, wewhich may ~~not~~adversely beimpact ~~able~~our tobusiness ~~execute~~and onresults ~~our~~of ~~business objectives~~operations.

•

Our ability to develop our product candidates and our platform technologies, as well as our future growth, depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel.

•

We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.

•

We rely on third parties to conduct our clinical trials, manufacturing and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product candidates may be delayed.

•

WeFailure ~~have~~to ~~identified~~establish ~~material~~and ~~weaknesses~~maintain ineffective ~~our~~ internal control over financial reporting. Ifcould ~~our~~have ~~remediation~~a ~~of the~~ material ~~weaknesses~~adverse iseffect ~~not~~on ~~effective,~~our orability ~~if we experience additional material weaknesses in the future or otherwise fail~~ to ~~maintain an effective system of internal controls in the future, we may not be able to accurately or timely~~ report our financial condition, or results of operations, ~~which~~or ~~may~~cash ~~adversely~~flows ~~affect~~accurately ~~investor confidence in us~~ and, ason a ~~result,~~timely ~~the~~basis ~~value~~and ofcould harm our ~~common stock~~reputation.

•

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

4136

Table of Contents

Risks related to our limited operating history, financial condition and need for additional capital

We are a clinical-stage biotechnology company with a limited operating history. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We have incurred significant losses since our inception in December 2019, have no products approved for commercial sale, have not generated any revenue from product sales, have financed our operations principally through private placements of convertible preferred stock, convertible promissory notes and our initial public offering of our common stock and expect to incur significant losses for the foreseeable future. We expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Our net loss was $98167.15 million and $4198.01 million for the years ended December 31, ~~2023~~2024 and ~~2022~~2023, respectively. As of December 31, ~~2023~~2024, we had an accumulated deficit of $~~145~~312.16 million. Our losses have resulted principally from expenses incurred in connection with our research and development activities, including our clinical and preclinical development activities, as well as the buildout of our platform technologies such as our CD2 platform, and from general and administrative costs associated with our operations.

We have devoted a significant portion of our financial resources and efforts to building our organization, conducting research and development, identifying and developing potential product candidates, executing preclinical studies and clinical trials, building and enhancing our platform technologies, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. We are in the early stages of clinical development and have not completed development and commercialization of any of our product candidates.

We expect our expenses and operating losses will continue to increase substantially for the foreseeable future as we expand our research and development efforts, expand the capabilities of our platform technologies, conduct clinical trials and preclinical studies, seek regulatory approval and commercialization of our product candidates and operate as a public company. We anticipate that our expenses will continue to increase substantially as we:

•

continue clinical and preclinical development of our current and future product candidates and initiate additional clinical trials and preclinical studies;

•

continue to build out and enhance our platform technologies;

•

seek regulatory approval of our current and future product candidates;

•

expand our operational, financial and management systems and increase personnel, including personnel to support our clinical and preclinical development, manufacturing and commercialization efforts;

•

~~to the extent we~~ acquire or in-license additional product candidates, technologies and other assets for our business;

•

continue to develop, perfect, maintain and protect our intellectual property portfolio; and

•

incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.

To become and remain profitable, we must succeed in identifying, developing, conducting successful clinical trials, obtaining regulatory approval for and eventually commercializing, manufacturing and supplying products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, continuing to discover and develop additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, developing manufacturing processes and methods, devising and implementing processes for transferring technology and manufacturing processes to a network of third-party manufacturing sites, establishing necessary quality control, ensuring current Good Manufacturing Practice (cGMP) readiness, establishing marketing capabilities, commercializing and ultimately selling any products. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve

4237

Table of Contents

or sustain profitability or to meet outside expectations for our profitability, the price of our common stock could be materially adversely affected.

Because of the numerous risks and uncertainties associated with pharmaceutical and biotechnology products and drug development, including the development of cell therapy product candidates, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration (FDA) or comparable foreign regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in commencing or completing our clinical trials or the development of any of our product candidates, our expenses could increase and any potential commercial revenue could be further delayed and become more uncertain, which will have a material adverse impact on our business.

Our limited operating history may make it difficult to evaluate our prospects and likelihood of success.

We are a clinical-stage biotechnology company with a limited operating history upon which you can evaluate our business and prospects. Since our inception in December 2019, we have devoted substantially all of our resources and efforts to building our organization, in-licensing technologies, building our platform technologies, identifying and developing potential product candidates, preparing for, and as the case may be, initiating clinical trials and preclinical studies, developing manufacturing processes and methods, devising and implementing processes for transferring technology and manufacturing processes to a network of third-party manufacturing sites, ensuring supply of critical reagents and final products to support the clinical trials and eventually commercialization, organizing and staffing our company, business planning, establishing, maintaining and protecting our intellectual property portfolio, raising capital and providing general and administrative support for these operations. All of our product candidates are in either clinical development or in preclinical stages of development, and we have not yet demonstrated our ability to successfully complete any late-stage or ~~registration~~registrational clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third-party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical-stage companies in rapidly evolving fields. For example, in January 2025 we announced our election to discontinue the FIRCE-1 Phase 2 study of firi-cel because we believe the results do not support a competitive benefit-risk profile for the intended patient populations. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, it could have a material adverse effect on our business.

We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.

Developing biotechnology products, including conducting clinical trials and preclinical studies, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and our expenses will continue to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned preclinical studies and clinical trials of, and seek regulatory approval for, our current product candidates and future product candidates we may develop or otherwise acquire. In addition, as our product candidates progress through development and toward commercialization, we will need to make milestone payments to the licensors and other third parties from whom we have in-licensed our product candidates or certain proprietary products used in the manufacturing of our clinical products, including The Board of Trustees of the Leland Stanford Junior University (Stanford University), The National Cancer Institute (the NCI) and Oxford Biomedica (UK) Limited (Oxford). Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate, including manufacturing and supply costs, as well as costs associated with establishing a sales and end-to-end supply chain management infrastructure. To date, we have funded our operations principally through private financings and our recently completed initial public offering. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development and manufacturing of our product candidates,

4338

Table of Contents

chain management infrastructure. To date, we have funded our operations principally through private financings and our recently completed initial public offering. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development and manufacturing of our product candidates, continuing to develop and enhance our platform technologies, commence additional clinical trials and preclinical studies and continue to identify and develop additional product candidates.

In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and end-to-end supply chain management between the treatment sites and manufacturing sites. Furthermore, following the completion of our initial public offering, we have incurred, and expect to continue to incur, additional costs as we operate as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future regulatory approval or commercialization efforts.

We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. We may also raise additional financing on an opportunistic basis in the future. We expect to continue to expend significant resources for the foreseeable future. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors, including but not limited to:

•

the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;

•

the number of clinical trials required for regulatory approval of our current or future product candidates;

•

the costs, timing and outcome of regulatory review of any of our current or future product candidates;

•

the costs associated with developing and enhancing our platform technologies, including our current CD2 platform;

•

the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any future milestone, royalty or other payments due in connection with such acquisition or license;

•

the cost of manufacturing clinical and commercial supplies of our current or future product candidates, including the costs associated with end-to-end supply chain management between the treatment sites and manufacturing sites;

•

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;

•

our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;

•

the costs and timing of future commercialization activities, including manufacturing, marketing, sales and end-to-end supply chain management, for any of our product candidates for which we receive regulatory approval;

•

the revenue, if any, received from commercial sales of our product candidates for which we receive regulatory approval;

•

expenses to attract, hire and retain skilled personnel;

•

the costs of operating as a public company;

~~our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;~~39

Table of Contents

•

~~addressing~~our ~~any~~ability ~~potential~~to ~~interruptions~~establish ora ~~delays~~commercially ~~resulting~~viable ~~from~~pricing ~~factors~~structure ~~related~~and toobtain ~~pandemics,~~approval ~~such~~for ascoverage ~~the COVID-19 pandemic,~~ and ~~adverse~~adequate ~~political~~reimbursement ~~events~~from ~~such~~third-party asand government ~~shutdowns~~payors;

•

addressing any potential interruptions or delays resulting from factors related to health epidemics, pandemics, other widespread outbreaks of contagious disease, and adverse political events such as government shutdowns;

•

the effect of competing technological and market developments; and

•

the extent to which we acquire or invest in business, products and technologies.

Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations. Because of the numerous risks and uncertainties associated with research, product development and commercialization of product candidates, we are unable to predict the timing or amount of our working capital requirements or when or if we will be able to achieve or maintain profitability.

Accordingly, we will need to continue to rely on additional financing to achieve our business objectives and adequate additional financing may not be available to us on acceptable terms, or at all.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash and cash equivalents, any future equity or debt financings and upfront and milestone and royalty payments, if any, received under any future licenses or collaborations. We do not have any committed external source of funds. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the trading price of our common stock to decline. Debt financing and preferred equity financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business.

If we raise additional funds through collaborations, strategic alliances or marketing, supply or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of common stock. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects.

In connection with our ~~recent~~ license agreements, we entered into arrangements whereby the counterparties to such agreements are entitled to substantial contingent consideration payments upon the occurrence of certain events. For example, under the terms of our license agreement with Stanford University, in addition to the annual license maintenance fees of up to $0.1 million per year, we may also be required to pay up to $12.0 million in milestone payments upon achievement of specific intellectual property, clinical, regulatory and commercial milestone events. In addition, under this license agreement we will be obligated to pay low single-digit percentage royalties on net sales. We are also obligated to pay Stanford University a percentage of non-royalty revenue received by us from our right to sublicense at defined percentages.

In addition, under the terms of our license agreement with Oxford Biomedica for the manufacture and supply of lentiviral vectors for clinical and potentially commercial purposes, we may also be required to pay up to $9.3 million if certain development, regulatory and commercial milestones are achieved. Additionally, we are obligated to pay low single-digit percentage royalties on net sales of products generated under the Oxford Agreement. Further, under the 40

Table of Contents

In addition, under the terms of our license agreement with Oxford, as amended, for the manufacture and supply of lentiviral vectors for clinical and potentially commercial purposes, we may also be required to pay up to $13.8 million if certain regulatory and commercial milestones, in the aggregate, are achieved under our firi-cel and CRG-023 programs, and pay up to $9.0 million for each additional target program other than our firi-cel or CRG-023 programs if certain regulatory and commercial milestones, in the aggregate, are achieved for each such additional target program. Additionally, we are obligated to pay low single-digit percentage royalties on net sales of certain products generated under the Oxford Agreement. Further, under the terms of our license agreements we entered into with the NCI in 2022 and 2023, pursuant to which we obtained exclusive worldwide, royalty-bearing licenses under certain patent rights to research, develop, manufacture and commercialize products covered by such licensed patents, we may be required to pay up to $18.0 million and up to $17.8 million in milestone payments upon achievement of specific intellectual property, ~~and~~ clinical and commercial milestone events, respectively, and low single-digit percentage royalties on net sales of products incorporating the licensed patent rights from the NCI. Additionally, under the terms of each license agreement with the NCI, in the event we are granted a priority review voucher (PRV), we would be obligated to pay the NCI a minimum of $5.0 million upon the sale, transfer or lease of the PRV or $0.5 million upon submission of the PRV for use by the FDA. We are also obligated to pay the NCI a royalty based on a percentage of the fair market value of the consideration we receive for any assignment of the 2022 NCI License to a non-affiliate (upon the NCI’s prior written consent) or on an allocated portion of the fair value of consideration received in connection with a change in control (including an IPO). On the closing of our IPO in November 2023, the change of control milestone was achieved, and the parties have exchanged communications regarding the amount of, and underlying methodology to determine the amount of this milestone. We continue to believe that the accrual remains appropriate. However, there can be no assurances that the amount accrued will be the amount agreed to between the parties.

In order to satisfy our obligations to make these payments, if and when they are triggered, we may need to issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash and cash equivalents or incur debt obligations to satisfy the payment obligations in cash, which may adversely affect our financial position. In addition, these obligations may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.

See the section titled “Business — License agreements” elsewhere in this Form 10-K for additional information regarding these agreements.

Risks related to our business

Our ability to generate revenue from sales of any of our approved product candidates, which we do not expect will occur for atmany ~~least the next several~~ years, if ever, depends heavily on the successful identification, development, regulatory approval and eventual commercialization of any product candidates, which may never occur. We have invested substantially all of our efforts and financial resources in acquiring or in-licensing our current product candidates and conducting clinical trials and preclinical studies. We have never generated revenue from sales of any products, and we may never be able to develop, obtain regulatory approval for or commercialize, a marketable product. All of our product candidates will require significant clinical development, regulatory approval, establishment of sufficient manufacturing supply, including commercial manufacturing supply, and may require us to build a commercial organization and make substantial investment and significant marketing efforts before we generate any revenue from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates.

The successful development of our product candidates will depend on several factors, including, but not limited to, the following:

•

successful and timely completion of clinical trials and preclinical studies for which the FDA, or any comparable foreign regulatory authority, agree with the design, endpoints or implementation;

Table of Contents

•

sufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;

•

receiving regulatory allowances or authorizations for conducting future clinical trials;

•

initiation and successful patient enrollment in, and successful and timely completion of, clinical trials on a timely basis;

•

if we are required to supplement our clinical development plans to include additional clinical trials or studies, ~~such~~beyond asthose ~~the~~we ~~addition~~currently ofcontemplate afor ~~double-blind,~~our ~~placebo-controlled,~~product ~~randomized study of CRG-022~~candidates;

•

the frequency and severity of adverse events in clinical trials;

•

maintaining and establishing relationships with contract development and manufacturing organizations (CDMOs), contract research organizations (CROs) and clinical sites for the clinical development of our product candidates both in the United States and internationally;

•

46our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe, pure and potent, or effective for its intended uses;

•

Table of Contents

our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate is safe, pure and potent, or effective as for its intended uses;

our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the applicable product candidate’s risk-benefit ratio for its proposed indication is acceptable;

•

timely receipt of regulatory approvals for our product candidates from applicable regulatory authorities;

•

addressing any potential interruptions or delays resulting from factors related to ~~the~~health ~~COVID-19~~epidemics, ~~pandemic~~pandemics, other widespread outbreaks of contagious disease, and adverse political events such as government shutdowns;

•

the extent of any post-marketing commitments or requirements agreed to with applicable regulatory authorities;

•

establishing, scaling up and scaling out, either alone or with third-party manufacturers, manufacturing capabilities of clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved, including ability to produce final product using our intended commercial manufacturing process when applied to using patient cells as starting material;

•

the protection of our rights in our intellectual property portfolio; and

•

our ability to compete with other therapies.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially adversely affect our business, financial condition and results of operations.

Additionally, clinical or regulatory setbacks to other companies developing similar products or within adjacent fields, including those in gene editing and gene therapy and allogenic cell-based therapies, may impact the clinical development of and regulatory pathway for our current or future product candidates, or may negatively impact the perceptions of value or risk of our technologies.

We ~~have~~may ~~experienced~~be ~~rapid~~unable ~~operational growth since our inception in December 2019, and expect~~ to ~~continue~~realize ~~to grow in~~ the ~~future~~level asof ~~our clinical trials progress, we begin to advance~~ the ~~development~~anticipated ofbenefits ~~new~~that ~~product candidates and as our headcount increases. If~~ we ~~fail~~expect tofrom ~~effectively~~restructuring ~~manage~~ our ~~growth~~operations, wewhich may ~~not~~adversely beimpact ~~able~~our tobusiness ~~execute~~and onresults ~~our~~of ~~business objectives~~operations.

WeIn ~~have~~January ~~experienced~~2025, ~~rapid~~we ~~growth~~announced ~~since~~a ~~our~~reduction ~~inception~~in force in ~~December~~connection ~~2019,~~with ~~and~~the ~~expect~~announcement toof ~~continue~~our election to ~~grow~~discontinue in the ~~future.~~FIRCE-1 ~~For~~Phase ~~example,~~2 asstudy of ~~December~~firi-cel ~~31,~~to ~~2019,~~streamline weour ~~had~~business nooperations, ~~full-time~~reduce ~~employees~~costs and, ascreate offurther ~~December~~operating 31efficiencies, ~~2023,~~which weimpacted ~~had grown to~~ approximately ~~116~~50% ~~full-time~~of ~~employees~~our workforce. In ~~addition~~connection with these actions, we have ~~developed~~incurred aand ~~broad~~may ~~portfolio~~continue ofto ~~product~~incur ~~candidates~~restructuring ~~and~~costs ~~discovery~~in ~~programs~~the ~~that~~near ~~includes~~term ~~one~~of ~~product~~between ~~candidate~~$31 inmillion aand ~~potentially~~$37 ~~pivotal~~million ~~Phase~~in 2total, ~~clinical~~including ~~trial.~~severance, Webenefits, ~~expect~~payroll ~~continued~~taxes, ~~growth~~and inother ~~the~~termination ~~number~~costs oftotaling ~~our~~approximately ~~employees~~$4 ~~and~~million ~~the~~to ~~scope~~$5 ofmillion, ~~our~~contract ~~operations,~~termination ~~particularly~~costs astotaling weapproximately ~~continue~~$20 ~~our~~million ~~current~~to $22 million and future costs to wind-down the firi-cel clinical ~~trials~~development ~~and~~program ~~preclinical~~totaling ~~studies,~~approximately ~~initiate~~$7 ~~and~~million ~~conduct~~to ~~IND-enabling~~$10 ~~studies~~million. ~~and~~These ~~build~~actions ~~out~~may ~~our~~result ~~clinical~~in ~~operations~~unintended consequences, asincluding ~~well~~employee asattrition beyond our ~~platform~~intended ~~technologies.~~reduction in force, damage to our

To manage our anticipated future growth, we will continue to implement and improve our managerial, operational and financial systems, expand our facilities and recruit and train additional qualified personnel. Due to the complexity in managing a company that has scaled very quickly and anticipates continued growth, we may not be able to scale our headcount and operations effectively to manage the expansion of our product pipeline or recruit and train the necessary additional personnel. As our operations expand, we also expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.42

In addition, future growth imposes significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining and motivating additional employees; managing our internal development efforts effectively, including the clinical development and FDA review processes for our product candidates, while complying with our contractual obligations to contractors and other third parties; and improving our operational, financial and management controls, reporting systems and procedures.

Table of Contents

Wecorporate ~~currently~~culture ~~rely on certain independent organizations, advisors~~ and ~~consultants~~decreased toemployee ~~provide~~morale ~~certain~~among ~~services,~~our ~~including~~remaining ~~strategic~~employees, ~~financial,~~diversion ~~business development and research and development services, as well as certain aspects~~ of ~~regulatory~~management ~~approval and manufacturing. There can be no assurance that the services of independent organizations~~attention, ~~advisors~~adverse ~~and~~effects ~~consultants will continue~~ to beour ~~available~~reputation toas usan onemployer, aloss ~~timely~~of ~~basis when needed~~continuity, orinstitutional ~~that~~knowledge weand ~~can find qualified replacements. In addition~~expertise, ifand wepotential ~~are~~failure ~~unable to effectively manage our outsourced activities~~ or ifdelays ~~the~~to ~~quality~~meet oroperational ~~accuracy~~and ofgrowth ~~the~~targets. ~~services provided by consultants or contract manufacturing organizations is compromised for any reason~~Further, our ~~clinical~~business ~~trials~~ may ultimately not be ~~extended,~~more ~~delayed~~efficient or ~~terminated,~~effective and we may ~~not~~ be ~~able~~unable to ~~obtain~~achieve ~~regulatory~~anticipated ~~approval~~operating ofenhancements ~~our product candidates~~ or ~~otherwise~~cost ~~advance~~reductions, ~~our~~which ~~business.~~would ~~There~~adversely ~~can~~affect ~~be no assurance that we will be able to manage~~ our ~~existing~~business, ~~consultants~~competitive orposition, ~~find~~operating ~~other~~results ~~competent outside contractors~~ and ~~consultants~~financial ~~on reasonable terms, or at all~~condition.

If our product candidates do not achieve projected development milestones or commercialization in the announced or expected timeframes, the further development or commercialization of such product candidates may be delayed, and our business will be harmed.

We have estimated and may in the future estimate, the timing of the accomplishment of various scientific, clinical, manufacturing, regulatory and other product development objectives. These milestones have and may in the future include our expectations regarding the commencement or completion of clinical trials and preclinical studies, data readouts, the submission of regulatory ~~filings~~applications, the receipt of regulatory approval or the realization of other commercialization objectives. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, including assumptions regarding capital resources, constraints and priorities, progress of and results from development activities and the receipt of key regulatory approvals or actions, any of which may cause the timing of achievement of the milestones to vary considerably from our estimates. If we fail to achieve announced milestones in the expected timeframes, the commercialization of ~~the~~our product candidates may be delayed, our credibility may be undermined, our business and results of operations may be harmed and the trading price of our common stock may decline.

Our success depends upon the continued contributions of our key management, scientific and clinical personnel, many of whom have been instrumental for us and have substantial experience with our product candidates and platform technologies. Given the specialized nature of our product candidates and our platform technologies there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific or technical qualifications specific to each program. The loss of key personnel, in particular our senior leadership team, would delay our research and development activities. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and pharmaceutical industries is intense, and our future success depends upon our ability to attract, retain and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business.

In addition, our research and development programs, as well as the development and enhancement of our platform technologies depend on our ability to attract and retain highly skilled scientists, particularly in California. There is powerful competition for skilled personnel in these geographical markets, and we have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.

Table of Contents

We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do.

The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.

Table of Contents

approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of organizations, including large pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.

With the proliferation of new drugs and therapies for our target indications, we expect to face increasingly intense competition as new technologies become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. Our competitors may, among other things:

•

have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do;

•

develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer or have fewer or less severe side effects;

•

obtain quicker regulatory approval;

•

establish superior proprietary positions covering our products and technologies;

•

implement more effective approaches to sales and marketing; or

•

form more advantageous strategic alliances.

Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products approaches may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing ~~our~~such ~~product candidates~~products.

In addition, any collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license to them, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition and results of operations.

Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

We may expend our limited resources to pursue a particular product candidate, indication or platform technology and fail to capitalize on product candidates, indications or platform technologies that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on product candidates, research programs and platform technologies that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other platform technologies or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future product candidates, research programs and platform technologies for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.

4944

Table of Contents

greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future product candidates, research programs and platform technologies for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.

Our product candidates and platform technologies are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.

We have concentrated our research and development efforts on our engineered T cell therapy, including related product candidates and platform technologies, and our future success depends on the successful development of this therapeutic approach. WeThere ~~are in the early stages of developing our pipeline and platforms and there~~ can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.

In addition, the clinical study requirements of the FDA, EMA and other regulatory agencies and the criteria these regulators use to determine the safety, purity, potency and/or efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing CAR T therapies may not be indicative of what these regulators may require for approval of our product candidates. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from other CAR T therapies that have previously been approved. Unexpected clinical outcomes would significantly impact our business.

~~Any~~Developing ~~product~~process ~~candidates~~and ~~that~~analytical wemethods ~~may~~for ~~develop~~cell ~~will~~therapy beproducts ~~novel~~is ~~and may be~~ complex and ~~difficult~~challenging. Unexpected totechnical ~~manufacture,~~challenges ~~and if we experience manufacturing problems, it~~ could ~~result~~arise induring ~~delays~~CMC in development and ~~commercialization~~manufacturing ofthat ~~such~~may ~~product~~result ~~candidates~~in orsubstantial ~~otherwise~~timeline ~~harm our business~~delays.

Our product candidates involve or will involve novel technology and will require processing steps that are more complex than those required for most small molecule drugs, resulting in a relatively higher manufacturing cost. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that such product will perform in the intended manner. Although we intend to employ multiple steps to control the manufacturing processes for our product candidates, we may experience manufacturing issues with any of our product candidates, critical reagents or raw materials that could cause production interruptions, including contamination, equipment or reagent failure, improper installation or operation of equipment, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error, disruptions in the operations of our suppliers, inconsistency in cell growth and variability in product characteristics. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA or other comparable applicable standards or specifications with consistent and acceptable production yields and costs. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which such product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Our manufacturing process for any CAR T-cell therapy product candidate that we develop will be susceptible to product loss or failure due to the quality of the raw materials, failure of the products to meet specifications, logistical issues associated shipping such material to the manufacturing site, freezing the manufactured product, shipping the final product globally, thawing and infusing patients with such product. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, delays in initiating or completing clinical trials, product recalls, product liability claims or insufficient inventory.

50As product candidates are developed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is possible that various aspects of the development program, such as manufacturing process and methods, may be altered along the way in an effort to help optimize processes and results. Such changes carry the risk that they will not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently from the previous Phase 1 clinical trials and affect the results of future clinical trials or our reliance on results of trials that have previously been conducted using the product candidate in its previous

Table of Contents

~~product~~form. ~~defects~~If orthe manufacturing ~~failures~~process ~~that~~is ~~result~~changed induring ~~lot~~the ~~failures~~course of product development, ~~delays~~we inmay ~~initiating~~be required to repeat some or ~~completing~~all ~~clinical~~of the previously conducted trials or conduct additional bridging trials or alternatively, ~~product~~we ~~recalls~~may need to re-develop the manufacturing process and methods, ~~product~~which ~~liability~~could ~~claims~~increase our costs and delay or ~~insufficient~~impede ~~inventory~~our ability to obtain regulatory approval.

As product candidates are developed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is possible that various aspects of the development program, such as manufacturing process and methods, may be altered along the way in an effort to help optimize processes and results. Such changes carry the risk that they will not achieve the intended objectives, and any of these changes could cause our product candidates to perform differently from the previous Phase 1 clinical trials and affect the results of future clinical trials or our reliance on results of trials that have previously been conducted using the product candidate in its previous form. If the manufacturing process is changed during the course of product development, we may be required to repeat some or all of the previously conducted trials or conduct additional bridging trials or alternatively, we may need to re-develop the manufacturing process and methods, which could increase our costs and delay or impede our ability to obtain regulatory approval.

In addition, the facilities used by us and our contract manufacturers to manufacture our product candidates must be evaluated for the manufacture of our product candidates by the FDA or foreign regulatory authorities pursuant to inspections that will be conducted after we submit a Biologics License Application (BLA) to the FDA, or similar foreign applications to foreign regulatory authorities. We do not control the manufacturing process of our contract manufacturers and are dependent on their compliance with cGMP or similar foreign requirements for their manufacture of our product candidates.

The FDA and other foreign regulatory authorities may require us to submit samples of any lot of any product that may receive approval together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or other foreign regulatory authorities may require that we not distribute a lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business.

~~Certain~~The ~~license~~estimates ~~agreement~~of ~~counterparties~~market ~~currently~~opportunity ~~conduct~~and ~~clinical~~forecasts ~~trials~~of ~~under~~market ~~their~~growth ~~own~~included ~~Investigational~~in ~~New~~our ~~Drug~~SEC ~~Applications~~filings ~~(INDs)~~or press releases may prove to be smaller than we believe, ~~which~~and ~~could~~even ~~generate~~if ~~unknown~~the ormarkets ~~unexpected~~in ~~clinical~~which ~~results~~we ~~outside~~compete ofachieve the forecasted growth, our ~~control~~business may not grow at similar rates, or at all.

~~Certain~~Our projections of ~~our~~addressable ~~license~~patient ~~agreement~~populations ~~counterparties~~within ~~continue~~any toparticular ~~conduct~~disease ~~clinical~~state ~~trials~~that ~~with~~may anbenefit ~~investigative~~from ~~candidate~~treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts we may provide to the ~~same~~market ~~CAR~~are ~~sequence~~subject asto ~~CRG-022~~significant uncertainty and are based on assumptions and estimates. InThese ~~addition~~estimates, ~~the~~which ~~Phase~~have 1been ~~trial~~derived from a variety of ~~CRG-022~~sources, isincluding ~~ongoing~~scientific literature, ~~with~~surveys ~~the~~of ~~investigators~~clinics, onpatient ~~such~~foundations ~~trial~~and ~~continuing~~market research, may prove to ~~release~~be ~~cuts~~incorrect. ofFurther, ~~clinical~~new ~~data~~studies atmay ~~different~~change ~~time~~the ~~points.~~estimated Ifincidence ~~either~~or prevalence of these ~~activities~~diseases. ~~generate~~Additionally, ~~unforeseen~~the orpotentially ~~unexpected~~addressable ~~efficacy~~patient orpopulation ~~safety~~for ~~data,~~our weproduct candidates may ~~need~~not toultimately ~~refer~~be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market with such ~~data~~patients, infor example, being too sick to receive treatment. If any of our ~~regulatory~~estimates ~~filings~~prove to be inaccurate, orthe ~~otherwise~~market ~~disclose~~opportunity ~~this~~for ~~information,~~any ~~which~~product ~~could~~candidate ~~harm~~that we or our ~~business~~strategic orpartners ~~regulatory~~develop ~~strategy~~could ifbe ~~the~~significantly ~~data~~diminished ~~are~~and ~~negative.~~have an adverse material impact on our business.

InOur ~~addition,~~business weis dosubject ~~not anticipate being able~~ to ~~incorporate~~risks ~~any~~arising ~~prior CRG-022 data~~ from ~~studies~~health ~~conducted under third-party INDs in future regulatory filings. As a result~~epidemics, ~~we may need to conduct additional clinical trials and could be limited in the scope of the labels we pursue~~pandemics, ~~among~~ other ~~adverse~~widespread ~~consequences.~~outbreaks ~~The consequences~~ of ~~any~~contagious ofdisease, ~~the~~including ~~foregoing could be costly to us and otherwise harm our business~~COVID-19.

51Significant outbreaks of contagious diseases and other adverse public health developments pose the risk that we or our employees, contractors, including our CROs, CDMOs, suppliers and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. For example, COVID-19 and the post-COVID environment, including supply chain, labor market and other disruptions, as well as volatility in the global financial markets, in each case driven by the pandemic, have affected segments of the global economy and our operations. The continued spread of disease and the measures taken by the governments of countries affected could, in addition to disrupting our clinical trials, adversely impact other aspects of our business and operations. In addition, health pandemics and epidemics, such as COVID-19, could continue to produce significant and prolonged disruption of or volatility in global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. The extent to which health epidemics, pandemics, other widespread outbreaks of contagious disease impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. Furthermore, the COVID-19 pandemic, the post-COVID environment or any future pandemic or other outbreak of contagious disease could exacerbate the other risks described in this section.

Table of Contents

The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 10-K and our other public filings or press releases may prove to be smaller than we believe, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.

We intend to initially focus our product candidate development on treatments for various lymphomas. Our projections of addressable patient populations within any particular disease state that may benefit from treatment with our product candidates are based on our estimates. Market opportunity estimates and growth forecasts we may provide to the market are subject to significant uncertainty and are based on assumptions and estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. For example, the observed persistence of CD22 expression following patients becoming relapsed or refractory to CD19 CAR T-cell therapy may not be as high as we expect. Similarly, the percentage of the population with CD22 expression could be lower than we anticipate. In both instances, the pool of potential patients that our CD22 product candidates could address could be substantially smaller than we anticipate. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market with such patients, for example, being too sick to receive treatment. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.

Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic.

The COVID-19 pandemic continues to impact worldwide economic activity. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, including our CROs, CDMOs, suppliers and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the full impact that COVID-19 could have on our business, the continued spread of new variants of COVID-19 and the measures taken by the governments of countries affected could, in addition to disrupting our clinical trials, adversely impact other aspects of our business and operations. The COVID-19 pandemic and mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which the COVID-19 pandemic, or any other pandemic, impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.

Even if approved, our products may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations.

Even if the FDA or any comparable foreign regulatory authority approves ~~the marketing of~~ any product candidates that we develop, physicians, healthcare providers, patients or the medical community may not accept or use them. Additionally, the product candidates that we are developing are based on our proprietary platforms, which are new technologies. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our product candidates will depend on a variety of factors, including:

•

the timing of market introduction of the product candidate, as well as competitive products;

•

the clinical indications for which a product candidate is approved;

•

the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;

•

the terms of any approvals and the countries in which approvals are obtained;

•

the number and clinical profile of competing products;

•

the potential and perceived advantages of our product candidates over alternative treatments;

•

our ability to provide acceptable evidence of safety, purity, potency and/or efficacy;

•

Table of Contents

the prevalence and severity of any side effects;

•

the availability of an approved product candidate for use as a combination therapy;

•

relative convenience and ease of administration;

•

cost-effectiveness;

•

patient diagnostics and screening infrastructure in each market;

•

the effectiveness of sales and marketing efforts;

•

approval of other new therapies for the same indications;

•

marketing, manufacturing and supply support;

•

adverse publicity about our product candidates;

•

potential product liability claims;

•

availability of coverage, adequate reimbursement and sufficient payment from health maintenance organizations and other insurers, both public and private, for our product candidates, or the procedures utilizing our product candidates, if approved;

•

the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors and government authorities; and

•

other potential advantages over alternative treatment methods.

If our product candidates are approved but fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues.

We currently have no marketing, sales or supply chain infrastructure and we intend to either establish a sales and marketing infrastructure or outsource this function to a third-party. Either of these commercialization strategies carries substantial risks to us.47

Given our stage of development, we currently have no marketing, sales and end-to-end supply chain management capabilities. If any of our product candidates complete clinical development and are approved, we intend to either establish a sales and marketing organization with technical expertise and supporting end-to-end supply chain management capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third-party. There are risks involved if we decide to establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. We have no prior experience as a company in the marketing, sale and end-to-end supply chain management of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products.

To the extent that we enter into collaboration agreements with respect to marketing, sales or end-to-end supply chain management, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products or that our collaborator’s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator’s business strategy.

Table of Contents

We currently have no marketing, sales or supply chain infrastructure and we must either build out a sales and marketing infrastructure or outsource this function to a third-party. Either of these commercialization strategies carries substantial risks to us.

Given our stage of development, and our recently announced reduction in force, we currently have no marketing, sales and end-to-end supply chain management capabilities. If any of our product candidates complete clinical development and are approved, we must either build out a sales and marketing organization with technical expertise and supporting end-to-end supply chain management capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third-party. There are risks involved if we decide to build out our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. We have no prior experience as a company in the marketing, sale and end-to-end supply chain management of biopharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products.

To the extent that we enter into collaboration agreements with respect to marketing, sales or end-to-end supply chain management, our product revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks, including that we may not be able to control the amount or timing of resources that our collaborative partner devotes to our products, that our collaborator may not comply with legal and regulatory requirements, or that our collaborator may not have a willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business combinations or significant changes in our collaborator’s business strategy.

If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition and results of operations.

We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims.

We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for commercialization of our product candidates.

Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.

Even successful defense against product liability claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: decreased demand for our product candidates; injury to our reputation; withdrawal of clinical trial participants; initiation of investigations by regulators; costs to defend the related litigation; a diversion of management’s time and our resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any available insurance and our capital resources; the inability to commercialize any product candidate; and a decline in our share price.

Although we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain regulatory approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.

Table of Contents

commercial products if we obtain regulatory approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims, and our business operations could be impaired.

We may not realize the benefits of technologies that we have acquired, or will acquire in the future, or other strategic transactions that we have or will consummate.

Our platform represents an aggregation of innovation and technology from multiple companies and academic institutions, including the NCI, Oxford, and Stanford University. Further, a key component of our strategy is to acquire and in-license technologies to support the growth of our product pipeline, as well as to build upon and enhance our platform technologies. As such, we actively evaluate various strategic transactions on an ongoing basis. We may acquire other assets, businesses, products or technologies, as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions and any future strategic transactions depends on the risks and uncertainties involved including:

•

unanticipated liabilities related to acquired companies or joint ventures;

•

difficulties integrating acquired personnel, technologies and operations into our existing business;

•

retention of key employees;

•

Table of Contents

diversion of management time and focus from operating our business to management of acquisition and integration efforts, strategic alliances or joint ventures challenges;

•

increases in our expenses and reductions in our cash available for operations and other uses;

•

disruption in our relationships with collaborators or suppliers;

•

possible write-offs or impairment charges relating to acquired businesses or joint ventures; and

•

challenges resulting from health epidemics, pandemics, other widespread outbreaks of contagious disease, including the COVID-19 pandemic and the post-COVID-19 environment, making it more difficult to integrate acquisitions into our business.

If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.

Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses, impairments or write-offs of goodwill or impairments and write-offs of in-process research and development assets, any of which could harm our financial condition.

Our information technology systems, or those used by our third-party contract research organizations or other contractors or consultants, may fail or suffer security breaches.

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information, preclinical and clinical trial data, and personal information of our employees and contractors) (Confidential Information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such Confidential Information. We also have outsourced elements of our operations to third parties, and as a result we rely on the information technology systems of and manage a number of third-party contractors who have access to our Confidential Information.

Despite the implementation of security measures, our information technology systems and those of our CROs, CDMOs and other contractors and consultants are vulnerable to attack and damage or interruption from a variety of threats, including computer viruses and malware (e.g., ransomware), malicious code, natural disasters, terrorism, war, telecommunications and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated national-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization.

We and certain of our service providers are from time to time subject to cyberattacks and security incidents. Although to our knowledge we have not experienced any such material system failure, accident or security breach to date, if such an event were to occur and negatively affect our operations, it could result in a material disruption of our development programs and our business operations. Further, there can be no assurance that our cybersecurity risk management program and processes, including our policies, controls or procedures or our other data protection efforts and our investment in information technology, or those of third parties on which we rely, will be fully implemented, complied with or effective to prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may 49

Table of Contents

bethreats, ~~unable~~including tocomputer ~~adequately~~viruses ~~investigate~~and ormalware ~~remediate~~(e.g., ~~incidents~~ransomware), ormalicious ~~breaches~~code, ~~due~~natural todisasters, ~~attackers~~terrorism, ~~increasingly~~war, ~~using~~telecommunications ~~tools~~and electrical failures, hacking, cyberattacks, phishing attacks and ~~techniques~~other ~~that~~social ~~are~~engineering ~~designed~~schemes, toemployee ~~circumvent~~theft ~~controls~~or misuse, tohuman ~~avoid~~error, ~~detection~~fraud, denial or degradation of service attacks, sophisticated national-state and tonation-state-supported ~~remove~~actors or ~~obfuscate~~unauthorized ~~forensic~~access ~~evidence.~~or use by persons inside our organization, or persons with access to systems inside our organization.

For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their information technology systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in an actual or perceived loss of, or damage to, our data or applications, or inappropriate disclosure of Confidential Information, the further development and commercialization of our product candidates could be delayed.

Any such security compromise or other event that leads to actual or suspected, or is alleged to lead to, unauthorized access, use, or disclosure of Confidential Information, including personal information regarding our clinical trial subjects or employees, could also harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and fines or mandatory corrective action, and otherwise subject us to liability and proceedings (such as class actions), including under laws and regulations that protect the privacy and security of personal information, and/or significant incident response, system restoration or remediation and future compliance costs, which could adversely ~~effect~~affect our results of operations, business or financial condition.

Further, we rely on third-party service providers and technologies to operate critical business systems to process ~~sensitive~~Confidential ~~information~~Information in a variety of contexts, including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.

In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been compromised. We have and will enter into collaboration, license, contract research and/or manufacturing relationships with organizations that operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, and we may be at heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft or intrusion destroy the proprietary nature of our intellectual property.

Table of Contents

heightened risk of losing our proprietary intellectual property rights around the world, including outside of such countries, to the extent such theft or intrusion destroy the proprietary nature of our intellectual property.

Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our data privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.

We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.

In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share (collectively, processing) personal information and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security.

Table of Contents

activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security.

In the United States, federal, state and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal information privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act) and other similar laws. For example, the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, HIPAA), imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information, such as information we may obtain from research institutions from which we obtain clinical trial data. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. The California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, (collectively, CCPA) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business’s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business’s behalf. Other states have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these laws, like the CCPA, may also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us, and the third parties upon whom we rely.

Outside the United States, an increasing number of laws, regulations and industry standards govern data privacy and security. For example, the European Union’s General Data Protection Regulation (EU GDPR), the United Kingdom’s GDPR (UK GDPR), Brazil’s General Data Protection Law (Lei Geral de Proteção de Dados Pessoais (LGPD)) (Law No. 13,709/2018) and China’s Personal Information Protection Law (PIPL) impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20.0 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of the annual global revenue of a non-compliant undertaking, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.

In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.

Table of Contents

Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK’s standard contractual clauses, the UK’s International Data Transfer Agreement / Addendum, the EU-U.S. Data Privacy Framework (DPF), and the UK Extension to the DPF (which allows for transfers from the EEA or UK to U.S.-based organizations who self-certify compliance under the DPF), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.

If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups.

Our employees and personnel may use generative artificial intelligence (AI) technologies to perform their work, and the use of such generative AI in connection with our Confidential Information may result in leaks, disclosure, or otherwise unauthorized or unintended access to such information, including if such information is used to further refine and train the underlying generative AI models. The disclosure and use of personal information in generative AI technologies is subject to various privacy laws and other privacy obligations and governments have passed and are likely to pass additional laws regulating generative AI. For example, on August 1, 2024, the EU Artificial Intelligence Act (EU AI Act) entered into force, and establishes a comprehensive, risk-based governance framework for AI in the EU market. The majority of the substantive requirements will apply from August 2, 2026. The EU AI Act applies to companies that develop, use and/or provide AI in the EU and includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose AI and foundation models, and fines for breach of up to 7% of worldwide annual turnover. Further, our ability to continue to develop or use such technologies may depend on access to specific third-party software and infrastructure, such as processing hardware or third-party AI models, and we cannot control the availability or pricing of such third-party software and infrastructure, especially in a highly competitive environment. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.

Table of Contents

technologies is subject to various privacy laws and other privacy obligations and governments have passed and are likely to pass additional laws regulating generative AI. Further, our ability to continue to develop or use such technologies may depend on access to specific third-party software and infrastructure, such as processing hardware or third-party AI models, and we cannot control the availability or pricing of such third-party software and infrastructure, especially in a highly competitive environment. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.

Negative public opinion and increased regulatory scrutiny of research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. In addition, given the novel nature of gene engineering technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.

Table of Contents

Risks related to the regulatory environment for the development and commercialization of our product candidates

The regulatory landscape that will apply to development of our product candidates is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.

All of our product candidates are based on cell therapy technology, and our future success depends on the successful development of product candidates utilizing our novel approach. We cannot assure you that any development problems we or other cell therapy companies experience in the future related to such technology will not cause significant delays or unanticipated costs in the development of our product candidates, or that such development problems can be solved. In addition, the clinical study requirements of the FDA, and other regulatory agencies, as well as the criteria these regulators use to determine the safety, purity, potency and/or efficacy of a product candidate, vary substantially according to the type, complexity, novelty and intended use and market of the product candidate. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied therapeutic modalities. Further, as we are developing novel treatments for diseases in which there may be limited clinical experience, there is heightened risk that the FDA or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, relatively few cell therapy products have been approved by the FDA or comparable foreign regulatory authorities, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States or other jurisdictions. Further, approvals by one regulatory agency may not be indicative of what other regulatory agencies may require for approval in their respective jurisdictions.

Regulatory requirements governing cell therapy products have evolved and may continue to change in the future. For example, the FDA has established the Office of Therapeutic Products within its Center for Biologics Evaluation and Research (CBER), to consolidate the review of cell therapy and comparable products, as well as the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.

Table of Contents

For example, the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) require supervision of human gene transfer trials, including evaluation and assessment by an Institutional Biosafety Committee (IBC), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.

We are subject to significant regulatory oversight by the FDA in connection with our clinical trials, and in addition, the applicable IBC and Institutional Review Board (IRB) of each institution at which we conduct clinical trials of our product candidates, or a central IRB if appropriate, may need to review and approve the proposed clinical trial prior to initiation.

Changes in applicable regulatory guidelines for product candidates such as ours may lengthen the regulatory review process, require us to perform additional studies or trials beyond those we contemplate, increase our development costs, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with evolving regulations and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we may anticipate. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all, and could seriously harm our business.

Table of Contents

Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome. Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects.

Preclinical and clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study or clinical trial process, including due to factors that are beyond our control. The historical failure rate for product candidates in our industry is high. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. For example, ~~although~~in weJanuary ~~believe~~2025 ~~the~~we ~~results~~announced ~~from~~our ~~Stanford~~election ~~University’s~~to ~~Phase~~discontinue 1the ~~clinical trial of its CD22 CAR T~~FIRCE-~~cell~~1 ~~therapy under its own IND support further development of this product candidate, there is no guarantee we will observe similar results in our ongoing~~ Phase 2 ~~clinical~~study ~~trial~~ of ~~CRG~~firi-~~022~~cel ~~being~~because ~~conducted~~we ~~under~~believe ~~our~~the ~~own~~results ~~IND~~would ~~due~~not tosupport a ~~variety~~competitive ofbenefit-risk ~~factors~~profile ~~which~~for wethe dointended ~~not~~patient ~~have control over~~populations. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and regulatory authorities may not agree with the conclusions we draw from our clinical trials and preclinical studies. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.

Before obtaining approval from regulatory authorities for the commercialization of any of our product candidates, we must conduct extensive clinical trials to demonstrate the safety purity, potency or efficacy of the product candidate in humans. We have limited experience in conducting clinical trials, and as an organization, have not yet completed a clinical for any of our product candidates.

59Prior to initiating clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical or non-clinical studies, or complete additional activities relating to chemistry, manufacturing and controls (CMC) for any product candidate before such authorities allow us to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical development programs. In particular, the manufacturing of autologous CAR T-cell therapies remains an emerging and evolving field. Accordingly, we expect CMC-related topics, including product specifications, will remain a focus for such regulatory authorities during their reviews of our applications. Moreover, even as we continue and/or commence new clinical trials, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our product candidates could significantly affect our product development timelines and product development costs and harm our financial position.

Table of Contents

Prior to initiating clinical trials for any product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical or non-clinical studies, or complete additional activities relating to chemistry, manufacturing and controls (CMC) for any product candidate before such authorities allow us to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays and increase the costs of our preclinical development programs. In particular, the manufacturing of autologous CAR T-cell therapies remains an emerging and evolving field. Accordingly, we expect CMC-related topics, including product specifications, will remain a focus for such regulatory authorities during their reviews of our applications. Moreover, even as we continue our current Phase 2 clinical trial and commence new clinical trials, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our product candidates could significantly affect our product development timelines and product development costs and harm our financial position.

We do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all. The timing for commencement, data readouts and completion of clinical trials can be delayed for a number of reasons, including delays related to:

•

inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials;

•

obtaining allowance or approval from regulatory authorities to commence a trial or reaching a consensus with regulatory authorities on trial design;

•

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;

•

if we are required to supplement our clinical development plans to include additional clinical trials or studies~~, such as the addition of a double-blind, placebo-controlled, randomized study of CRG-022 as part of the potentially pivotal Phase 2 clinical trial~~;

•

any failure or delay in reaching an agreement with CROs, CDMOs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, CDMOs and trial sites;

•

the level of CD22 expression in the patient population in the trial not aligning with our expectations;

•

delays in identifying, recruiting and training suitable clinical investigators;

Table of Contents

•

obtaining approval from one or more IRBs or ethics committees at clinical trial sites;

•

IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;

•

changes or amendments to the clinical trial protocol;

•

clinical sites deviating from the trial protocol or dropping out of a trial;

•

failure by our CROs or CDMOs to perform in accordance with Good Clinical Practice (GCP) requirements or applicable regulatory rules and guidelines in other countries;

•

manufacturing sufficient quantities of necessary critical reagents such as viral vectors, and of our product candidates for use in our clinical trials;

•

subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up, including subjects failing to remain in our trials;

•

patients choosing an alternative product for the indications for which we are developing our product candidates, or participating in competing clinical trials;

•

lack of adequate funding to continue a clinical trial, or costs being greater than we anticipate;

•

Table of Contents

subjects experiencing severe or serious unexpected treatment-related adverse effects;

•

occurrence of serious adverse events in trials of the same class of agents conducted by other companies that could be considered similar to our product candidates;

•

selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting data;

•

transfer of manufacturing processes to larger-scale facilities operated by a CDMO delays or failure by our CDMOs or us to make any necessary changes to such manufacturing process, or failure of our CDMOs to produce clinical trial materials in accordance with cGMP regulations or other applicable requirements; and

•

third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.

Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities’ legal requirements, regulations and guidelines, and remain subject to oversight by these governmental agencies and ethics committees or IRBs at the medical institutions where such clinical trials are conducted. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or applicable clinical trial protocols, adverse findings from inspections of clinical trial sites by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.

Further, conducting clinical trials in foreign countries, as we may do for our future product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled subjects in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes and political and economic risks, including war, relevant to such foreign countries.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.

In addition, many of the factors that cause, or lead to, the termination suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any resulting delays to our clinical trials could shorten any period during which we may have the exclusive right to commercialize our product candidates. In such cases, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects.55

Table of Contents

foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.

We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials will depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial’s conclusion as required by the FDA or other comparable regulatory authorities. The conditions for which we currently plan to evaluate our product candidates are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.

Patient enrollment in clinical trials may be affected by other factors, including:

•

size and nature of the targeted patient population;

•

severity of the disease or condition under investigation;

•

availability and efficacy of approved therapies for the disease or condition under investigation;

•

patient eligibility criteria for the trial in question as defined in the protocol;

•

perceived risks and benefits of the product candidate under study;

•

clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any products that may be approved for, or any product candidates under investigation for, the indications we are investigating;

•

efforts to facilitate timely enrollment in clinical trials;

•

patient referral practices of physicians;

•

the ability to monitor patients adequately during and after treatment;

•

proximity and availability of clinical trial sites for prospective patients;

•

difficulty identifying and enrolling patients for clinical trials to expand into earlier lines of LBCL;

•

continued enrollment of prospective patients by clinical trial sites; and

•

the risk that patients enrolled in clinical trials will drop out of such trials before completion.

Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also rely on, and will continue to rely on, CROs, CDMOs and clinical trial sites to ensure proper and timely conduct of our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, may lead us to abandon one or more clinical trials altogether, or may lead the FDA and other regulatory authorities to require us to conduct additional clinical trials before we are able to seek regulatory approvals for our product candidates, if ever. Any enrollment issues in our clinical trials may therefore result in increased development costs for our product candidates and jeopardize our ability to obtain regulatory approval for the sale of our product candidates, which would adversely affect our business and financial condition.

~~Use~~Furthermore, ofgiven ~~our~~the ~~product~~nature ~~candidates~~of ~~could~~the bediseases ~~associated~~we ~~with~~are ~~adverse side effects~~targeting, ~~adverse~~there ~~events~~is ora ~~other~~significant ~~properties~~risk orof ~~safety~~patient ~~risks,~~dropout ~~which~~due ~~could~~to ~~delay~~disease ~~or preclude approval~~progression, ~~cause~~potential usinfections ~~to suspend~~ or ~~discontinue~~illnesses ~~clinical~~(including ~~trials~~COVID-19), ~~abandon~~or adeath ~~product~~during ~~candidate, limit~~ the ~~commercial~~course ~~profile~~ of anour ~~approved~~clinical ~~product~~trials. orThese ~~result~~factors incould ~~other~~lead ~~significant~~to ~~negative~~increased ~~consequences~~rates ~~that~~of ~~could~~patient ~~severely~~withdrawal ~~harm~~from our ~~business~~trials, ~~prospects,~~potentially ~~operating~~impacting ~~results and financial condition.~~

Table of Contents

~~candidates~~the ~~are~~integrity ~~approved,~~of ~~result~~our intrial adata ~~more~~and ~~restrictive~~increasing ~~label~~the duration and ~~other~~cost ~~post-approval~~of ~~requirements.~~our ~~Any~~clinical ~~treatment-related~~development ~~side~~programs. ~~effects~~If ~~could~~a ~~also~~substantial ~~affect~~number ~~patient~~of ~~recruitment~~patients drop out or ~~the~~miss ~~ability~~critical offollow-up ~~enrolled~~assessments, ~~patients~~we may be required to ~~complete~~enroll ~~the~~additional ~~trial~~patients, orextending ~~could~~the ~~result~~timeline inand ~~potential~~increasing ~~product~~the ~~liability~~cost ~~claims~~of our clinical trials. ~~Any~~This ofcould ~~these~~delay ~~occurrences~~our ~~may~~development ~~harm~~programs and adversely affect our ~~business~~ability to demonstrate the safety, ~~financial~~purity, ~~condition~~potency and/or ~~prospects~~efficacy ~~significantly~~of our product candidates.

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, may lead us to abandon one or more clinical trials altogether, or may lead the FDA and other regulatory authorities to require us to conduct additional clinical trials before we are able to seek regulatory approvals for our product candidates, if ever. Any enrollment issues in our clinical trials may therefore result in increased development costs for our product candidates and jeopardize our ability to obtain regulatory approval for the sale of our product candidates, which would adversely affect our business and financial condition.

Use of our product candidates could be associated with adverse side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved product or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.

Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates, whether used alone on in combination with other therapies, could cause us or regulatory authorities to interrupt, delay or halt clinical trials or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities, or, if such product candidates are approved, result in a more restrictive label and other post-approval requirements. Any treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial, or could result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials, when used alone or in combination with other approved product, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.

Patients in our ongoing and planned clinical trials may suffer significant adverse events or other side effects, including adverse events not observed in our preclinical studies or in previous clinical trials evaluating our product candidates. Patients treated with our product candidates may also be undergoing surgical, radiation or chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients’ illnesses.

If such significant adverse events or other side effects are observed in any of our ongoing or planned clinical trials, we may have difficulty recruiting patients to the clinical trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities, or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Even if the side effects do not preclude the product candidate from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance due to tolerability concerns as compared to other available therapies. Any of these developments could materially harm our business, financial condition and prospects.

Moreover, adverse developments in clinical trials conducted by others of cell therapy products or product candidates, may cause the FDA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing our technologies, either of which could materially harm our business. For example, on November 28, 2023, the FDA announced that it was investigating reports of reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA-or CD19-directed autologous CAR T cell immunotherapies, and in January 2024, the FDA required the manufacturers of certain CAR-T therapies to add boxed warnings to product labeling cautioning against the risk of T-cell malignancies., ~~If we are able to successfully develop~~ and ~~obtain~~has ~~approval~~continued ~~of any of our product candidates, the FDA may require such products~~ to ~~carry~~update ~~similar~~applicable warnings orfor ~~adopt~~these ~~other~~products. ~~precautions~~If ~~that~~we ~~could~~are ~~adversely~~able ~~affect~~to ~~such products’ commercial prospects.~~

Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (REMs) to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or end-to-end supply chain management systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop. Other potentially significant negative consequences associated with adverse events include:57

Table of Contents

successfully develop and obtain approval of any of our product candidates, the FDA may require such products to carry similar warnings or adopt other precautions that could adversely affect such products’ commercial prospects.

Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or end-to-end supply chain management systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop. Other potentially significant negative consequences associated with adverse events include:

•

we may be required to suspend marketing of a product, or we may decide to remove such product from the marketplace;

•

regulatory authorities may withdraw or change their approvals of a product;

•

Table of Contents

regulatory authorities may require additional warnings on the label or limit access of a product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment;

•

we may be required to create a medication guide outlining the risks of a product for patients, or to conduct post-marketing studies;

•

we may be required to change the way a product is administered;

•

we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and

•

a product may become less competitive, and our reputation may suffer.

Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of our product candidates, if approved by the FDA or other regulatory authorities.

Interim, “topline” and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose interim, topline or preliminary data from our clinical trials and preclinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.

Interim data from clinical trials that we may complete are further subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, topline or preliminary data and final data could significantly harm our business prospects. Further, disclosure of such data by us or by our competitors could result in volatility in the price of our common stock.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

We have not successfully completed the testing of our product candidates in clinical trials and any favorable data from trials conducted by Stanford University or the NCI may not be replicated in our clinical trials.58

In December 2023, we announced the dosing of the first seven patients in our Phase 2 clinical trial of our lead product candidate, CRG-022, in patients with R/R LBCL whose disease has progressed after CD19-directed CAR T-cell therapy. We have only recently initiated our first clinical trial of CRG-022 and have not successfully completed

Table of Contents

~~the~~product ~~test~~and of our ~~product~~company ~~candidates~~ in ~~clinical trials, including our lead program CRG-022~~general. ~~Specifically~~In addition, ~~while~~ the ~~CRG-022~~information ~~CAR~~we ~~has~~choose ~~been~~to ~~included~~publicly indisclose ~~CD22~~regarding ~~CAR~~a ~~T-cell~~particular ~~products~~study ~~dosed~~or inclinical ~~more~~trial ~~than~~is ~~120~~based ~~patients~~on inwhat ~~separate~~is ~~clinical~~typically ~~trials~~extensive ~~conducted~~information, ~~by Stanford University~~ and ~~the~~you ~~NCI,~~or ~~these~~others ~~trials~~may ~~were~~not ~~designed~~agree ~~and~~with ~~conducted~~what bywe ~~third~~determine ~~parties.~~is ~~Further,~~material weor ~~also~~otherwise ~~did~~appropriate ~~not~~information ~~control~~to ~~the~~include ~~preclinical~~in ~~development~~our ~~of CRG-022~~disclosure, ~~which was conducted by Stanford University~~ and ~~NCI.~~any Asinformation awe ~~result~~determine ofnot ~~the~~to ~~foregoing,~~disclose ~~there~~may ~~are~~ultimately ~~certain~~be ~~aspects~~deemed ofsignificant ~~these~~with ~~clinical~~respect ~~trials which could lead~~ to ~~our~~future ~~Phase~~decisions, 2conclusions, ~~clinical trial producing different results. For example~~views, itactivities isor ~~possible~~otherwise ~~that~~regarding ~~the~~a ~~selection~~particular ofproduct ~~patients~~candidate ~~dosed~~or ~~in the Phase 1 clinical trial conducted by Stanford being different than the selection criteria we utilize in~~ our ~~Phase 2 clinical trial~~business. If ~~that~~the ~~were to occur~~interim, ~~the~~topline ~~results~~or wepreliminary ~~receive~~data inthat ~~our~~we ~~Phase~~report 2differ ~~clinical~~from ~~trial~~actual ~~may be different~~results, ~~such~~or asif aothers, ~~lower~~including ~~complete~~regulatory ~~response rate and overall response rate as well as a shorter median survival~~authorities, ~~than~~disagree ~~what~~with ~~was observed in~~ the ~~Phase~~conclusions 1reached, ~~clinical~~our ~~trial~~ability ~~conducted~~to byobtain ~~Stanford~~approval ~~University.~~for, ~~Different~~and ~~results~~commercialize, ~~may require us to augment~~ our ~~clinical~~product ~~development~~candidates ~~plans,~~may ~~which could~~ be ~~costly~~harmed, orwhich could ~~result~~harm inour usbusiness, ~~abandoning~~operating ~~the~~results, ~~development~~prospects ofor ~~CRG-022.~~financial ~~The occurrence of either event would harm our business~~condition.

In addition, we have changed the manufacturing process of CRG-022 in an effort to improve manufacturing yields and efficiency. These improvements are reflected in the CRG-022 being used in our potentially pivotal Phase 2 clinical trial and in December 2023, we successfully manufactured CRG-022 and dosed our first seven patients. While we have conducted comparability analysis of our CRG-022 to the CAR T therapy used in the Stanford study and concluded that the two are comparable, we cannot assure you that such comparability will result in the outcome in our Phase 2 clinical trial being consistent with the outcome observed in the Stanford University conducted Phase 1 clinical trial. In such case, additional clinical and or CMC development work may be required to address the differences in the outcome.

If our Phase 2 clinical trial results are not consistent with the results from the Phase 1 clinical trial conducted by Stanford University, the development of CRG-022 may be adversely impacted, which could harm our business, operating results, prospects or financial condition.

Further, while we received allowance to proceed from the FDA in connection with our IND for CRG-022, which included our comprehensive package to establish the comparability of our intended commercial process to the process used for the Stanford clinical trial, we cannot assure you going forward that the FDA will agree with our claim of comparability and the sufficiency of the data to support it, or agree with our ability to reference the preclinical, manufacturing or clinical data generated by the Stanford clinical trial even if we receive a right of reference from Stanford. If so, the FDA may require us to obtain and submit additional preclinical, manufacturing or clinical data before we may initiate further clinical trials and/or obtain any regulatory approvals. Any of these occurrences may harm our business, financial condition and prospects.

The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and end-to-end supply chain management of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., we are not permitted to market our product candidates in the U.S. until we receive regulatory approval of a BLA from the FDA. The process of obtaining such regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and comparable regulatory have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the large number of biologics in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized.

Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe, pure and potent or efficacious ~~with~~ for their intended uses and that we can consistently and reliably manufacture the product candidate. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe available preclinical or clinical data support the safety, purity, potency and/or efficacy of our product candidates, such data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.

Table of Contents

we believe available preclinical or clinical data support the safety, purity, potency or efficacy of our product candidates, such data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.

The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:

•

such authorities may disagree with the design or execution of our clinical trials;

•

negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;

•

serious and unexpected treatment-related side effects may be experienced by participants in our clinical trials or by individuals using therapies similar to our product candidates;

•

the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;

•

such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country;

•

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

Table of Contents

•

such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;

•

such authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates;

•

approval may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions on end-to-end supply chain management and use;

•

such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies;

•

such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission; or

•

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities.

Even if we eventually complete clinical trials and receive approval of a BLA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation of a REMS, which may be required because the FDA believes it is necessary to ensure safe use of the product after approval. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.

66If we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of any of our product candidates, and we do not obtain, or face delays in obtaining, FDA approval of such companion diagnostic, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.

~~Table~~If the FDA believes that the safe and effective use of ~~Contents~~any of our product candidates depends on an in vitro diagnostic (IVD), then it may require approval or clearance of that diagnostic as a companion diagnostic at the same time that the FDA approves our product candidates, if at all. According to FDA guidance, if the FDA determines that a companion diagnostic is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. Depending on the data from our clinical trials, we may decide to collaborate with diagnostic companies during our clinical trial enrollment process to help identify patients with characteristics that we believe will be most likely to respond to our product candidates. If a satisfactory companion diagnostic is not commercially available in this situation, we may be required to develop or obtain such test, which would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostic is time-consuming and costly.

If we are required by the FDA to obtain approval of a companion diagnostic in connection with approval of any of our product candidates or a companion diagnostic we contemplate developing with collaborators in connection with our CD22 CAR T-cell therapy, and we do not obtain, or face delays in obtaining, FDA approval of such companion diagnostic, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.

If the FDA believes that the safe and effective use of any of our product candidates depends on an in vitro diagnostic (IVD), then it may require approval or clearance of that diagnostic as a companion diagnostic at the same time that the FDA approves our product candidates, if at all. According to FDA guidance, if the FDA determines that a companion diagnostic is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. Depending on the data from our clinical trials, we may decide to collaborate with diagnostic companies during our clinical trial enrollment process to help identify patients with characteristics that we believe will be most likely to respond to our product candidates. If a satisfactory companion diagnostic is not commercially available in this situation, we may be required to develop or obtain such test, which would be subject regulatory approval requirements. The process of obtaining or creating such diagnostic is time-consuming and costly.

Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and the FDA has generally required premarket approval of companion diagnostics for cancer therapies. The approval or clearance of a companion diagnostic as part of the therapeutic product’s further labeling limits the use of the therapeutic product to only those patients who express the specific characteristic that the companion diagnostic was developed to detect. In addition, in January 2024, the FDA announced its intention to initiate the process to reclassify into Class II most IVDs that are currently regulated as Class III medical devices, including certain companion diagnostic IVDs. If such reclassification efforts occur, any companion diagnostics that are the subject of the down-classification may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process. However, there is no assurance that any companion diagnostic required for our development programs will benefit from the reclassification, or that the reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.

Table of Contents

If the FDA or a comparable foreign regulatory authority requires approval or clearance of a companion diagnostic for any of our product candidates, whether before or after the product candidate obtains regulatory approval, we and/or third-party collaborators may encounter difficulties in developing and obtaining approval or clearance for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval or clearance of a companion diagnostic could delay or prevent approval or continued marketing of the relevant product. We or our collaborators may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidates, if approved, on a timely or profitable basis, if at all.

We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.

We may in the future seek accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.

67The accelerated approval pathway may be used in cases in which the advantage of a new biologic over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional confirmatory studies to verify and describe the biologic’s clinical benefit. If such post-approval studies fail to confirm the biologic’s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the biologic on an expedited basis. Under the Food and Drug Omnibus Reform Act of 2022, the FDA was provided statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial well underway prior to such approval being granted. Since the enactment of this legislation, the FDA has issued draft guidance documents further clarifying its intent to require confirmatory trials to be underway prior to granting any accelerated approval, which with respect to oncology therapeutics, may include the requirement that such trials be fully enrolled at time of BLA approval.

Table of Contents

intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.

The accelerated approval pathway may be used in cases in which the advantage of a new biologic over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional confirmatory studies to verify and describe the biologic’s clinical benefit. If such post-approval studies fail to confirm the biologic’s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the biologic on an expedited basis. In addition, in December 2022, President Biden signed an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022, which among other things, provided FDA new statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted.

Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA seeking accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for our product candidates, there can be no assurance that such application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

A Breakthrough Therapy designation from the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive FDA approval.61

We may seek Breakthrough Therapy designations for CRG-022 and our product candidates where we believe the clinical data support such designation. A “Breakthrough Therapy” is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as Breakthrough Therapies, increased interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as Breakthrough Therapies also receive the same benefits associated with the FDA’s Fast Track designation program, including eligibility for rolling review of a submitted BLA, if the relevant criteria are met.

Although we have not applied for or received Breakthrough Therapy Designation in connection with our IND for CRG-022, Stanford University has received Breakthrough Therapy designation from the FDA for its CD22 CAR T-cell therapy candidate for, following fludarabine and cyclophosphamide, the treatment of adult patients with relapsed or refractory large B cell lymphoma after CD19-directed CAR T-cell therapy. Although Stanford University’s CD22 CAR T is an earlier version of CRG-022, our CRG-022 program will not receive the benefits of this designation until and unless we obtain the rights to Stanford University’s IND for the program and the FDA agrees to transfer the designation to our IND for CRG-022, or until we otherwise request and obtain such designation from the FDA with respect to our IND for CRG-022. We cannot assure you that the FDA will agree with our claim of comparability and the sufficiency of the data to support it, or agree with our ability to reference the preclinical, manufacturing or clinical data generated by the Stanford clinical trial even if we obtain a right of reference from Stanford. If the FDA disagrees, there may be limitations on the inclusion of Phase 1 data in the product label.

Table of Contents

~~Designation~~A asdesignation afrom ~~Breakthrough Therapy is within~~ the ~~discretion of the~~ FDA~~. Accordingly~~, even if wegranted ~~believe~~for ~~one~~any of our product candidates ~~meets the criteria for designation as a Breakthrough Therapy~~, ~~the FDA~~ may ~~disagree and instead determine~~ not lead to ~~make such designation. In any event, the receipt of~~ a ~~Breakthrough Therapy Designation for a product candidate may not result in a~~ faster development ~~process,~~or regulatory review or approval ~~compared~~process, ~~to drugs considered for approval under standard FDA review procedures~~ and does not ~~assure~~increase ~~ultimate approval by~~ the ~~FDA.~~likelihood Inthat ~~addition, even if one or more of~~ our product candidates ~~qualify~~will asreceive ~~Breakthrough Therapies, the~~ FDA ~~may later decide that the product candidate no longer meets the conditions for qualification and rescind the designation, or otherwise decide that the time period required for FDA review or~~ approval ~~will not be reduced~~.

~~Disruptions~~The atFDA and comparable foreign regulatory authorities offer certain designations for product candidates that are designed to encourage the ~~FDA~~research and ~~other~~development ~~government~~of ~~agencies~~product ~~caused~~candidates bythat ~~funding~~are ~~shortages~~intended orto ~~global~~address ~~health~~serious ~~concerns~~and ~~could~~life-threatening ~~hinder~~conditions. ~~their~~These ~~ability~~designations tomay ~~hire~~confer benefits, ~~retain~~but orthere ~~deploy~~can ~~key~~be ~~leadership~~no ~~and~~assurance ~~other~~that ~~personnel,~~we ~~prevent~~will ~~new~~successfully orobtain ~~modified~~any ~~products~~such ~~from~~designations ~~being~~for ~~developed,~~any ~~review~~product candidates. In addition, ~~approved~~while orsuch ~~commercialized~~designations incould aexpedite ~~timely~~the ~~manner~~development or atreview ~~all~~processes, ~~which~~they ~~could~~do ~~negatively~~not ~~impact~~change ~~our~~the ~~business~~standards for approval, nor do such designations guarantee that any approved indication will not be narrower than the designated indication.

~~The~~For ~~ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors~~example, ~~including~~we ~~government~~may ~~budget~~seek ~~and~~Breakthrough ~~funding~~Therapy ~~levels,~~designations ~~statutory,~~for ~~regulatory~~one ~~and policy changes, the FDA’s~~ or ~~foreign~~more ~~regulatory authorities’ ability to hire and retain key personnel and accept the payment~~ of ~~user~~our ~~fees,~~product ~~and~~candidates ~~other~~where ~~events~~we ~~that~~believe ~~may otherwise affect~~ the ~~FDA’s~~clinical ordata ~~foreign~~support ~~regulatory~~such ~~authorities’ ability to perform routine functions~~designation. ~~Average~~A ~~review~~“Breakthrough ~~times~~Therapy” atis ~~the~~defined ~~FDA and foreign regulatory authorities have fluctuated in recent years~~ as a ~~result.~~drug Inor ~~addition,~~biologic ~~government funding of other government agencies~~ that ~~fund research and development activities~~ is ~~subject to the political process~~intended, ~~which~~alone isor ~~inherently~~in ~~fluid~~combination ~~and~~with ~~unpredictable.~~one ~~Disruptions~~or atmore ~~the~~other ~~FDA~~drugs ~~and~~or ~~other agencies~~biologics, ~~such~~to astreat ~~the~~a ~~EMA~~serious ~~following~~or ~~its~~life-threatening ~~relocation~~disease toor ~~Amsterdam~~condition, ~~and~~where ~~resulting~~preliminary ~~staff~~clinical ~~changes,~~evidence ~~may~~indicates ~~also~~that ~~slow~~ the ~~time~~drug ~~necessary~~or ~~for~~biologic ~~new~~may ~~biologics~~demonstrate orsubstantial ~~modifications~~improvement toover ~~approved~~existing ~~biologics~~therapies toon beone ~~reviewed and/~~or ~~approved~~more byclinically ~~necessary~~significant ~~government agencies~~endpoints, ~~which~~such ~~would~~as ~~adversely~~substantial ~~affect~~treatment ~~our~~effects ~~business.~~observed ~~For~~early ~~example,~~in ~~over~~clinical ~~the last several years, the U~~development.S. ~~government~~For ~~has~~product ~~shut~~candidates ~~down~~that ~~several~~have ~~times~~been ~~and~~designated ~~certain regulatory agencies, such~~ as ~~the~~Breakthrough ~~FDA~~Therapies, ~~have~~increased ~~had~~interaction ~~to furlough critical FDA employees~~ and ~~stop~~communication ~~critical~~between ~~activities. In addition, during~~ the ~~COVID-19~~FDA ~~pandemic,~~and the ~~FDA~~sponsor ~~postponed most inspections~~ of ~~domestic~~the ~~and~~trial ~~foreign~~can ~~manufacturing~~help ~~facilities~~to atidentify ~~various points. Even though~~ the ~~FDA~~most ~~has~~efficient ~~resumed~~path ~~standard~~for ~~inspection~~clinical ~~operations,~~development ~~any~~while ~~resurgence~~minimizing ofthe ~~COVID-19~~number ~~or emergence~~ of ~~new~~patients ~~variants~~placed ~~may~~in ~~lead~~ineffective tocontrol ~~inspectional or administrative delays~~regimens. IfBiologics adesignated ~~prolonged~~as ~~government~~Breakthrough ~~shutdown~~Therapies ~~occurs,~~also orreceive ifthe ~~global~~same ~~health~~benefits ~~concerns~~associated ~~prevent~~with the FDA’s orFast ~~other~~Track ~~regulatory~~designation ~~authorities from conducting their regular activities~~program, itincluding ~~could~~eligibility ~~significantly~~for ~~impact~~rolling ~~the~~review ~~ability~~ of ~~the~~a ~~FDA~~submitted ~~or other regulatory authorities to timely review and process our regulatory submissions~~BLA, ~~which~~if ~~could~~the ~~have~~relevant acriteria ~~material~~are ~~adverse effect on our business~~met.

We may also seek Regenerative Medicine Advanced Therapy (RMAT) designation for one or more of our product candidates. A biological product candidate is eligible for RMAT designation if: (1) it meets the definition of a regenerative medicine therapy, which the FDA defines as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) the candidate is intended to treat, modify, reverse, or cure a serious disease or condition; and (3) preliminary clinical evidence indicates that the candidate has the potential to address unmet medical needs for such disease or condition. Similar to Breakthrough Therapy designation, RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, including potential surrogate endpoints for future clinical studies, and eligibility for rolling review and priority review of submitted BLAs. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or through reliance upon data obtained from a meaningful number of sites, including through expansion to a sufficient number of sites, as appropriate. RMAT-designated product candidates that receive accelerated approval may, as appropriate, be able to fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real-world evidence (such as electronic health records), through the collection of larger confirmatory data sets, or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.

Designations, such as a Breakthrough Therapy and RMAT are within the sole discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies or receive RMAT designation, the FDA may later decide that the product candidate no longer meets the conditions for qualification and rescind such designation or otherwise decide that the time period required for FDA review or approval will not be reduced.

Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, review, approved or commercialized in a timely manner or at all, which could negatively impact our business.

The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA’s or foreign regulatory authorities’ ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s or foreign regulatory authorities’ ability to perform routine

Table of Contents

functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow the time necessary for new biologics or modifications to approved biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. If a prolonged government shutdown occurs, or if funding shortages, staffing limitations or renewed global health concerns prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize such candidates in any other jurisdiction, which would limit our ability to realize their full market potential.

In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.

Table of Contents

Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.

For any regulatory approvals that we may receive for our product candidates, the manufacturing processes, labeling, packaging, end-to-end supply chain management, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with cGMPs for manufacturing, as well as GCPs for any clinical trials that we may conduct. In addition, manufacturers of biological products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and other applicable standards. In addition, any regulatory approvals we may receive will require the submission of reports to regulatory authorities and surveillance to monitor the safety, purity, potency and/or efficacy of the product candidate, and such approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.

If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, such regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:

Table of Contents

withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:

•

restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;

•

restrictions on end-to-end supply chain management or use of product, or requirements to conduct post-marketing studies or clinical trials;

•

fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;

•

refusal by the FDA to approve pending applications or supplements to approved applications submitted by us or suspension or revocation of approvals;

•

product seizure or detention, or refusal to permit the import or export of our products; and

•

injunctions or the imposition of civil or criminal penalties.

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be promulgated or other events could occur that could prevent, limit or delay marketing authorization of any product candidates we develop. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs and biologics. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe, pure and potent or effective, by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs and biologics for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications that are specifically approved by the FDA.

Table of Contents

safe, pure and potent or effective, by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs and biologics for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those indications that are specifically approved by the FDA.

If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion any product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.

We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.64

Table of Contents

During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.

The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.

The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.

If we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would be subject to ceiling prices set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to be in violation of any applicable obligations. Further, the evolving reimbursement policy landscape creates substantial uncertainty and may significantly impact our ability to generate revenue from any approved products.

Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.

71In addition, in the event that we develop companion diagnostic tests for use with our products, if approved, such companion diagnostic tests may require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical product. For example, in the outpatient setting, the need for separate reimbursement of companion diagnostic tests could create additional payment complexities for our product candidates, if approved, and may delay or limit their adoption. In the inpatient setting, where companion diagnostic tests are typically not reimbursed separately, hospitals may be reluctant to adopt our therapies if they perceive the associated companion diagnostic tests as an additional unreimbursed expense. The unavailability of adequate reimbursement for companion diagnostic tests could reduce healthcare providers’ willingness to prescribe and patients’ willingness to use our products, thereby limiting our revenue. Similar challenges to obtaining coverage and reimbursement applicable to pharmaceutical products will apply to companion diagnostics tests.

Table of Contents

successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. In addition, in the event that we develop companion diagnostic tests for use with our products, once approved, such companion diagnostic tests will require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical product. Similar challenges to obtaining coverage and reimbursement applicable to pharmaceutical products will apply to companion diagnostics tests.

There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.

Specifically, due to the high cost of CAR T-cell therapies, payors may be reluctant to provide coverage or may impose significant restrictions on reimbursement or require additional rebates. These challenges could include: implementing high co-payments that patients may find unaffordable, imposing stringent prior authorization requirements, limiting coverage to specific patient populations or conditions potentially narrower than any approved label, requiring additional levels of approval for subsequent CAR T-cell therapies after an initial treatment, and mandating outcomes-based payment models that tie reimbursement to clinical effectiveness. Further, payors may adopt more conservative reimbursement approaches, which could result in more restrictive utilization management tools, potentially delaying or denying coverage for some patients. Delays in obtaining reimbursement approvals may cause healthcare professionals to consider alternative, less expensive, or less logistically complex treatment options, particularly for patients with rapidly progressing disease. Furthermore, Medicare’s coverage of CAR T-cell therapies is currently limited to those meeting specific criteria set forth in a national coverage decision. If we are unable to secure favorable coverage and reimbursement terms, healthcare providers may be hesitant to prescribe our therapies, and patients may be unable to afford treatment. This could substantially limit the adoption of our product candidates, if approved, and materially adversely affect our business, financial condition, and results of operations.

Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that changes in these rules and regulations are likely.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our product candidates, if approved in these jurisdictions. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain regulatory approval for and commercialize our product candidates and may affect the prices we may set.

In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. In particular, there have been and continue to be a number

7266

Table of Contents

reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.

For example, in March 2010, the ACA was enacted in the United States. and substantially changed the way healthcare is financed by both the government and private insurers. The ACA contains provisions that may reduce the profitability of drug products. Among other things, the ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers’ Medicaid rebate liability to covered outpatient drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the 340B drug pricing program; and increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare & Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA, and on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in place in its current form.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory cap on the Medicaid drug rebate, beginning January 1, 2024. The rebate was previously capped at 100% of a drug’s Average Manufacturer Price. Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for products.

Most significantly, onin August ~~16,~~ 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare ~~(beginning in 2026)~~, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new ~~discounting~~manufacturer discount program (beginning in 2025). CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the subsequent 15 drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update ~~its~~ guidance ~~documents~~ as these programs are implemented~~. On August 29~~, ~~2023,~~although ~~HHS announced~~ the ~~list~~Medicare ofdrug ~~the first ten drugs that will be subject to~~ price ~~negotiations,~~negotiation ~~even~~program ~~though~~is ~~this~~currently ~~part of the IRA remains~~ subject to ~~ongoing~~ legal challenges. The impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined but is likely to be significant. Additional drug pricing proposals could appear in future legislation.

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.

We expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

7367

Table of Contents

private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

We are subject to various U.S. federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain regulatory approval. Such laws include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease or order, or arranging for or recommending the purchase, lease or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;

•

the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

•

HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

•

the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare & Medicaid Services (CMS), information related to payments and other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives), and teaching hospitals and other healthcare providers, as well as ownership and investment interests held by such healthcare professionals and their immediate family members; and

•

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biotechnology companies to report information on the pricing of certain drug products; and some state and local laws that require the registration or pharmaceutical sales representatives.

74Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain advisory board agreements we have entered into with physicians who are paid, in part, in the form of stock or stock options, may not comply with current or future

Table of Contents

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain advisory board agreements we have entered into with physicians who are paid, in part, in the form of stock or stock options, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.

Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of employee fraud or other misconduct. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, agents, contractors or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition and patient privacy and other privacy laws and regulations. Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. ItWe are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. We adopted a code of conduct and an insider trading policy applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy.

Table of Contents

Risks related to our dependence on third parties

We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain regulatory approval for or commercialize our product candidates may be delayed.

We are dependent on third parties to conduct our clinical trials and preclinical studies. Specifically, we rely on, and will continue to rely on, medical institutions, clinical investigators, CROs, CDMOs and consultants to conduct clinical trials and preclinical studies, in each case in accordance with trial protocols and regulatory requirements. These CROs, CDMOs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such CROs, CDMOs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, while we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and requirements, and our reliance on our CROs, CDMOs and other third parties does not relieve us of our regulatory responsibilities.

Table of Contents

clinical trials and preclinical studies, in each case in accordance with trial protocols and regulatory requirements. These CROs, CDMOs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such CROs, CDMOs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future, or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, while we have and will have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and requirements, and our reliance on our CROs, CDMOs and other third parties does not relieve us of our regulatory responsibilities.

In addition, we and our CROs and CDMOs are required to comply with Good Laboratory Practice (GLP) and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs, CDMOs or trial sites fail to comply with applicable GLP, GCP, cGMP or other requirements, the data generated in our preclinical studies or clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional studies or trials before approving our marketing applications, if ever. Furthermore, our clinical trials must be conducted with materials manufactured in accordance with cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

There is no guarantee that any of our CROs, CDMOs, investigators or other third parties will devote adequate time and resources to such trials or studies or perform as contractually required, including in compliance with GCPs and GMPs. Third parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials or studies. If any of these third parties fails to meet expected deadlines, carry out their contractual duties or obligations, adhere to our clinical protocols or meet regulatory requirements or otherwise perform in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other activities that could harm our competitive position.

In addition, our CROs and CDMOs have the right to terminate their agreements with us in the event of an uncured material breach and under other specified circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, CDMOs, investigators and other third parties involves additional cost and requires our management’s time and focus. In addition, there is a natural transition period when a new CRO or CDMO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we work to carefully manage our relationships with our CROs and CDMOs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

We currently rely on third parties for the manufacture of our product candidates during clinical development, and expect to continue to rely on third parties for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of critical reagents, raw materials and our final product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development or potential commercialization efforts.

We do not own or operate manufacturing facilities at this time. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates, lentiviral vector and related raw materials for clinical development, as well as for commercial manufacture if any of our product candidates receives regulatory approval. The facilities used by our third-party manufacturers must be approved for the manufacture of our product candidates by the FDA, or any comparable foreign regulatory authority, pursuant to inspections that will be conducted after we submit a BLA to the FDA, or submit a comparable marketing application to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of our product candidates. If these third-party manufacturers cannot successfully manufacture material or components thereof that conforms to our specifications and the strict regulatory requirements

7670

Table of Contents

~~development, as well as for commercial manufacture if any~~ of ~~our product candidates receives regulatory approval. The facilities used by our third-party manufacturers must be approved for~~ the ~~manufacture of our product candidates by the~~ FDA, or any comparable foreign regulatory authority, pursuant to inspections that will be conducted after we submit a BLA to the FDA, or submit a comparable marketing application to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of our product candidates. If these third-party manufacturers cannot successfully manufacture material or components thereof that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval for the use of their manufacturing facilities and will cause supply disruption.

In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve these facilities for the manufacture our product candidates, or if such authorities withdraw any such approval in the future, we may be required to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial position.

Our or a third party’s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP or other regulatory requirements could adversely affect our business in a number of ways, including:

•

an inability to initiate or complete clinical trials of our product candidates in a timely manner;

•

delay in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;

•

additional inspections by regulatory authorities of third-party manufacturing facilities or our manufacturing facilities;

•

requirements to cease development or to recall batches of our product candidates; and

•

in the event of approval to market and commercialize any product candidate, an inability to meet commercial demands.

In addition, we do not have any noncancellable long-term commitments or supply agreements with any third-party manufacturers. We may be unable to establish any long-term supply agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our product candidates or such quantities at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

•

failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;

•

breach of the manufacturing agreement by the third party;

•

failure to manufacture our product candidates according to our specifications;

•

failure to manufacture our product according to our schedule or at all;

•

misappropriation of our proprietary information, including our trade secrets and know-how; and

•

termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

Further, while we do not have any noncancellable long-term commitments or supply agreements with third-party manufacturers, many of our agreements with such parties have liquidated damage provisions in them which require us to pay cancellation fees for any manufacturing work that we cancel but had already been scheduled or otherwise committed to by us, as well as certain out-of-pocket expenses. Such cancellation fees could be significant and if we are required to pay them, our operational results and business may be harmed.

Table of Contents

otherwise committed to by us, as well as certain out-of-pocket expenses. Such cancellation fees could be significant and if we are required to pay them, our operational results and business may be harmed.

In addition, certain of the third parties we use for our manufacturing processes provide services that would be difficult to replace. As a result, if such parties were to increase the cost of their services, we may be required to either pay higher amounts or alternatively develop and or procure an alternative solution. If either were to occur, our results of operations and business may be harmed.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval, and any related remedial measures may be costly or time-consuming to implement. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all, which would have a material adverse impact on our financial position. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods.

Table of Contents

manufacturers and we may be unable to replace them on a timely basis or at all, which would have a material adverse impact on our financial position. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods.

Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all.

We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our current clinical trials and preclinical studies and intend to continue to rely on these third parties for any future clinical trials that we undertake. There are a limited number of suppliers for raw materials that we use to manufacture our product candidates and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our preclinical studies, clinical trials and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event a new supplier must be used. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates.

We may not realize the benefits of any licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects and results of operations may be materially adversely affected.

Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. Therefore, for some of our product candidates we may enter into collaborations with pharmaceutical or biotechnology companies for the development and potential commercialization of those product candidates.

We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all. If our strategic collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. Moreover, our estimates of the potential revenue we are eligible to receive under any strategic collaborations we may enter into may include potential payments related to therapeutic programs for which our collaborators may discontinue development in the future. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.

7872

Table of Contents

and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. Moreover, our estimates of the potential revenue we are eligible to receive under any strategic collaborations we may enter into may include potential payments related to therapeutic programs for which our collaborators may discontinue development in the future. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenue.

In instances where we do enter into collaborations, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition:

•

we may not be able to control the amount and timing of resources that is required of us to complete our development obligations or that the collaboration partner devotes to the product development or marketing programs;

•

the collaboration partner may experience financial difficulties;

•

collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

•

we may be required to relinquish important rights such as marketing, end-to-end supply chain management and intellectual property rights;

•

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;

•

a collaborator could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors;

•

we and our collaboration partner may disagree regarding the development plan for product candidates on which we are collaborating (for example, we may disagree with a collaboration partner regarding target indications or inclusion or exclusion criteria for a clinical trial); or

•

business combinations or significant changes in a collaborator’s business strategy may adversely affect our willingness to complete our obligations under any arrangement.

If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.

Risks related to intellectual property

We depend on intellectual property licensed from third parties and we are currently party to in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our proprietary technologies and product candidates. If we breach our obligations under these agreements or if any of these agreements is terminated, or otherwise experience disruptions to our business relationships with our licensors, we may be required to pay damages, lose our rights to such intellectual property and technology, or both, which would harm our business.

We are dependent on patents, know-how, and proprietary technology, both our own and licensed from others. We are a party to intellectual property license agreements and in the future, we may enter into additional license agreements. For example, with respect to developing our product candidates, we have licensed certain intellectual property from the NCI, Oxford, and Stanford University. These license agreements impose, and we expect that future license and acquisition agreements will impose, various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under current or future intellectual property license agreements, we may be required to pay damages and the licensor may have the right to terminate the license. Any termination of these licenses could result in the loss of significant rights and could harm our ability to develop, manufacture, use and/or commercialize our product candidates or platform technologies. See the section titled “Business–Intellectual property–License agreements” for additional information regarding these key agreements.

79In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or

Table of Contents

~~license~~impair ~~and~~our ~~acquisition~~ability ~~agreements~~to ~~will~~maintain ~~impose,~~our ~~various~~current ~~diligence~~licensing arrangements on commercially acceptable terms, ~~milestone~~we ~~payment~~may be unable to successfully develop, ~~royalty~~manufacture, use and/or ~~other~~commercialize ~~obligations~~the onaffected ~~us.~~product Ifcandidates weor ~~fail~~platform totechnologies. ~~comply~~Our ~~with~~business ~~our~~also ~~obligations~~would ~~under~~suffer if any current or future ~~intellectual~~licensors ~~property~~fail ~~license~~to ~~agreements~~abide by the terms of the license, weif ~~may~~the belicensors ~~required~~fail to ~~pay~~enforce ~~damages~~licensed ~~and~~patents ~~the~~against ~~licensor~~infringing ~~may~~third ~~have~~parties, if the ~~right~~licensed patents or other rights are found to ~~terminate~~be ~~the~~invalid ~~license.~~or ~~Any~~unenforceable ~~termination~~or ofif ~~these~~we are unable to enter into necessary licenses ~~could~~on ~~result~~acceptable interms. ~~the~~Moreover, ~~loss~~our oflicensors ~~significant~~may ~~rights~~own ~~and~~or ~~could~~control ~~harm~~intellectual ~~our~~property ~~ability~~that has not been licensed to ~~develop,~~us ~~manufacture~~and, ~~use~~as ~~and/or~~a ~~commercialize~~result, ~~our~~we ~~product~~may ~~candidates~~be orsubject ~~platform~~to ~~technologies.~~claims, ~~See~~regardless ~~the~~of ~~section~~their ~~titled~~merit, ~~“Business—Intellectual~~that ~~property—License~~we ~~agreements”~~are ~~for~~infringing ~~additional~~or ~~information~~otherwise ~~regarding~~violating ~~these~~the ~~key~~licensor’s ~~agreements~~rights.

In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop, manufacture, use and/or commercialize the affected product candidates or platform technologies. Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor’s rights.

In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop, manufacture and commercialize products, we may be unable to achieve or maintain profitability.

If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may also arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including those relating to:

•

the scope of rights granted under the license agreement and other interpretation-related issues;

•

whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;

•

our right to sublicense patent and other rights to third parties under collaborative development relationships;

•

whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;

•

the priority of invention of patented technology;

•

rights upon termination of the license agreements;

•

the scope and duration of exclusivity obligations of each party to the license agreements;

•

the amount and timing of payments owed under license agreements; and

•

the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners.

Table of Contents

The resolution of any contractual interpretation dispute that may arise, if unfavorable to us, could have a material adverse effect on our business, financial condition, results of operations and prospects. Such resolution could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations under the relevant agreement or decrease the third party’s financial or other obligations under the relevant agreement. Furthermore, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.

Table of Contents

We depend, in part, on our licensors to file, prosecute, maintain, defend and enforce certain patents and patent applications that are material to our business.

Certain patents and patent applications relating to our product candidates, platform technologies or certain products used in the manufacturing of our clinical products are owned or controlled by certain of our licensors, including Stanford University, the NCI and Oxford. In some circumstances, we may not have the right to control the preparation, filing, prosecution, maintenance and defense of patent applications or patents covering technology that we license from third parties. In such circumstances, our licensors generally have rights to file, prosecute, maintain and defend the licensed patents in their name, generally with our right to comment on such filing, prosecution, maintenance and defense, with some obligation for the licensor to consider or incorporate our comments. We generally have the first right to enforce our exclusively licensed patent rights against third parties, although our ability to settle such claims often requires the consent of the licensor. If our licensors or any future licensees having rights to file, prosecute, maintain and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, including due to the impact of health epidemics, pandemics, or other widespread outbreaks of contagious disease, including the COVID-19 pandemic and the post-COVID-19 environment, on our licensors’ business operations, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using or selling competing products. We cannot be certain that such activities by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even in the circumstances where we have the right to pursue such enforcement or defense, we cannot ensure the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to or after our assuming control. This could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.

Furthermore, the U.S. government and/or government agencies have provided, and in the future may provide, funding or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. We rely on our licensors to ensure compliance with applicable obligations arising from such funding or assistance, such as timely reporting, an obligation associated with in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents.

We may not be successful in obtaining or maintaining necessary rights for our product pipeline which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.

We own or license from third parties certain intellectual property rights necessary to develop our product candidates. The growth of our business will likely depend in part on our ability to acquire or in-license additional proprietary rights, including to expand our product pipeline. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third-party rights, we may be required to license technology from additional third parties to further develop, manufacture or commercialize our product candidates. We may be unable to acquire or in-license any relevant third-party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop, manufacture or commercialize the affected product candidates, which would harm our business. We may need to cease use of the

8175

Table of Contents

Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third-party rights, we may be required to license technology from additional third parties to further develop, manufacture or commercialize our product candidates. We may be unable to acquire or in-license any relevant third-party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop, manufacture or commercialize the affected product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors’ access to the same technologies licensed to us.

The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.

We may be dependent on intellectual property for which development was funded or otherwise assisted by, the U.S. government and/or government agencies, such as The National Cancer Institute, for development of our technology and product candidates. Failure to meet our own obligations to such government agencies, may result in the loss of our rights to such intellectual property, which could harm our business.

The U.S. government and/or government agencies have provided, and in the future may provide, funding, facilities, personnel or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. The U.S. government and/or government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses, could result in the loss of significant rights and could harm our ability to commercialize licensed products and harm our competitive position, business, financial condition, results of operations and prospects. For example, the research resulting in certain of our in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology.

Our proprietary position may depend upon patents that are manufacturing, formulation or method-of-use patents, which may not prevent a competitor or other third party from using the same product candidate for another use.

Composition-of-matter patents on the active pharmaceutical ingredient (API) in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because such patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. We currently have claims in our in-licensed issued U.S. patents that cover the composition-of-matter of our product candidates that expire in 2033 without taking into account any possible patent term adjustments or extensions. We are pursuing claims in our pending owned or in-licensed patent applications that cover the manufacturing, formulation or method-of-use of our product candidates. Our proprietary patent position of our product candidates after 2033 may depend upon issuance of patents from such patent applications. The claims in such patents may not prevent a competitor or other third party from using the same product candidate for a noncovered use, from using a noncovered formulation or from making the same product candidate by a noncovered process.

8276

Table of Contents

If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.

We or our licensors have filed, and we anticipate that in the future we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:

•

if and when any patents will issue;

•

whether any of our patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage, including the degree and range of protection our patents that may be issued will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;

•

whether any of our intellectual property will provide any competitive advantage;

•

whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;

•

whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or

•

whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our platform and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel discoveries and technologies that are important to our business.

Obtaining and enforcing patents is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner, including as a result of health epidemics, pandemics, or other widespread outbreaks of contagious disease, including the COVID-19 pandemic and the post-COVID-19 environment impacting our or our licensors’ operations. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

Our ability to enforce patent rights also depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. If we initiate lawsuits to protect or enforce our patents, or litigate against third-party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel.

Composition of matter patents for biological and pharmaceutical products often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the United States Patent and ~~Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents~~

8377

Table of Contents

Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label” for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement can be difficult to prevent or prosecute.

The strength of patents in the biotechnology and pharmaceutical fields can be uncertain, and evaluating the scope of such patents involves complex legal, factual and scientific analyses and has in recent years been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, which have increased uncertainties asaround to the ability to enforce patent rights in the future. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize, our product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.

Patent positions of life sciences companies can be uncertain and involve complex factual and legal questions. Recent years have witnessed constant changes in policy governing the scope of claims allowable in the field of antibodies and adoptive cell therapy in the United States. The scope of patent protection in jurisdictions outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in any jurisdiction ~~that~~in which we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights, and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of our patents and any that we may license.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.

We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party’s pending application will issue with claims of relevant scope. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

One aspect of the determination of patentability of our inventions depends on the scope and content of the “prior art,” information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are ~~not~~unaware ~~aware~~ that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any

8478

Table of Contents

patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.

Our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in post-grant review procedures, oppositions, derivations, reexaminations or inter partes review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with respect to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

•

others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;

•

we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;

•

we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

•

it is possible that our pending patent applications will not lead to issued patents;

•

issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;

•

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•

we may not develop additional proprietary technologies that are patentable;

•

we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries;

•

the claims of any patent issuing based on our patent applications may not provide protection against competitors or any competitive advantages, or may be challenged by third parties;

•

if enforced, a court may not hold that our patents are valid, enforceable and infringed;

•

we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly and time-consuming whether we win or lose;

8579

Table of Contents

•

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property;

•

the laws of foreign countries may not protect our or our licensors’, as the case may be, proprietary rights to the same extent as the laws of the United States;

•

the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents or become hostile to us or the patents or patent applications on which they are named as inventors;

•

it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;

•

we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;

•

we may fail to adequately protect and police our trademarks and trade secrets; and

•

the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.

Should any of these events occur, they could significantly harm our business, results of operations and prospects.

Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know-how, information or technology that is ~~not~~or cannot covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Trade secrets and confidential information, however, may be difficult to protect. We seek to protect our trade secrets, know-how and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors and collaborators. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course of their employment. With our consultants, contractors and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors and collaborators might intentionally or inadvertently disclose our trade secret information to competitors. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same

8680

Table of Contents

manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.

Courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our products, including aspects of sample preparation, methods of manufacturing, cell culturing conditions, computational-biological algorithms and related processes and software, are based on unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees’ former employers or our consultants’ or contractors’ current or former clients or customers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If we are not successful, we could lose access or exclusive access to valuable intellectual property.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.

Some of our employees were previously employed at other pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or our employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.

Third-party claims of intellectual property infringement against us or our collaborators may prevent or delay our product discovery and development efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post-grant review and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Furthermore, patent reform and changes to patent laws in the United States and in foreign jurisdictions add uncertainty to the possibility of challenge to our patents in the future, and could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. We cannot assure you that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time-consuming

8781

Table of Contents

and, even if resolved in our favor, is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or supply chain activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:

•

infringement and other intellectual property claims, which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management’s attention from our core business;

•

substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party’s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner’s attorneys’ fees;

•

a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do;

•

if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and

•

redesigning our product candidates or processes so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time.

Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. We cannot provide any assurances that valid third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Third parties may assert that we infringe their patents or other intellectual property, or that we are otherwise employing their proprietary technology without authorization and may sue us. There may be third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates. We are aware of certain third-party patents and patent applications, including by parties such as Juno Therapeutics, Kite Pharma, the United States Department of Health and Human Services, University of Pennsylvania, and Fred Hutchinson Cancer Research Center with claims to compositions and methods that may be relevant to our product candidates. We believe that we have reasonable defenses against possible allegations of infringement, such as noninfringement or invalidity defenses. There can be no assurance that these defenses will succeed. It is also possible that patents owned by third parties of which we are aware or might become aware, but which we believe are not valid, or do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties, our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained, or may apply for or obtain patents in the future that may prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, and may claim that use of our technologies or the manufacture, use or sale of our product candidates infringes upon these patents. IfAs ~~any~~the ~~such~~number ~~third-party patents were held by a court~~ of ~~competent~~competitors ~~jurisdiction~~in ~~to cover~~ our ~~technologies~~market orgrows ~~product~~and ~~candidates,~~the ornumber ifof wepatents ~~are~~issued ~~found~~in tothis ~~otherwise~~area ~~infringe a third-party’s intellectual property rights~~increases, the ~~holders~~possibility of ~~any~~patent ~~such~~infringement ~~patents~~claims ~~may~~against beus ~~able~~may toincrease. ~~block~~Moreover, ~~including~~individuals byand ~~court~~groups ~~order,~~that ~~our~~are ~~ability~~non-practicing ~~to develop~~entities, ~~manufacture~~commonly orreferred ~~commercialize~~to ~~the~~as ~~applicable~~“patent ~~product~~trolls,” ~~candidate~~purchase ~~unless we obtain a license under the applicable~~ patents orand other intellectual property, orassets ~~until~~for ~~such~~the ~~patents~~purpose ~~expire~~of ormaking ~~are~~claims ~~finally~~of ~~determined~~infringement toin beorder ~~held~~to ~~invalid~~extract ~~or unenforceable~~settlements. ~~Such~~From atime ~~license~~to time, we may ~~not~~receive bethreatening ~~available~~letters, onnotices ~~commercially~~or ~~reasonable~~“invitations ~~terms~~to license,” or atmay ~~all.~~be ~~Even~~the subject of

8882

Table of Contents

claims that our product candidates or technologies and business operations infringe, misappropriate or otherwise violate the intellectual property rights of others. If any such third-party patents were held by a court of competent jurisdiction to cover our technologies or product candidates, or if we are found to otherwise infringe a third-party’s intellectual property rights, the holders of any such patents may be able to block, including by court order, our ability to develop, manufacture or commercialize the applicable product candidate unless we obtain a license under the applicable patents or other intellectual property, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.

The pharmaceutical and biotechnology industries have produced a considerable number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents, and there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion.

Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible on a cost-effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may not be able to protect our intellectual property rights throughout the world.

Patents are of national or regional effect, and filing, prosecuting, maintaining and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. In addition, the laws of some foreign countries, particularly certain developing countries, do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or adequate to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such

8983

Table of Contents

substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third-party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patents, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology or other product candidates or enter into development partnerships that would help us bring our product candidates to market.

We may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe our patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. In addition, in an infringement proceeding or a declaratory judgment action, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.

Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.

Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

9084

Table of Contents

because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.

If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent, including lack of novelty, obviousness, non-enablement or insufficient written description or that that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, derivation and equivalent proceedings in foreign jurisdictions, such as opposition or derivation proceedings. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party’s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. § 271(e)(1). With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and such an outcome may limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Such a loss of patent protection could have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Changes in U.S. patent law or the patent laws of other countries could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1) file any

9185

Table of Contents

regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (1) file any patent application related to our product candidates and other proprietary technologies we may develop or (2) invent any of the inventions claimed in our or our licensor’s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on decisions by Congress, the federal courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in a series of cases, the U.S. Supreme Court held that certain claims, doincluding those to diagnostic methods and companion diagnostics are not ~~present~~drawn ~~patentable~~to patent eligible subject matter under the Patent Act (Mayo Collaborative Services v. Prometheus Laboratories, Inc. (2012); Assoc. for Molecular Pathology v. Myriad Genetics, Inc. (2013); Alice Corp. v. CLS Bank International (2014)). ~~For~~In ~~example~~addition, the U.S. Supreme Court has held that certain claims covering a genus of antibodies do not satisfy either the enablement or the written description requirement of the Patent Act (Amgen Inc. et al. v. Sanofi et al. (2023)). Although we do not believe that any of the patents owned or licensed by us will be found invalid based on these decisions, we cannot predict how their interpretation and future decisions by Congress, the federal courts or the USPTO may impact the value of our patents and may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual property, including the narrowing of the scope of our patents and any that we may license.

Similarly, changes in patent laws and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary patent system took effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (the UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC over the first seven years of the court’s existence and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.

~~The lives of our patents may not be sufficient to effectively protect our products and business.~~86

Patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the

Table of Contents

~~life~~time ~~of a patent~~limits, ~~and~~non-payment ~~the protection it affords, is limited. Given the amount~~ of ~~time~~fees ~~required~~and ~~for~~failure ~~the~~to ~~development,~~properly ~~testing~~legalize and ~~regulatory~~submit ~~review~~formal ofdocuments. ~~new~~In ~~product~~any ~~candidates, patents protecting~~ such ~~candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained~~event, ~~once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. The launch of a generic version of one of~~ our ~~products~~competitors inmight ~~particular would~~ be ~~likely~~able to ~~result~~enter ~~in an immediate and substantial reduction in~~ the ~~demand for that product~~market, which ~~could~~would have a material adverse effect on our business~~, financial condition, results of operations and prospects~~. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, although upon issuance in the United States a patent’s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution.

The terms of our patents may not be sufficient to effectively protect our products and business.

Patents have a limited lifespan or term. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. In addition, although upon issuance in the United States a patent’s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution.

A patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each regulatory approval, and any patent can be extended only once, for a single product. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, or 5 years from the expiration date of the patent to be extended. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, if we do not obtain patent term extension and data exclusivity for any of our current or future product candidates, our business may be materially harmed. We may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.

Our use of open -source software could impose limitations on our ability to commercialize our product candidates.

Our use of open -source software could impose limitations on our ability to commercialize our product candidates. Our technology may use open -source software that contains modules licensed for use from third-party authors under open -source licenses. Some of the software may be provided under license arrangements that allow use of the software for research or other non-commercial purposes. As a result, in the future, as we seek to use our platform in connection with commercially available products, we may be required to license that software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that permit its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and/or additional regulatory approvals.

Use and distribution of open -source software may entail greater risks than use of third-party commercial software, as open -source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open -source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open -source software we use. If we combine our proprietary software with open -source software in a certain manner, we could, under certain of the open -source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open -source software, the terms of many open -source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to re-engineer our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects.

9387

Table of Contents

licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue offering our product candidates, to re-engineer our product candidates or to discontinue the sale of our product candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We or our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that we or our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our patents, including in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or descriptive, or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions.

Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.

Table of Contents

~~for~~third ~~confusion~~parties, ~~with~~such ~~other~~as ~~product names~~distributors. IfThough ~~the~~these ~~FDA~~license ~~(or~~agreements anmay ~~equivalent~~provide ~~administrative~~guidelines ~~body~~for inhow ~~a foreign jurisdiction) objects to any of~~ our ~~proposed~~trademarks ~~proprietary~~and ~~product~~trade names, it may be ~~required~~used, ~~to expend significant additional resources in an effort to identify~~ a ~~suitable~~breach ~~substitute~~of ~~name~~these ~~that~~agreements ~~would~~or ~~qualify~~misuse ~~under applicable trademark laws, not infringe the existing rights~~ of ~~third~~our ~~parties~~trademarks and betradenames ~~acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted~~ by ~~the~~our ~~owner~~licensees ~~of a senior trademark. At times, competitors or other third parties~~ may ~~adopt~~jeopardize ~~trade names or trademarks similar to ours, thereby impeding~~ our ~~ability~~rights toin ~~build brand identity and possibly leading to market confusion. In addition, there could be potential trade name~~ or ~~trademark~~diminish ~~infringement~~the ~~claims~~goodwill ~~brought~~associated bywith ~~owners of other registered trademarks or trademarks that incorporate variations of~~ our ~~registered or unregistered~~ trademarks orand trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.

Risks related to ownership of our common stock

Our stock price has been, and is likely to continue to be highly volatile or may decline regardless of our operating performance, resulting in substantial losses for investors.

The trading price of our common stock has been, and is likely to continue to be, highly volatile and may fluctuate substantially as a result of a variety of factors, some of which are related in complex ways. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. The trading price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors described in this “Risk factors” section:

•

the timing, progress, costs, commencement, enrollment or results of current and future clinical trials and preclinical studies we may conduct, or changes in the development status of our product candidates;

•

adverse results or delays in clinical trials;

•

unanticipated serious safety concerns related to the use of our product candidates;

•

any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including, without limitation, the issuance by the FDA of a “refusal to file” letter or a request for additional information;

•

changes in laws or regulations in the United States or other countries, including, but not limited to, preclinical study or clinical trial requirements for approvals;

•

changes in the structure of healthcare payment systems;

•

successful or negative clinical outcomes or other adverse events related to product candidates being developed by others in the oncology or cell therapy fields;

•

publication of research reports about us or our industry, or cell therapy programs in particular ~~including~~, ~~but not limited to, any publications Stanford University~~ or ~~the NCI may make regarding the development of their CD22 programs, or~~ positive or negative recommendations or withdrawal of research coverage by securities analysts;

•

any changes to our relationship with manufacturers, suppliers, collaborators or other strategic partners;

•

manufacturing or supply challenges;

•

our failure to commercialize our product candidates;

•

additions or departures of key scientific or management personnel;

Table of Contents

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

variations in our results of operations or those of companies that are perceived to be similar to us;

•

Table of Contents

our cash position;

•

an inability to obtain additional funding;

•

our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

•

announcements made by us or our competitors of new product and service offerings, acquisitions, strategic relationships, joint ventures or capital commitments;

•

our inability to establish collaborations, if needed;

•

our ability to effectively manage our growth;

•

changes in the market valuations of similar companies;

•

press reports, whether or not true, about our business;

•

sales or perceived potential sales of our common stock by us or our stockholders in the future;

•

overall fluctuations in the equity markets;

•

ineffectiveness of our internal controls;

•

changes or developments in the global regulatory environment;

•

litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

•

fluctuations in the valuation of companies perceived by investors to be comparable to us;

•

announcement or expectation of additional financing efforts;

•

expiration of market stand-off or lock-up agreements;

•

general political and economic conditions;

•

share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; and

•

other events or factors, many of which are beyond our control.

In addition, the stock market in general and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the trading price of our common stock, regardless of our actual operating performance. If the trading price of our common stock does not exceed the initial public offering price, you may not realize any return on, and may lose some or all of, your investment. In addition, because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management’s attention and resources from our business.

Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

We expect our operating results to be subject to fluctuations. Our net loss and other operating results will be affected by numerous factors, including:

•

timing and variations in the level of expense related to the current or future development of our programs;

•

stock-based compensation estimates;

•

our ability to enroll patients in clinical trials and timing and status of enrollment for our clinical trials;

Table of Contents

•

timing and results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners;

•

the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;

•

competition from products that compete with our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;

•

Table of Contents

any delays in regulatory review or approval of our product candidates;

•

our execution of any collaboration, licensing or similar arrangements and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements;

•

any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;

•

additions and departures of key personnel;

•

strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;

•

if any product candidates we may develop receive regulatory approval, the timing and terms of such approval and market acceptance and demand for such product candidates, which may be difficult to predict;

•

the timing and cost to establish a sales, marketing and supply chain infrastructure to commercialize any products for which we may obtain regulatory approval and intend to commercialize on our own or jointly with current or future collaborators;

•

the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with any of our product candidates;

•

our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties;

•

our ability to establish and maintain collaborations, licensing or other arrangements;

•

our ability to adequately support future growth;

•

potential unforeseen business disruptions that increase our costs or expenses;

•

future accounting pronouncements or changes in our accounting policies;

•

regulatory developments affecting current or future product candidates or those of our competitors;

•

impact from health epidemics, pandemics, or other widespread outbreaks of contagious disease, including the COVID-19 pandemic and the post-COVID-19 environment, on us or third parties with which we engage; and

•

changes in general global market, political and economic conditions.

If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

9791

Table of Contents

WeAs ~~have~~a ~~identified~~publicly ~~material~~traded ~~weaknesses~~company, inwe ~~our~~are ~~internal~~subject ~~control~~to ~~over~~the ~~financial~~Securities ~~reporting.~~Exchange AAct ~~material~~of ~~weakness~~1934 is(the aExchange ~~deficiency,~~Act) orand athe ~~combination~~Sarbanes-Oxley Act of ~~deficiencies,~~2002 in(Sarbanes-Oxley ~~internal~~Act). ~~control~~The ~~over~~Sarbanes-Oxley ~~financial~~Act ~~reporting,~~requires ~~such~~ that ~~there~~we ismaintain aeffective ~~reasonable~~disclosure ~~possibility~~controls ~~that~~and aprocedures ~~material~~and ~~misstatement~~internal ofcontrol ~~our~~over ~~annual or interim~~ financial ~~statements~~reporting. ~~will~~As ~~not~~part beof ~~prevented~~its orannual ~~detected~~review onof athe ~~timely~~effectiveness ~~basis.~~of InCARGO’s ~~preparing~~internal ~~the~~control over financial ~~statements~~reporting as of ~~and for the year ended~~ December 31, ~~2022~~2024, management has ~~identified~~concluded itthat ~~had~~CARGO’s ~~not~~internal ~~fully~~control ~~maintained~~over ~~components~~financial ofreporting ~~the~~was ~~COSO~~effective. ~~framework,~~Material aweaknesses ~~system~~identified ~~for~~in ~~establishing~~preparing ~~internal~~the ~~controls,~~financial ~~which~~statements ~~constituted~~as ~~material~~of ~~weaknesses.~~and ~~Specifically,~~for the ~~control~~year ~~deficiencies~~ended ~~related~~December ~~to:~~31, ~~(i)~~2022, anwhich ~~insufficient~~were ~~complement~~previously ofdisclosed ~~personnel~~in ~~with~~our anAnnual ~~appropriate~~Report ~~level~~on ofForm ~~technical~~10-K ~~knowledge~~for ~~to create~~ the ~~proper~~year ~~environment~~ended ~~for~~December ~~effective internal control over financial reporting~~31, ~~(ii) the lack of an effective risk assessment process~~2023, ~~(iii)~~and ~~the~~in ~~lack~~our ofQuarterly ~~formalized~~Reports ~~processes~~on ~~and~~Form ~~control~~10-Q ~~activities~~for ~~to support~~ the ~~appropriate~~periods ~~segregation~~ended ofMarch ~~duties~~31, ~~over~~June ~~the~~30 ~~review of account reconciliations~~ and ~~journal~~September ~~entries~~30, ~~and~~2024, ~~(iv)~~have ~~the~~been ~~lack~~remediated ofafter ~~monitoring~~newly ~~and~~implemented ~~communication~~controls ofhad ~~control~~been ~~processes~~operating ~~and~~effectively ~~relevant~~for ~~accounting~~a ~~policies~~sufficient ~~and~~period ~~procedures~~of time.

~~These~~Although these material weaknesses ~~resulted~~were remediated as of December 31, 2024, there is no assurance that additional material weaknesses will not arise in ~~adjustments~~the future. Any failure to achieve and maintain effective internal control over financial reporting could have a material adverse effect on the market for our ordinary shares. For a discussion of our internal control over financial ~~statements~~reporting, see “Part II, Item 9A. Controls and Procedures” of this Annual Report on Form 10-K.

To remediate these material weaknesses, we are in the process of implementing measures designed to review and document financial processes and controls, formalizing policies and procedures to improve our internal controls over financial reporting, as well as hiring of qualified resources to the finance department, including supervisory roles. As of December 31, 2023, these material weaknesses have not yet been remediated.

We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis.

If we fail to remediate our existing material weaknesses or identify new material weaknesses in our internal controls over financial reporting, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to conclude that our internal controls over financial reporting are effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting when we are no longer an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be negatively affected. As a result of such failures, we could also become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and financial condition or divert financial and management resources from our regular business activities.

An active, liquid trading market for our common stock may not be maintained.

We can provide no assurance that we will be able to maintain an active trading market for our common stock. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products or technologies by using our common stock as consideration.

Table of Contents

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates own ~~approximately~~a ~~74.8%~~significant majority of our outstanding voting stock as of December 31, ~~2023~~2024. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.

Our common stock price could decline as a result of sales of a large number of shares of common stock in the public market or the perception that these sales could occur. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, future lock-up agreements and Rule 144 under the Securities Act of 1933, as amended, or the Securities Act and Rule 701 under the Securities Act. These sales, or the ~~possibility~~perception that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.

The lock-up agreements entered into in connection with our IPO will expire at the close of business on May 7, 2024. J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, in their sole discretion, may permit our equity holders who are subject to these lock-up agreements to sell shares prior to the expiration of the lock-up agreements. After the lock-up agreements expire, the shares of common stock will be eligible for sale in the public market. Approximately 38.4% of these additional shares are owned by directors, executive officers and other affiliates and will be subject to certain limitations of Rule 144 under the Securities Act. In addition, ~~approximately~~certain ~~7.6~~holders ~~million shares~~ of ~~common stock that are either subject to outstanding options or reserved for future issuance under~~ our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. In addition, the holders of approximately 18.9 million shares, or 45.9% of our total outstanding common, have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price of our common stock.

Table of Contents

In addition, in the future, we may issue additional shares of common stock, or other equity or convertible debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.

We do not currently intend to pay dividends on our common stock, so any returns will be limited to the value of our common stock.

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value of our common stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the trading price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

•

Table of Contents

our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

establish a staggered board of directors divided into three classes serving staggered three-year terms, such that not all members of the board of directors will be elected at one time;

•

authorize our board of directors to issue new series of preferred stock without stockholder approval and create, subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock;

•

eliminate the ability of our stockholders to call special meetings of stockholders;

•

eliminate the ability of our stockholders to fill vacancies on our board of directors;

•

establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at our annual stockholder meetings;

•

permit our board of directors to establish the number of directors;

•

provide that our board of directors is expressly authorized to make, alter or repeal our amended bylaws;

•

provide that stockholders can remove directors only for cause and only upon the approval of not less than 66-2/3% of all outstanding shares of our voting stock;

•

require the approval of not less than 66-2/3% of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and

•

the jurisdictions in which certain stockholder litigation may be brought.

As a Delaware corporation, we will be subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least two-thirds of the outstanding disinterested shares. The application of Section 203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company.

Table of Contents

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees or the underwriters or any offering giving rise to such claim.

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3) any action asserting a claim against us or any director, officer or other employee arising pursuant to the Delaware General Corporation Law, (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or amended and restated bylaws or (5) any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court’s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act.

100

Table of Contents

Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may result in increased costs to stockholders to bring a claim for any such dispute and may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

Our ability to use our net operating loss carryforwards and other tax attributes may be limited.

We have incurred substantial losses during our history, do not expect to become profitable in the near future, and we may not achieve profitability. As of December 31, ~~2023~~2024, we had U.S. federal and state net operating loss carryforwards (NOLs) of $1038.82 million and $2183.38 million, respectively. Our federal NOL carryforwards of $1038.82 million carry forward indefinitely. The state NOL carryforwards of $2183.38 million begin to expire in ~~2040~~2041. In addition, as of December 31, ~~2023~~2024, we have U.S. federal and state research and development tax credits of $213.30 million and $14.97 million, respectively. The federal research and development tax credits of $213.30 million begin to expire in 2042. The state research and development tax credits of $14.97 million carry forward indefinitely.

~~Changes~~Under inSections ~~tax~~382 ~~laws~~and or383 ~~regulations~~of ~~may~~the ~~adversely~~Code, ~~impact~~if ~~our~~a ~~ability~~corporation toundergoes ~~utilize~~an ~~all~~“ownership change,” orgenerally ~~any,~~defined ofas ~~our~~a ~~NOL~~greater ~~carryforwards.~~than ~~For~~50 ~~example,~~percentage ~~legislation~~point ~~enacted~~change (by value) in ~~2017,~~its ~~informally~~equity ~~titled~~ownership ~~the~~by ~~Tax~~certain ~~Cuts~~stockholders ~~and~~over ~~Jobs~~a ~~Act~~three-year (period, the ~~TCJA),~~corporation’s ~~significantly~~ability ~~revised~~to ~~the~~use ~~Internal~~its ~~Revenue~~pre-change ~~Code~~net ofoperating ~~1986~~loss carryforwards and other pre-change tax attributes (~~the~~such ~~Code~~as research and development tax credits), asto ~~amended.~~offset ~~Future~~its ~~guidance~~post-change ~~from~~income ~~the~~or ~~Internal~~taxes ~~Revenue~~may ~~Service~~be ~~and~~limited. ~~other~~We ~~tax~~may ~~authorities~~have ~~with~~experienced ~~respect~~ownership tochanges in the ~~TCJA~~past and may ~~affect~~experience ~~us,~~ownership ~~and~~changes ~~certain~~as ~~aspects~~a result of ~~the~~our ~~TCJA~~acquisitions ~~could~~of beassets ~~repealed~~ and/or ~~modified~~subsequent shifts in ~~future~~our ~~legislation.~~stock ~~For~~ownership ~~example,~~(some ~~the~~of ~~Coronavirus~~which ~~Aid,~~are ~~Relief~~outside our control). As a result, ~~and~~our ~~Economic~~ability ~~Security~~to ~~Act~~use ~~(the~~our ~~CARES~~pre-change ~~Act)~~NOLs ~~modified~~and ~~certain~~tax ~~provisions~~credits ofto ~~the~~offset ~~TCJA.~~future ~~Under~~taxable ~~the~~income, ~~TCJA~~if any, ascould ~~modified~~be bysubject ~~the~~to ~~CARES~~limitations. ~~Act,~~Similar ~~unused~~provisions ~~losses~~of ~~generated~~state intax ~~taxable~~law ~~years~~may ~~ending~~also ~~after~~apply. ~~December~~As 31a result, ~~2017~~even ~~will~~if ~~not~~we ~~expire~~attain ~~and~~profitability, we may be ~~carried~~unable ~~forward~~to ~~indefinitely,~~use ~~but~~a ~~the~~material ~~deductibility~~portion of ~~such~~our NOLs inand tax ~~years~~credits. ~~beginning~~As ~~after~~of December 31, ~~2020~~2024, iswe ~~limited~~have toa ~~80%~~valuation allowance for the full amount of ~~taxable~~our ~~income.~~net Itdeferred istax ~~uncertain~~assets ifas ~~and~~the torealization ~~what~~of ~~extent~~the ~~various~~net ~~states~~deferred ~~will~~tax ~~conform~~assets is not determined to ~~the~~be more likely than not. In addition, changes in tax laws or regulations may adversely impact our ability to ~~the~~utilize ~~TCJA~~all, or ~~the~~any, ~~CARES~~of ~~Act~~our NOL carryforwards.

Under Sections 382 and 383 of the Code, if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We may have experienced ownership changes in the past and may experience ownership changes as a result of our acquisitions of assets and/or subsequent shifts in our stock ownership (some of which are outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset future taxable income, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits. As of December 31, 2023, we have a valuation allowance for the full amount of our net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not.94

Table of Contents

General Risk Factors

If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.

The trading market for our common stock is influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.

101

Table of Contents

publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.

We are an “emerging growth company” as defined in the JOBS Act and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including:

•

not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;

•

reduced disclosure obligations regarding executive compensation in our periodic reports and annual report on Form 10-K; and

•

exemptions from the requirements of holding non-binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We could be an emerging growth company for up to five years following the completion of our initial public offering. Our status as an emerging growth company will end as soon as any of the following takes place:

•

the last day of the fiscal year in which we have ~~more~~at ~~than~~least $1.235 billion in annual revenue;

•

the date we qualify as a “large accelerated filer,” with at least $700.0 million of equity securities held by non-affiliates;

•

the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; or

•

the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering.

Even after we no longer qualify as an emerging growth company, we may continue to qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation. In addition, if we are a smaller reporting company with less than $100.0 million in annual revenue, we would not be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (Section 404).

We cannot predict if investors will find our common stock less attractive if we choose to rely on any of the exemptions afforded to emerging growth companies and smaller reporting companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the trading price of our common stock may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for any new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

~~The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention.~~ 95

102

Table of Contents

~~Sarbanes-Oxley~~The ~~Act~~requirements ~~requires,~~of ~~among~~being ~~other~~a ~~things,~~public ~~that~~company wemay ~~maintain~~strain ~~effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in~~ our ~~internal control and procedures on a quarterly basis. In order to maintain and~~resources, ifresult ~~required,~~in ~~improve~~more ~~our~~litigation ~~disclosure controls~~ and ~~procedures~~divert ~~and internal control over financial reporting to meet this standard, significant resources and~~ management ~~oversight may be required. As a result, management~~’s attention ~~may be diverted from other business concerns, which could adversely affect our business and operating results~~. ~~We may also need to hire additional employees or engage outside consultants to continue to comply with these requirements, which will increase our costs and expenses.~~

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the Dodd-Frank Act), the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to continue to comply with these requirements, which will increase our costs and expenses.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.

These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.

By disclosing information in this Annual Report on Form 10-K and in future filings required under the Exchange Act, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management’s resources and seriously harm our business.

Failure to comply with governmental laws and regulations could harm our business.

Our business is subject to regulation by various federal, state, local and foreign governments. Noncompliance with applicable regulations or requirements could subject us to investigations, sanctions, enforcement actions, disgorgement of profits, fines, damages, civil and criminal penalties, injunctions or other collateral consequences. If any governmental sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, operating results, and financial condition could be materially adversely affected. In addition, responding to any action will likely result in a significant diversion of management’s attention and resources and an increase in professional fees. Enforcement actions and sanctions could harm our business, reputation, operating results and financial condition.

Table of Contents

Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.

103

Table of Contents

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that future deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment, political unrest, or continued unpredictable and unstable market or other macroeconomic or geopolitical conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.

If we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired.

Pursuant to Section 404 of Sarbanes-Oxley and the related rules of the SEC, our management ~~will~~is be required to report on the effectiveness of our internal control over financial reporting beginning with ~~the~~this annual report on the form 10-K for our fiscal year ending December 31, 2024. When we lose our status as an “emerging growth company” and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

Table of Contents

We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if we and/or our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial statements, the trading price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

104

Table of Contents

of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.

The preparation of financial statements in conformity with generally accepted accounting principles in the United States (U.S. GAAP), requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, as provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical accounting policies and estimates.” The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our financial statements include but are not limited to stock-based compensation and evaluation of acquisitions of assets and other similar transactions as well as clinical trial accruals. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.

Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our audited or unaudited financial statements and related notes. Such changes to existing standards or changes in their interpretation may also have an adverse effect on our reputation, business, financial position and profit.

We could be subject to changes in tax rates, the adoption of new tax legislation or could otherwise have exposure to additional tax liabilities, which could harm our business.

Changes to tax laws or regulations in the jurisdictions in which we operate, or in the interpretation of such laws or regulations, could significantly increase our effective tax rate, and otherwise have a material adverse effect on our financial condition. In addition, other factors or events, including business combinations and investment transactions, changes in stock-based compensation, changes in the valuation of our deferred tax assets and liabilities, adjustments to taxes upon finalization of various tax returns or as a result of deficiencies asserted by taxing authorities, increases in expenses not deductible for tax purposes, changes in available tax credits, changes in transfer pricing methodologies, other changes in the apportionment of our income and other activities among tax jurisdictions and changes in tax rates, could also increase our effective tax rate. Our tax filings are subject to review or audit by the U.S. Internal Revenue Service (the IRS) and state, local and foreign taxing authorities. We may also be liable for taxes in connection with businesses we acquire. Our determinations are not binding on the IRS or any other taxing authorities, and accordingly the final determination in an audit or other proceeding may be materially different than the treatment reflected in our tax provisions, accruals and returns. An assessment of additional taxes because of an audit could harm our business.

~~We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.~~98

105

Table of Contents

~~substantial~~financial ~~cost~~condition. ~~and~~In beaddition, aother ~~distraction~~factors toor ~~our~~events, ~~management~~including ~~and~~business ~~employees.~~combinations Ifand ~~our~~investment ~~defenses~~transactions, tochanges ~~these~~in ~~claims~~stock-based ~~fail~~compensation, changes in ~~addition~~the tovaluation ~~requiring~~of usour todeferred ~~pay~~tax ~~monetary~~assets ~~damages~~and liabilities, aadjustments ~~court~~to ~~could~~taxes ~~prohibit~~upon usfinalization ~~from~~of ~~using~~various ~~technologies~~tax returns or ~~features~~as ~~that~~a ~~are~~result ~~essential~~of todeficiencies ~~our~~asserted ~~product~~by ~~candidates~~taxing authorities, ifincreases ~~such~~in ~~technologies~~expenses ornot ~~features~~deductible ~~are~~for ~~found~~tax topurposes, ~~incorporate~~changes orin beavailable ~~derived~~tax ~~from~~credits, ~~the~~changes ~~trade~~in ~~secrets~~transfer orpricing methodologies, other ~~proprietary~~changes ~~information~~in of the ~~former~~apportionment ~~employers.~~of ~~Moreover,~~our ~~any~~income ~~such~~and ~~litigation~~other oractivities ~~the~~among ~~threat~~tax ~~thereof~~jurisdictions ~~may~~and ~~adversely~~changes ~~affect~~in ~~our~~tax ~~reputation~~rates, ~~our~~could ~~ability~~also toincrease ~~form~~our ~~strategic~~effective ~~alliances~~tax orrate. ~~sublicense~~Our ~~our~~tax ~~rights~~filings are subject to ~~collaborators,~~review ~~engage~~or ~~with~~audit ~~scientific~~by ~~advisors~~the orU.S. ~~hire~~Internal ~~employees~~Revenue orService ~~consultants~~(IRS) and state, ~~each~~local ofand ~~which~~foreign ~~would~~taxing ~~have~~authorities. anWe ~~adverse~~may ~~effect~~also onbe ~~our~~liable ~~business,~~for ~~results~~taxes ofin ~~operations~~connection ~~and~~with ~~financial~~businesses ~~condition~~we acquire. ~~Even~~Our ifdeterminations we are ~~successful~~not inbinding ~~defending~~on ~~against~~the ~~such~~IRS ~~claims~~or any other taxing authorities, ~~litigation~~and ~~could~~accordingly ~~result~~the final determination in ~~substantial~~an ~~costs~~audit ~~and~~or other proceeding may be amaterially ~~distraction~~different tothan ~~management~~the treatment reflected in our tax provisions, accruals and returns. An assessment of additional taxes because of an audit could harm our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that individuals working for or collaborating with us do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information proprietary to these third parties or our employees’ former employers, or that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. We may be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants, advisors or other third parties, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been instituted against companies following periods of volatility in the trading price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources, which would harm our business, operating results or financial condition. Additionally, the dramatic increase in the cost of directors’ and officers’ liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs, settlements and damages awarded to plaintiffs.

Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.

Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and strategic partners, any of which could adversely affect our business and

Table of Contents

operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended (FCPA), the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Cybersecurity Risk Management and Strategy

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. ~~Our cybersecurity risk management program includes a cybersecurity incident response plan.~~

We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST). This does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.

~~106~~Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.

~~Table~~Key elements of ~~Contents~~our cybersecurity risk management program include:

Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.

Our cybersecurity risk management program includes:

• overall risk assessment;

• a technology team leveraging a third-party Security Operations Center (SOC) partner to monitor, manage and respond to cybersecurity incidents;

• the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;

100

Table of Contents

• cybersecurity awareness training of our employees and regular phishing campaigns;

• a cybersecurity incident response policy that includes procedures for responding to cybersecurity incidents; and

• a third-party risk management process for key service providers, ~~suppliers,~~based ~~and~~on ~~vendors~~our ~~that~~assessment ~~have~~of ~~access~~their criticality to our ~~critical~~operations ~~systems~~ and ~~information~~respective risk profile.

We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. ~~For~~See ~~more information, see the section titled~~ “Risk Factors—Risks related to our business—Our information technology systems, or those used by our third-party contract research organizations or other contractors or consultants, may fail or suffer security breaches.”

Cybersecurity Governance

Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (Committee) oversight of cybersecurity ~~and other information technology~~ risks., ~~The~~including ~~Committee~~oversight ~~oversees~~of management’s implementation of our cybersecurity risk management program.

The Committee receives quarterly updates from management on our cybersecurity risks. In addition, management updates the Committee, aswhere ~~necessary~~it deems appropriate, regarding ~~any material~~ cybersecurity incidents, asit ~~well~~considers asto ~~any~~be ~~incidents~~significant ~~with~~or ~~lesser~~potentially ~~impact potential~~significant.

The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program.

Our management team, including the Vice President of IT ~~and the Senior Vice President of Finance, General & Administrative,~~ is primarily responsible for assessing and managing our material risks from cybersecurity threats. The ~~team~~Vice President of IT has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. Our management team’s experience includes over 25 years of experience leading technology management functions within biotech companies as well as interacting with the Board. Specifically, the Vice President of IT has been leading IT, compliance and security in various biotech companies including presenting and delivering cybersecurity roadmaps and risk management to executive teams and boards.

Our management team ~~supervises~~takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in ~~the~~our IT environment.

Item 2. Properties.

Our principal office is currently located at ~~1900~~835 ~~Alameda~~Industrial ~~Las Pulgas~~Road, ~~Suite 350,~~ San ~~Mateo~~Carlos, California, where we lease an approximately 3199,~~117~~557 square foot facility, used as laboratory, research and office space which expires in ~~November 2024. In December 2023, our lease of 99,557 square foot of laboratory and office space at 835 Industrial Road, San Carlos, California commenced and the lease expires in~~ May 2031. ~~We intend to move our principal office to the new leased location in San Carlos.~~ See Note 5 to our financial statements included elsewhere in this Annual Report on Form 10-K for additional information. We believe that our current facilities are suitable and adequate to meet our current needs.

107

Table of Contents

Item 3. Legal Proceedings.

We are not currently a party to any material legal proceedings. From time to time, we may, however, in the ordinary course of business become involved in legal proceedings. Regardless of outcome, litigation could have a material adverse effect on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.

Item 4. Mine Safety Disclosures.

Not applicable.

~~108~~101

Table of Contents

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is traded on the NASDAQ Global Market under the symbol “CRGX.”

Holders of Record

As of March 135, ~~2024~~2025, there were 4422 holders of record of our common stock. The actual number of holders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.

Dividend Policy

We have never declared or paid cash dividends on our capital stock. We do not expect to pay dividends on our common stock for the foreseeable future. Instead, we anticipate that all of our earnings, if any, will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and capital requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors.

Equity Compensation Plan Information

The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.

Use of Proceeds from our Initial Public Offering

On November 9, 2023, our registration statement on Form S-1 (File No. 333-275113) (the Prospectus) relating to our initial public offering (IPO) became effective pursuant to which we issued and sold 21,262,181 shares of our common stock at a public offering price of $15.00 per share. We received net proceeds of $291.0 million, after deducting the underwriting discounts, commissions and offering expenses. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to our affiliates. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Truist Securities, Inc. who acted as joint book-running managers for the offering.

There has been no material change in the planned use of proceeds from the IPO from that described in the Prospectus.

Recent Sales of Unregistered Securities

~~In October 2023, we issued and sold an aggregate of 6,341,150 shares of our Series A-1 redeemable convertible preferred stock, par value $0~~None.~~001 per share, to the purchasers listed on Exhibit A of the Series A Preferred Stock Purchase Agreement at a purchase price of $13.57 per share, for net proceeds of approximately $86.0 million.~~

Issuer Repurchases of Equity Securities

During the quarter ended December 31, ~~2023~~2024, we did not repurchase any equity securities.

Item 6. [Reserved].

~~109~~102

Table of Contents

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with the audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, and expectations related to future events and our future performance that involves risks, uncertainties, and assumptions, such as statements regarding our intentions, plans, objectives, and expectations for our business. Our actual results and the timing of selected events could differ materially from those discussed in the forward-looking statements as a result of several factors including those set forth in the section titled “Risk Factors.” See also the section titled “Special Note Regarding Forward-Looking Statements”.

Overview

We are a clinical-stage biotechnology company ~~uniquely~~focused ~~positioned~~on todesigning, ~~advance~~engineering and developing next generation, potentially curative cell therapies for cancer patients. Our programs, ~~platform technologies~~platforms, and manufacturing strategy are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. A CAR is aan engineered protein that ~~has~~is ~~been~~delivered ~~engineered~~into ~~to modify~~ T cells, soenabling ~~they~~recognition ~~can recognize~~ and ~~destroy~~destruction of cancer cells. We believe the limitations of ~~these~~approved CAR T-cell therapies include limited durability of effect, safety concerns and unreliable supply. Our ~~lead~~pipeline ~~program,~~includes CRG-~~022~~023, an ~~autologous~~investigational ~~(derived~~tri-specific ~~from~~CAR aT ~~patient’s~~designed ~~cells)~~to ~~CD22~~address ~~chimeric~~several ~~antigen~~known ~~receptor~~causes (of relapse associated with existing CAR) T-cell ~~product~~therapies ~~candidate,~~such ~~the~~as ~~underlying~~loss ~~CAR~~ of ~~which~~tumor weantigen ~~exclusively licensed~~expression, isloss ~~being~~of ~~studied~~co-stimulation by(e.g., ~~Stanford~~via ~~University~~CD58/CD2 ~~(Stanford~~signaling) inand aT ~~Phase~~cell 1exhaustion, ~~clinical~~resulting ~~trial~~ in ~~patients~~the ~~with~~potential ~~large~~to ~~B-cell~~address ~~lymphoma~~a ~~(LBCL)~~broad ~~whose~~range ~~disease~~of ~~relapsed or was refractory (R/R) to CD19 CAR T~~B-cell ~~therapy.~~malignancies Onwith the ~~basis~~goal of ~~the~~providing ~~results~~more ~~from~~patients ~~the~~with ~~clinical~~a ~~trial,~~durable wecomplete ~~are~~response. ~~evaluating~~ CRG-~~022~~023 ~~in a potentially pivotal Phase 2 clinical trial in patients with LBCL whose disease~~ is ~~R/R~~designed to ~~CD19~~target ~~CAR~~the TB-cell ~~therapy.~~lineage Weantigens ~~also~~(CD19, ~~plan~~CD20, toCD22) ~~evaluate~~via ~~CRG~~tri-~~022~~cistronic inexpression ~~patients at earlier stages~~ of ~~disease,~~three ~~including~~distinct ~~LBCL~~CARs ~~and~~from ~~other~~a ~~hematologic~~single ~~malignancies.~~lentiviral ~~Beyond our lead program~~vector, weeach ~~are~~with ~~leveraging~~its ~~our~~own ~~proprietary~~co-stimulatory ~~cell~~domain. ~~engineering~~One ~~platform~~co-stimulatory ~~technologies~~domain toincorporates ~~develop~~CD2 asignaling ~~pipeline~~into ofthe ~~programs~~tri-specific ~~that incorporate multiple transgene therapeutic “cargo” designed to enhance~~ CAR T~~-cell~~ ~~persistence~~cell, asthe ~~well~~design asof towhich ~~help~~has ~~safeguard~~been ~~against~~informed ~~tumor~~by ~~resistance and T~~immune-~~cell~~evasion ~~exhaustion. Our founders are pioneers~~ and ~~world-class experts in~~ CAR T-cell ~~therapy,~~resistance ~~and~~mediated ~~our~~by ~~team~~the ~~has~~loss ~~significant~~of ~~experience~~CD58 ~~and~~expression ~~success~~(the ~~developing,~~ligand ~~manufacturing,~~of ~~launching~~the ~~and~~CD2 ~~commercializing~~co-stimulatory ~~oncology and cell therapy products~~receptor). ~~We aim to become a fully integrated, leading cell therapy company. Together, we are united in our mission to outsmart cancer and deliver more cures for patients.~~

~~Based~~In onJanuary ~~data~~2025, ~~from~~ the ~~Phase~~FDA 1allowed ~~clinical~~our ~~trial~~IND ~~conducted~~for byCRG-023 ~~Stanford~~to ~~and~~proceed. ~~pending~~We ~~data~~intend ~~from~~to ~~our~~evaluate ~~ongoing~~CRG-023 in a Phase 21 ~~clinical~~dose ~~trial~~escalation study in ~~R/R~~3L+ ~~LBCL~~large –B-cell ~~post~~lymphoma ~~CD19~~(LBCL) including CAR T,-naïve wepatients. ~~intend~~We ~~are~~plan into ~~discussions~~leverage ~~with~~proof-of-concept ~~the~~data ~~FDA~~to onsupport ~~the~~moving ~~initiation~~quickly into earlier lines of atherapy ~~Phase~~and 2to ~~program~~evaluate inCRG-023 ~~LBCL~~additional –B-cell ~~CAR~~malignancies Tfor ~~naïve~~CRG-023. ~~without~~Enrollment ~~completing~~for ~~earlier~~the ~~clinical~~Phase ~~trials~~1 instudy ~~LBCL~~is –expected ~~CAR~~to ~~T-naïve~~be ~~patients~~initiated by the second quarter of 2025.

OnWe ~~November~~are ~~14,~~also 20

Filing Compare · CARGO Therapeutics, Inc.